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Wilms' tumour 1 (WT1) is a transcription factor encoding a zinc finger protein that controls 
podocyte differentiation and is highly expressed in mature podocytes. WT1 mutations 
can lead to renal failure due to glomerular scarring, the underlying mechanisms, of which, 
are poorly understood. This project explored the mechanisms of glomerulosclerosis by 
using a tamoxifen-inducible Cre-LoxP system to delete Wt1 in adult mice. Following the 
fourth day post-induction with Tamoxifen, podocyte apoptosis was evident and increased 
as the disease progressed, highlighting Wt1’s key role in mature podocyte survival. At 
disease onset, increased podocyte Notch1 transcript and its downstream targets, 
including Nrarp and Hey2 were observed. Decreased expression of podocyte FoxC2 
transcript at the same time-point was noted, thereby supporting previous findings in lower 
vertebrates for a transcriptional relationship between Wt1/FoxC2/Notch in podocyte 
function. Podocyte Notch1 and Hes1 protein expression was observed in mutant mouse 
glomeruli at the onset of glomerulosclerosis. Induced podocyte Hes1 expression was 
associated with an upregulation of Snai1 and Slug transcripts, genes associated with 
epithelial to mesenchymal transition (EMT), thus proposing a role for Hes1 in mediating 
podocyte EMT. Moreover, early pharmacological inhibition of Notch, with gamma 
secretase inhibitors, ameliorated glomerulosclerosis and albuminuria. This data provides 
evidence that Wt1 deletion modulates podocyte Notch signalling in mature podocytes, 
leading to early events in WT1-related glomerulosclerosis. 
 




Nephrotic syndrome is characterised by excessive protein in the urine (proteinuria) and 
glomerulosclerosis, where children progress towards end-stage kidney disease. The 
Wilms’ tumour 1 (WT1) gene is expressed during kidney development and in mature 
podocytes. WT1 mutations have been associated with Denys-Drash Syndrome (DDS) 
and Frasier Syndrome (FS), disorders associated with glomerulosclerosis. 
 
This project aims to explore whether the Notch pathway is implicated in mammalian Wt1 
glomerulopathy, to add further literature on this subject, and to enable future treatments 
to be found for kidney disease. Mutant murine and patient tissue has been utilised in this 
project to explore the expression of Notch pathway components during the evolution of 
glomerulosclerosis. This project achieved its main objectives through the identification of 
increased expression of Notch transcripts and protein at disease manifestation in mice 
and provided the rationale for early therapeutic blockade by administration of gamma 
secretase inhibitors to repress Notch signalling. Harvesting of primary podocytes proved 
to be valuable in the identification of a Notch-specific signature at disease onset as we 
were able to investigate a homogeneous population of cells. 
 
The research, described herein, has provided me with the opportunity to present my 
findings at local, national and international meetings which afforded me the opportunity 
to network with fellow researchers in related fields of research. Future funding has been 
secured to investigate the role of Notch in mice carrying mutations relevant to human 
disease. My research, reported herein, is now published in a well-regarded scientific 
journal, and provides the foundation for future work to examine Notch as a new 
therapeutic strategy for WT1-related glomerular disease. This project provides a basis 
for early intervention for treating kidney disease and possible future treatments to 
prevent disease manifestation. 
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Chapter 1 - Introduction 
 
The mammalian kidney plays a crucial role in fluid homeostasis by preserving pH and 
electrolyte balance. Each human kidney comprises about one million nephrons, 
consisting of a glomerulus which filters plasma to the proximal nephron (Figure 1.1) 




Figure 1.1. The kidney glomerulus 
(A) Sagittal section demonstrating the gross structure of the mammalian kidney. (B) Cortex: the 
nephron, showing the glomerulus, along with the Bowman’s capsule (BC), Proximal tubule (PT), 
Distal tubule (DT). Medulla: loop of Henle, collecting duct and ureter. (C) Kidney glomerulus: 
Endothelial cells (E). glomerular basement membrane (GBM), BC, capillary loops (CL), mesangial 
cells (M), podocytes (P), Bowman’s space (BS), PT. Adapted from (Mimura and Nangaku, 2010, 
Quaggin and Kreidberg, 2008) 
 
1.1 Glomerular development  
 
1.1.1 Podocyte morphology and maintenance of the glomerular filtration barrier 
(GFB)  
 
Podocytes are terminally differentiated specialised epithelial cells that comprise the outer 
layer of the GFB (Figure 1.2) (Quaggin and Kreidberg, 2008, Asanuma, 2015). They 
exert their function through a unique architecture consisting of a cell body from which 
cytoplasmic processes (primary) extend and further branch into secondary and tertiary 
foot processes (FPs), which then interdigitate with adjacent FPs of neighbouring cells 
(Figure 1.3A, B, D). 
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Figure 1.2. The glomerular filtration barrier (GFB) 
(A) The GFB is comprised of the podocytes, endothelial cells, and GBM. The slit diaphragm (SD) 
between the interdigitating podocyte FPs control plasma filtration. The glomerular capillaries filter 
blood through the endothelium and GBM into the SD to produce primary urinary filtrate. (B) TEM 
demonstrating the layers of the GFB: The GBM lies between the podocytes and endothelium. The 
endothelial cells are fenestrated (black arrows) and line the capillary lumen. The glomerulus also 
contains parietal epithelial cells (PECs), which line the Bowman’s capsule and the mesangium. 
Adapted from (Miner, 2012). 
 
Primary processes are composed of predominantly intermediate filaments and 
microtubules, while a tightly regulated actin cytoskeleton underlies the architecture of 
secondary and tertiary FPs (Reiser et al., 2000, Schell and Huber, 2017). The podocytes 
encase the glomerular basement membrane (GBM) with their FPs through integrins and 
dystroglycans, namely α and β-dystroglycan, giving them structural support (Jefferson et 
al., 2011). The podocyte slit diaphragms (SDs), along with the endothelia and GBM, 
allow filtration of small solutes and plasma water, whilst retaining larger molecules in the 
plasma. Figure 1.3C illustrates a 3-dimensional reconstitution of the podocyte SD. Under 
normal conditions, cell membranes extend as cross-strands to form pores, preventing 
large proteins from entering the urine. 
 
Loss of glomerular permselectivity is associated with leakage of plasma proteins into the 
urine (proteinuria) (Schell et al., 2014, Greka and Mundel, 2012, Jefferson et al., 2011, 
Scott and Quaggin, 2015). Proteinuric diseases are associated with a loss of podocyte 
interdigitations (effacement), (Figure 1.3D), which are morphologically considered to 
represent a reversal to an immature cellular phenotype. (Grahammer et al., 2013).  
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Figure 1.3. Podocyte morphology  
(A, B) Transmission Electron Micrograph (TEM) representing FPs enwrapping the glomerular 
basement membrane (GBM); (B) Highlighting the FP, with the SD. (C) Electron tomography 
displaying a 3D reconstitution of the SD (blue) spanning the filtration slit between FPs (green). 
The podocyte cell membranes extend as cross-strands (white arrows), forming lateral pores and 
merge centrally into a longitudinal central density (CD), preventing proteins larger than the pores 
to enter the urine. (D) Scanning electron micrograph (SEM) of normal podocyte structure in mice; 
primary and secondary processes interdigitate forming FPs, which cover the GBM and capillaries, 
allowing filtration to take place. (E) SEM displaying FP effacement due to podocyte injury (Waters 
et al., 2008, Wartiovaara et al., 2004)  
 
1.1.2 Overview of podocytes in kidney development 
 
Podocyte precursors are cuboidal in shape and are first identified within the S-shaped 
body at the onset of glomerulogenesis. A series of morphological events occurs during 
kidney development, following induction of the metanephric mesenchyme (MM) 
(Costantini and Kopan, 2010, Seely, 2017). Condensation of the MM around each UB 
tip ensues forming the pretubular aggregate (PTA) (Saxen and Sariola, 1987, Kreidberg 
et al., 1993, Stark et al., 1994, Carroll et al., 2005) (Figure 1.4). The PTAs undergo 
mesenchymal-to-epithelial-transition (MET) to develop into the epithelial renal vesicle 
(RV), subsequently morphing into the comma-shaped bodies, developing a cleft at their 
distal end to form S-shaped bodies. Cells which proximate to the S-shape cleft give rise 
to the podocyte cells, while cells in the caudal region are specified towards the proximal 
tubule. The S-shaped body vascularises at the proximal end to form a single capillary 
loop, eventually forming a network of capillary loops to become the glomerulus, assisted 
by endothelial and mesangial cells (Figure 1.4) (Stark et al., 1994, Saxen and Sariola, 
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1987). The distal RV develops into proximal and distal tubules; proximal polarity 
establishes the proximal tubule segments and loop of Henle, distal segments form the 
distal tubules, which connect to the collecting duct (Kreidberg, 2010, Kreidberg et al., 
1993, Saxen and Sariola, 1987, Quaggin and Kreidberg, 2008). 
 
 
Figure 1.4. Kidney development 
Condensation of the metanephric mesenchyme (MM) leads to the formation of the renal vesicle, 
eventually becoming the comma- and S-shaped bodies. The podocyte precursors are expressed 
in the proximal medial region of the S-shaped body cleft (asterisk). Vascularisation of the S-
shaped body leads to a single capillary loop, ultimately forming a mature glomerulus through a 
network of capillaries. Adapted from (Saxen and Sariola, 1987). 
 
1.1.3 Podocyte differentiation 
 
The primitive podocytes are located within the inner aspect of the proximal cleft of the S-
shaped body (Figure 1.4). Columnar in shape, they are connected to each other at their 
lateral margins by tight junctions (Kreidberg, 2003, Quaggin and Kreidberg, 2008) 
(Figure 1.4, Figure 1.5) (Kreidberg, 2003, Quaggin and Kreidberg, 2008, Brunskill et al., 
2011). As the glomerular capillary loops develop, the podocyte precursors develop 
primary FPs which are anchored to the underlying GBM (Kreidberg, 2003) (Figure 1.5). 
Primary processes develop into secondary and tertiary FPs and become interdigitated 
with FPs of neighbouring podocytes (Figure 1.5C). 
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Figure 1.5. Podocyte differentiation  
(A) Podocyte progenitors (purple) begin as columnar epithelial cells adhered at their lateral 
margins, lying on the underlying developing glomerular capillary loop (blue). (B) Podocyte 
differentiation involves the dissociation of the podocyte cell bodies from one another, with 
cytoplasmic extensions arising from the basal aspect of the cell bodies. (C) Neighbouring foot 
processes become interdigitated with each other, wrapping around the capillary loops and forming 
the mature glomerulus. (D-F) Representative images showing corresponding stages of 
glomerular development. Adapted from (Quaggin and Kreidberg, 2008). 
 
1.1.4 The glomerular filtration barrier 
 
The formation of the GFB involves coordinated reciprocal interactions between the 
podocyte precursors and the developing capillary vasculature with interposition of the 
GBM. A single capillary loop is initiated in the glomerular cleft of proximal S-shaped body 
following the secretion of vascular endothelial growth factor-A (VEGF-A) by the podocyte 
precursors (Quaggin and Kreidberg, 2008, Eremina et al., 2003). The capillary loop 
further develops into six to eight loops whilst the podocytes produce structural 
components of the underlying GBM, which provides support to the developing glomerular 
vasculature. Platelet-derived growth factor- α and β (PDGF), produced by mesangial 
cells, also contributes to mesangial interposition in between developing capillary loops 
during glomerular development (Jefferson et al., 2011). Ultimately, the GBM lies 
interposed between the underlying fenestrated endothelium and an epithelial sheet 
composed of interdigitating podocyte FPs. 
 
Interaction between podocyte α3-β1 integrin and GBM β2 laminin mediates the 
attachment of the podocytes to the GBM (Foster et al., 2003, Eremina and Quaggin, 
2004, Sir Elkhatim et al., 2014, Eremina et al., 2007) (Figure 1.2). Podocyte precursors 
produce and secrete laminin-1 (α1β1γ1) and collagen IV (α1 and α2). As the GBM 
develops, the β1 chain of laminin is progressively lost and there is a shift to laminin 11 
(α5β2γ1) and collagen IV subunits (α3, α4, α5) at the capillary loop stage (Miner and 
Sanes, 1994, Abrahamson and St John, 1993, Miner, 1998). The α6 chain of collagen 
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IV is located in the Bowman’s capsule basement membrane. Mutations in collagen IV α3 
and α4 chains lead to Alport syndrome, a proteinuric kidney disease that arises from a 
defective GBM (Hudson et al., 1992). Mutations in LAMB2 are associated with Pierson 
syndrome, a proteinuric kidney disease which presents in the first year of life and is 
associated with glomerulosclerosis and defective GBM (Liapis, 2008).  
 
The podocyte SD comprises the size-selective layer of the GFB. Lying between the 
connecting FPs, SDs are composed of proteins such as nephrin (NPHS1), podocin 
(NPHS2) and CD2-associated protein (CD2AP) (Figure 1.6). 
 
 
Figure 1.6. Components of the podocyte foot process associated with proteinuria 
Proteinuria is a heterogenous disease which can be associated with mutations in genes encoding 
transcription factors involved in podocyte differentiation, cytoskeletal proteins important for FP 
integrity and SD function. Adapted from (Preston et al., 2017). 
 
1.1.4.1 Composition and function of podocyte foot processes 
 
Tertiary podocyte FPs play a critical role in the maintenance of glomerular 
permselectivity. In podocyte injury, proteinuria is associated with a broadening and 
flattening of podocyte FP, known as FP effacement (Ronco, 2007, Kerjaschki, 1994, 
Salant, 1994). FP morphology is regulated by a tightly structured intracytoplasmic 
network of cytoskeletal proteins such as actin, synaptopodin and myosin. Integrins, 
heterodimeric transmembrane receptors connect the FP actin cytoskeleton to the 
extracellular matrix of the GBM (Kikkawa et al., 1998, Kreidberg, 2000, Hynes, 2002). 
The main integrins that bind laminins are integrins α3β1 and α6β1, whereas integrins 
that bind to collagen are integrins α1β1 and α2β1. Deletion of integrin α3 in transgenic 
mice is associated with proteinuria and FP effacement in their first week of life (Sachs et 
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al., 2006). Moreover, deletion of integrin α3 and α5 laminin in mice leads to an inability 
to form FPs (Kreidberg et al., 1996). 
 
1.1.4.2 Development of the slit diaphragm (SD) 
 
SDs are located at the basolateral region of the podocyte FPs and prevent large 
molecular weight proteins such as albumin [MW 50kDa] from entering the urinary filtrate 
in Bowman’s capsule. SDs initiate as junctional complexes at the apical region of 
podocyte precursors within the proximal region of the S-shaped body. During podocyte 
maturation, these cell-cell junctions migrate to the basal aspect of the cell where the 
composition changes from that of a tight junction to a modified adherens junction at the 
basolateral aspects of the FPs. Numerous proteins participate in the formation of the SD, 




Nephrin (encoded by NPHS1) is one of the structural components of the SD. A member 
of the immunoglobulin superfamily, nephrin, consists of a short intracellular domain, a 
transmembrane domain and a long extracellular domain with a proximal fibronectin type 
III-like motif (Tryggvason et al., 2006, Martin and Jones, 2018). The nephrin extracellular 
domain forms the main outline of the SD by forming homo and heterodimers with itself 
and NEPH1 to maintain SD integrity (Gerke et al., 2003, Sellin et al., 2003). NEPH1 has 
shown to impact podocyte integrity; earlier work revealed that in murine models, Neph1 
deficiency resulted in proteinuria and loss of kidney function (Donoviel et al., 2001). 
Tyrosine phosphorylation of the intracellular domain of nephrin regulates its interaction 
with the adaptor proteins, NCK1 and NCK2, which interact with the actin cytoskeleton 
and regulate FP morphology (Verma et al., 2006, Qin et al., 2009). Mutations in NPHS1 
causes congenital nephrotic syndrome (CNS), characterised by proteinuria in the first 3 
months of life and progressive kidney failure (Kestila et al., 1998, Ruotsalainen et al., 
1999, Holthofer et al., 1999, Holzman et al., 1999). CNS is a heterogenous condition 
associated with mutations in a variety of genes such as NPHS2, which encodes podocin, 




Podocin (NPHS2) is a hairpin-like integral membrane 42kDa protein localised at the SD 
(Boute et al., 2000). It forms oligomers with the intracellular domains of nephrin and 
NEPH1, as well as with CD2AP (Schwarz et al., 2001, Huber et al., 2003b). Around 10-
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28% of all non-familial childhood recessive mutations of NPHS2 exhibit proteinuria and 
result in postnatal death (Roselli et al., 2002). Steroid-resistant nephrotic syndrome 
(SRNS) has been associated with the missense mutation, R138Q in NPHS2. 
Nphs2R140x/R140x transgenic mice exhibit proteinuria by postnatal day 10 and represent a 




CD2AP, an intracellular protein that interacts with the C-terminus of nephrin, forms a 
network with both nephrin and podocin to connect the actin cytoskeleton to the SD (Shih 
et al., 2001, Schwarz et al., 2001). Structurally, it consists of a coiled coil domain and 3 
Src homology 3 domains (SH3). CD2AP interacts with p85, an intermediary protein and 
prevents podocyte apoptosis through Nephrin-induced AKT signalling (Huber et al., 
2003a, Dustin et al., 1998, Welsch et al., 2001). New-born Cd2ap-/- mice develop 
proteinuria and FP effacement during their first week of life (Shih et al., 1999). 
 
Other SD proteins 
 
SD maintenance is further supported by additional proteins, including membrane-
associated guanylate kinase inverted 2 (MAGI-2), calcium/calmodulin-dependent serine 
protein kinase (CASK), α-actinin, ZO-1 (Patrakka and Tryggvason, 2007). Large 
transmembrane proteins, FAT1 and FAT2, are also necessary for SD structure (Inoue et 
al., 2001). Fat1-/- mice lack assembled FPs and SDs and suffer from proteinuria. Fat2-/- 
mice also develop proteinuria (Ciani et al., 2003). Myosin 1E (MYO1E), a protein which 
binds actin during podocyte synthesis, is required for the filtration barrier. Mutations in 
this gene in both humans and mouse knockout models cause FP effacement and 
proteinuria (Krendel et al., 2009, Chase et al., 2012). SD proteins implicated in human 
proteinuric conditions are highlighted in Table 1.1. 
 
1.2 Podocyte injury 
 
Podocyte injury plays a major role in glomerulosclerosis (GS), the scarring of the 
glomerulus (Marshall and Shankland, 2006, Liapis et al., 2013, Dimke et al., 2015). GS 
is a leading global cause of end-stage renal disease (ESRD) and accounts for 5% to 
10% of paediatric and adult ESRD. GS can recur in 30% to 50% of kidney transplants 
and therefore, represents a major economic health burden (Saran et al., 2016). Podocyte 
injury results in proteinuria (specifically albuminuria) which, when associated with 
oedema and hypoalbuminaemia, manifests as nephrotic syndrome (NS). 
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1.2.1 Nephrotic syndrome (NS) 
 
NS is a clinical entity characterised by albuminuria, oedema, hypoalbuminaemia, and 
hyperlipidaemia. It affects 1-2 per 100,000 children (Liebeskind, 2014, McKinney et al., 
2001). Classification is often based on clinical response to steroid therapy; NS can either 
be steroid-sensitive or steroid-resistant (SRNS). SRNS is more typically associated with 
GS which is a progressive kidney disease for which there are no specific treatments 
available (Tasic et al., 2015, Hostetter, 2001). Four genes (NPHS1, NPHS2, LAMB2, 
WT1) have been linked to 85% of SRNS in patients aged less than 3 months and 66% 
1-year olds (Sadowski et al., 2015). Table 1.1 outlines genes encoding podocyte proteins 
identified in human NS. 
 
Table 1.1. Genes implicated in human NS 






NPHS1 Nephrin Podocyte SD Autosomal recessive NS at birth 
or early life, congenital NS of the 
Finnish type, NPHS2 knockdown: 
FP effacement, mild proteinuria, 
narrowing of filtration slit 
(Kestila et al., 
1998, 
Bierzynska et 
al., 2014, Xu 
et al., 2014, Li 
et al., 2015)    
NPHS2 Podocin Podocyte FP Autosomal recessive NS, SRNS, 
minimal glomerular disease, 
familial FSGS 









Proteinuria, truncating mutations: 












Familial FSGS, progressive renal 




et al., 2011, 
Perico et al., 
2016) 





Familial FSGS, failed SD 
formation, proteinuria, GS 
Overexpression of TRPC6: 
podocyte injury, glomerular 
lesions 




Krall et al., 
2010) 
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SD Human diabetic kidney disease, 
global GS 
(Itoh et al., 
2014) 





Nail patella syndrome (NPS) 
Low no. glomeruli and 
glomerulosclerosis, over 
thickening of GBM & abnormal 










nephropathy, idiopathic NS, DMS 
hypercellularity, MCD 
(Barisoni et 
al., 1999, Yu 
et al., 2016) 
ACTN4 α-actinin-4 Podocyte FP, 
bundling actin 
filaments 






MYO1E Myosin IE SD & FP Proteinuria, FP effacement, 
delamination of GBM, autosomal 
recessive SRNS, FSGS 
(Bi et al., 
2013, Sanna-
Cherchi et al., 
2011, Krendel 
et al., 2009, 
Chase et al., 
2012) 




AD FSGS (Subramanian 
et al., 2016) 







FSGS (Gee et al., 
2015) 
MYH9 Myosin-9 Podocyte 
primary FP 
Severe glomerular disease, 
cytoskeletal damage & podocyte 
detachment 
(Miura et al., 
2013, Yuan et 
al., 2016) 
*MET, Mesenchymal-epithelial transition; DDS, Denys-Drash syndrome; FS, Frasier syndrome; 
MM, metanephric mesenchyme, UB, ureteric bud; FSGS, Focal segmental glomerulosclerosis; 
DMS, Diffuse mesangial sclerosis; GBM, Glomerular basement membrane; FP, Foot process; 
SD, Slit diaphragm; SRNS, Steroid-resistant nephrotic syndrome; MCD, Minimal change disease; 
AD, Autosomal dominant 
  
 Page 25 of 214 
 
1.2.2 Phenotypes of podocyte injury 
 
Histological characterisation of podocyte injury based on light microscopy and 
ultrastructural analysis by electron microscopy includes minimal change disease (MCD), 
focal segmental glomerulosclerosis (FSGS), diffuse mesangial sclerosis (DMS), and 
collapsing glomerulopathy (CG) (Waldman et al., 2007, D'Agati, 2008). 
 
1.2.2.1 Minimal change disease (MCD) 
 
MCD is a condition where NS occurs in the context of normal kidney histology as 
assessed by light microscopy. Ultrastructurally, however, FP effacement is evident by 
electron microscopy. 90% of paediatric patients are steroid responsive and are 
considered to have MCD (Braden et al., 2000, Bahiense-Oliveira et al., 2004). Several 
studies have supported an immunological basis for MCD. In particular, the efficacy of 
rituximab in steroid-dependent NS points to a central role for B-lymphocytes in mediating 
podocyte dysfunction in MCD (Vivarelli et al., 2017) 
 
1.2.2.2 Focal segmental glomerulosclerosis (FSGS) 
 
FSGS is characterised by a segmental scar within the glomerulus, occurring in a focal 
part of the kidney cortex. Around 5-10% of children and adults with FSGS progress to 
ESRD (Malaga-Dieguez et al., 2015). Other features include hyalinosis, podocyte 
hyperplasia/hypertrophy, apoptosis and capillary tuft collapse (Figure 1.7). 
 
 
Figure 1.7. Focal segmental glomerulosclerosis  
Periodic acid-Schiff (PAS)-stained kidney biopsies demonstrating (A) Normal glomerulus with 
normal thin capillary loops and tubular epithelium (Ramidi et al., 2011); (B) FSGS tip variant.  
 
Five histologic variants of FSGS have been proposed: collapsing, tip, cellular, perihilar 
and non-specific (D'Agati et al., 2004). Collapsing variant includes global mesangial 
expansion and extracapillary epithelial proliferation/hypertrophy. Tip lesions affect the 
glomerular tuft region, showing abnormal cell adhesion to the Bowman’s capsule and tip; 
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sclerosis and hypercellularity are also displayed in this phenotype. Cellular lesions are 
present as segmental endocapillary hypercellularity (Meehan et al., 2013). Peri-hilar 
variants are characterised by segmental sclerosis of the capillary loops with matrix 
expansion near the hilum (Rosenberg and Kopp, 2017). 
 
1.2.2.3 Diffuse mesangial sclerosis (DMS) 
 
DMS is characterised by global expansion of the mesangial matrix, hypertrophic capillary 
walls and podocyte hyperplasia and involving all glomeruli (Figure 1.8). DMS can be 
isolated or part of a WT1-mutation syndrome, Denys-Drash syndrome (DDS), a SRNS 
with severe proteinuria, gonadal dysgenesis with male pseudohermaphroditism 
(Kucinskas et al., 2005, Patek et al., 1999). DDS patients have a tendency to develop 
Wilm’s tumour, leading to renal failure during the first three years of life. 
 
 
Figure 1.8. Diffuse mesangial sclerosis 
Periodic acid-Schiff (PAS)-stained kidney biopsies demonstrating (A) Normal glomerulus with 
normal thin capillary loops and tubular epithelium (Ramidi et al., 2011); (B) Mesangial sclerosis 
with capillary lumen obliteration and patent Bowman’s space.  
 
1.2.3 Mechanisms of podocyte injury 
 
Several mechanisms of podocyte injury exist and include apoptosis, dedifferentiation, 
detachment, epithelial-to-mesenchymal-transition (EMT) and occasionally cell cycle re-
entry with proliferation, all of which can lead to GS (Marshall and Shankland, 2006). 
 
1.2.3.1 Podocyte apoptosis 
 
Podocyte apoptosis plays a central role in the pathogenesis of FSGS (Niranjan et al., 
2008). High doses of diphtheria toxin administered to rats expressing the diphtheria toxin 
receptor in podocytes leads to podocyte loss (Wharram et al., 2005). A 20-40% reduction 
in podocyte number results in FSGS, highlighting a crucial role for podocyte number in 
the pathogenesis of FSGS (Wharram et al., 2005). Podocytopenia has also been 
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associated with diabetic nephropathy (Meyer et al., 1999, Steffes et al., 2001). Over-
expression of TGF-β1 in podocytes results in podocyte apoptosis and FSGS, implying 
that podocyte apoptosis is mediated by TGF-β1 activation (Schiffer et al., 2001). Several 
mouse models of GS show increased expression of podocyte TGF-β1 such as CD2AP-
deficient mice as well as streptozotocin-induced (STZ) murine diabetic nephropathy 
(Schiffer et al., 2004, Niranjan et al., 2008). Podocyte apoptosis has also been observed 
in animal models of type 1 and type 2 diabetes following AngII and TGF-β1 treatment 
(Jia et al., 2008). Mouse models of diabetes show a correlation between podocyte 
apoptosis and the onset of albuminuria (Susztak et al., 2006). Increased podocyte 
apoptosis was demonstrated in ROS/NADPH oxidase induced rat models of diabetes, 
where p38-MAPK and caspase-3 were activated to stimulate podocyte apoptosis. TGF-
β1 exerts its function through p38-MAPK and caspase-3, inducing podocyte apoptosis 
(Susztak et al., 2006) (Figure 1.9). 
 
 
Figure 1.9. Signalling pathways for induction of podocyte apoptosis 
Reactive oxygen species (ROS) generated from NADHP can induce podocyte apoptosis by 
activating signalling pathways via TGF-β, including p38-MAPK and Caspase-3. Podocyte 
apoptosis is also triggered through TGF-β facilitated p21. Adapted from (Fakhruddin et al., 2017). 
 
Streptozotocin (STZ)-induced rat models of diabetes, and high glucose podocyte 
cultures with increased podocyte apoptosis, express high levels of Vegfa, Ap1 and Bcl-
2. Inhibition of Vegfa regulated Ap1 and Bcl-2 expression, ameliorating podocyte 
apoptosis (Bai et al., 2014). Collagen 4a3-deficient mouse models of Alport nephropathy 
show increased expression of tumour necrosis factor-α (TNF-α) in the podocytes and 
other glomerular cells, with podocyte apoptosis (Ryu et al., 2011). 
 
Podocyte apoptosis is a feature of adriamycin (ADR) and puromycin aminonucleoside 
(PAN) nephropathy; treatment with a selective cAMP/PKA activator reduces podocyte 
apoptosis and caspase-3 activation (Li et al., 2014). Patients with membranous 
nephropathy show reduced miR-186 with elevated levels of caspase-3 (Sha et al., 2015). 
Coactivator-associated arginine methyltransferase 1 (CARM1) degradation via 
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ubiquitination has been shown to promote podocyte apoptosis through Notch1 activation 
in diabetes, and preservation of this enzyme may prevent podocyte apoptosis (Kim et 
al., 2014). 
 
1.2.3.2 Epithelial to mesenchymal transition (EMT) 
 
EMT is a process by which epithelial cells lose their epithelial features and gain 
mesenchymal characteristics. Podocytes are visceral epithelial cells which retain 
mesenchymal features (spindle shape morphology, vimentin), therefore they may not 
necessarily undergo EMT in a diseased state unless it is extremely severe (Figure 1.10). 
Podocyte EMT results in loss of epithelial polarity and altered SD, along with a 
rearrangement in the actin cytoskeleton (Valcourt et al., 2005). A key feature of podocyte 
EMT is represented by loss of the SD and effaced FP in diseased podocytes.  
 
 
Figure 1.10. Epithelial and mesenchymal features of podocytes 
Podocytes exhibit both epithelial and mesenchymal characteristics, as highlighted above. 
Adapted from (May et al., 2014). 
 
TGF-β1 triggers podocyte EMT in human immortalised podocytes, increasing levels of 
α-smooth muscle actin (α-SMA), causing a switch of P-cadherin to N-cadherin, and 
upregulating the EMT transcription factors SNAIL and SLUG (Ghiggeri et al., 2013). 
Mouse podocytes in vitro demonstrate the same phenotypic transformations when 
exposed to TGF-β1, showing suppressed P-cadherin, Zo-1, and Nphs1 expression and 
an upregulation of Desmin, along with Collagen I and Fibronectin, which may contribute 
to GBM thickening, a distinct feature of diabetic nephropathy (Li et al., 2008, Jefferson 
et al., 2008). The mesenchymal marker, Desmin, has also been observed in podocytes 
of glomerular diseases associated with podocyte injury (Zou et al., 2006). 
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1.2.3.3 Podocyte proliferation 
 
Podocyte cell cycle re-entry has been reported in both human and murine tissue sections 
characterised by GS (Barisoni et al., 2000, Wang et al., 2004, Srivastava et al., 2003). 
Cyclins are regulatory subunits that mediate kinase activity by partnering with cyclin-
dependent kinases (CDKs). There are 20 members of the CDK family and they consist 
of a serine/threonine-specific catalytic core, allowing them to associate themselves with 
cyclins (Lim and Kaldis, 2013). Histological analysis of kidney sections of collapsing 
FSGS has revealed increased podocyte cyclin A expression (Barisoni et al., 2000, Wang 
et al., 2004). Cyclin D expression has also been observed in podocytes of FSGS biopsies 
(Srivastava et al., 2003). Upregulation of cyclin-dependent kinase inhibitors (CKI) has 
been seen in patients and in in vivo models of glomerulopathy, suggesting a role for 
podocytes to maintain cell cycle quiescence. CKI upregulation of p21 and p27 was 
observed in podocytes of Zucker diabetic fatty (ZDF) rats (Hoshi et al., 2002). Moreover, 
patients with collapsing glomerulopathy (CG), FSGS, and MCD all had altered p27 and 
p21 expression (Srivastava et al., 2003). 
 
1.2.3.4 Circulating factors associated with podocyte injury 
 
Mechanisms of podocyte injury can also be associated with circulating factors, resulting 
in specific phenotypes, including primary FSGS (Rosenberg and Kopp, 2017). Recurrent 
FSGS with FP effacement and proteinuria was demonstrated in a patient with primary 
FSGS receiving a kidney transplant, whilst another patient with ESRD receiving the 
paired kidney did not develop the same phenotype (Gallon et al., 2012). Recurrent FSGS 
has been linked to circulating factors, cardiotrophin-like cytokine factor 1 (Savin et al., 
2015), apoA1b (Lopez-Hellin et al., 2013), anti-CD40 antibody (Delville et al., 2014), and 
suPAR (serum urine-type plasminogen activator receptor) (Wei et al., 2011). 
 
1.3 Molecular regulation of podocyte differentiation 
 
Transcriptional regulation of podocyte differentiation requires a complex interplay of 
several genes (highlighted in Table 1.2). 
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Table 1.2. Genes regulating early podocyte differentiation 











DDS, FS, WAGR syndrome 
Null Wt1: MM degeneration, no 
kidneys 
Truncated zinc finger 3: DDS 
Intron 9 splice donor site 
mutation: lack of +KTS – FS 
Homozygous mice lacking – 






















Sadl et al., 
2002, Schell 







Capillary loop Arrested glomerular 
development at capillary loop 
stage 














Renal defects, no abnormal 
podocytes   
Foxc2 mutations mouse: FPs 







HES, HEY1 bHLH TF S-shape Ectopic expression in mature & 

















Osr1 knockout – lack of MM (Tomar et al., 
2014) 
*MET, Mesenchymal-epithelial transition; DDS, Denys-Drash syndrome; FS, Frasier syndrome; 
WAGR, Wilms tumour aniridia syndrome; MM, Metanephric mesenchyme; FSGS, Focal 
segmental glomerulosclerosis; DMS, Diffuse mesangial sclerosis; FP, Foot process 
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1.3.1 Wilms’ tumour-1 (WT1) 
 
WT1 was initially discovered in 1990 as a predisposition gene for Wilms’ tumour (Call et 
al., 1990, Gessler et al., 1990); a paediatric cancer affecting 1 in 10,000 children 
(Charlton and Pritchard-Jones, 2016). Around 15-20% of Wilms’ tumour-associated 
diseases have been linked to mutations in WT1 (Charlton and Pritchard-Jones, 2016). 
While WT1 classically behaves as a tumour suppressor gene, collective research has 
revealed WT1 to be active in specific types of cancer, suggesting its role as an oncogene 
(Miller-Hodges and Hohenstein, 2012, Hastie, 2017). Extensive research has revealed 
WT1’s critical role in development, homeostasis, and disease (Kreidberg et al., 1993, 
Pelletier et al., 1991, Wagner et al., 2002, Kreidberg, 2010, Parenti et al., 2015, Hastie, 
2017). Moreover, its alternative isoforms allow WT1 to participate in diverse activities. 
 
1.3.1.1 WT1 structure and isoforms  
 
WT1 spans approximately 50KB on chromosome 11p13 with 10 exons, encoding a 
transcript of about 3KB. The mammalian WT1 is composed of at least 36 isoforms, all of 
which carry four carboxy-terminal Kruppel- type (Cys2-His2) zinc fingers on their C-
terminus that bind to both RNA and DNA (Call et al., 1990, Gessler et al., 1990, Hastie, 
2017) (Figure 1.11). WT1 has numerous isoforms, however the main focus has been on 
3 different amino acids: lysine, threonine, and serine (KTS) at the end of exon 9 that may 
be included or excluded and as a consequence determine function in relation to RNA 
(+KTS) or DNA binding (-KTS and +KTS). WT1 protein usually exists at an approximately 
2:1 ratio of +KTS:-KTS in humans (Dong et al., 2015a). Mutations in +KTS and –KTS 
isoforms, resulting in an imbalanced +KTS/-KTS ratio, were identified in patients with 
Frasier syndrome; a syndrome associated with FSGS and male-to-female sex reversal, 
highlighting the importance of the KTS isoforms (Barbaux et al., 1997). 
 
The alternatively spliced exon 5, resulting in proteins with or without the central 17 amino 
acids, and the upstream CTG start codon in exon 1 have also been explored. No 
phenotypes were identified in these murine models and further research in this area is 
required to assess the function of these isoforms (Ozdemir and Hohenstein, 2014, Natoli 
et al., 2002b). Likewise, phenotypes were not observed in mice lacking WT1 extended 
isoforms, including the alternative translation start site (Miles et al., 2003). 
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Figure 1.11. Structure of WT1 and its isoforms 
(A) WT1 comprises 10 exons, which generate a 3Kb mRNA. There are at least 36 isoforms 
derived from alternative splicing, RNA editing and alternative start translation sites. Two major 
splice site forms include proteins having/or lacking 17 amino acids at exon 5, and proteins 
including or lacking the three amino acids +/-KTS between zinc fingers 3 and 4, encoded by exons 
7 to 10. (B) WT1 protein highlighting the N-terminus containing proline- and glutamine- rich 
domains involved in transcriptional regulation, self-association and RNA recognition. Zinc finger 
domains show the KTS sites at the C-terminal. Two alternative splice sites: +17aa in the trans-
regulatory domain and +/- KTS between the third and fourth zinc fingers (brown triangles).  
Adapted from (Brown and Malik, 2001). 
 
1.3.1.2 Wt1 expression during kidney development 
 
Wt1 is first detected at low levels in the undifferentiated mesenchyme of the intermediate 
mesoderm at E9 in mice, and dramatically increases in the condensed mesenchyme 
before MET (Mundlos et al., 1993). Expression levels remain high during nephrogenesis, 
becoming restricted to the proximal region of the S-shaped body after the RV morphs 
into the comma- and S-shaped bodies. Wt1 expression is sustained in the podocytes 
throughout adult life (Kreidberg et al., 1993, Armstrong et al., 1993, Guo et al., 2002, 
Hastie, 2017) (Figure 1.12). 
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Figure 1.12. WT1 expression during kidney development 
(A) At the early stages of development, WT1 is highly expressed in the condensing metanephric 
mesenchyme, along with other transcription factors. WT1 expression is increased in the epithelial 
cells and is continually expressed in the mature kidneys. (B) Stages of podocyte maturation 
highlighting WT1 presence. (C) Podocyte morphology at each stage of development. Adapted 
from (Dong et al., 2015a, Schell et al., 2014, Saxen and Sariola, 1987). 
 
WT1 is crucial for the survival and proliferation of the mesenchyme and MET by 
activating genes, including Wnt4, forming the nephron from the cap mesenchyme 
(Davies et al., 2004, Essafi et al., 2011). It is upstream of transcription factors, Pax2, 
Sal1, which are required for MM proliferation and self-renewal, along with Six2 and 
Hoxd1. Moreover, WT1 regulates Bmper, an inhibitor of BMP-pSMAD signalling that 
promotes apoptosis in the mesenchyme and activates FGF signalling by regulating 
Fgf16/20 and Gas1; this permits MM survival. Wnt signalling is also increased via Wnt9 
expression, localised beneath the ureteric tip near the MM; at this stage, the β-catenin-
LEF/TCF complex collaborates with Six2 and Wt1 to activate Fgf8 and Wnt4, inducing 
PTA formation (Dong et al., 2015a). 
 
1.3.1.3 Human WT1-associated disorders 
 
WT1 mutations result in a wide range of renal manifestations, which eventually lead to 
ESRD. The renal disorders associated with WT1 mutations include DDS, FS, WAGR 
(Wilms’ tumour, Aniridia, Genitourinary malformation and mental retardation), and 
SRNS, all of which are congenital mutations (Bielinska et al., 2017). As previously stated, 
WT1 +KTS and –KTS isoforms are expressed at a ratio of around 2:1 in healthy human 
 Page 34 of 214 
 
kidneys (Hohenstein and Hastie, 2006). Mutations of this gene in humans have been 
associated with urogenital abnormalities. FS and DDS are rare inherited diseases 
characterised by SRNS, resulting in kidney failure, gonadal tumour and male 
pseudohermaphroditism (Ezaki et al., 2015). 
 
DDS is a rapidly progressive glomerular disease with renal failure that may occur before 
the age of 1. It is caused by WT1 point mutations, typically missense mutations within 
exons 8 or 9, which encode zinc fingers 2 or 3, resulting in an abnormal WT1 protein 
(Saylam and Simon, 2003, Miller-Hodges and Hohenstein, 2012, Drash et al., 1970). It 
is characterised by DMS. Phenotypes associated with this syndrome include 
genitourinary abnormalities, specifically male pseudohermaphroditism. DDS has also 
been linked to mutations in WT1 DNA-binding domains, affecting its function as a 
transcription factor and resulting in DDS phenotypes (Little et al., 1995). Histological 
analysis of DDS kidneys reveals effaced podocytes with regions of continued 
proliferation, where there is reduced WT1 protein expression, as well as increased 
expression of PDGFA and TGF-β1 (Yang et al., 2004a). Furthermore, subsequent data 
has revealed that DDS podocytes do not fully differentiate; they continue to express 
VEGF-A, a component which induces glomerular endothelial cell proliferation and 
differentiation, and is only expressed at the S-shaped body stage. Mature podocytes 
normally express the inhibitory isoform VEGF165b during podocyte differentiation. DDS 
patient biopsies completely lack this isoform, resulting in a delay in podocyte maturation 
with expression of the early podocyte S-shaped body components, including collagen IV 
and laminin B1 (Schumacher et al., 2007). 
 
FS is characterised by male pseudohermaphroditism and FSGS, leading to NS and renal 
failure by the age of 20. It is caused by splice-site point mutations in exon 9 of WT1, 
where patients develop gonadoblastoma (Barbosa et al., 1999). FS KTS isoforms are 
imbalanced, resulting in a lower expression of the +KTS isoform and a higher expression 
of the –KTS isoform, affecting the post-transcriptional regulation of WT1 and its binding 
partners and subsequently leading to gonadal and renal abnormalities (Hammes et al., 
2001, Hastie, 2001, Larsson et al., 1995, Barbaux et al., 1997, Koziell and Grundy, 1999, 
Klamt et al., 1998) (Figure 1.11). 
 
WAGR syndrome was the first disease linked to WT1, resulting from 11p13 deletions 
and leading to the loss of WT1 and PAX6 (Fischbach et al., 2005). WAGR patients 
commonly show FSGS in their biopsies, and around 50% develop Wilms’ tumour 
(Fischbach et al., 2005, Muto et al., 2002). Patients with FSGS who do not develop 
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Wilms’ tumour do not display proteinuria or NS, suggesting that the absence of one WT1 
allele may promote FSGS (Iijima et al., 2012). 
 
1.3.1.4 Transgenic mouse models highlighting the role of Wt1 during podocyte 
development 
 
WT1-associated kidney disease has been extensively investigated in vivo and in vitro, 
highlighting WT1’s relevance during podocyte differentiation and its role in kidney 
development and disease.  
 
A model for urogenital abnormalities was developed by Kreidberg by generating mice 
carrying a targeted mutation of the Wt1 gene (Kreidberg et al., 1993). Homozygotes of 
Wt1 mutation led to embryonic lethality. Furthermore, the UB ceased to develop at day 
11 gestation due to apoptosis of the metanephric blastemal. A later study performed 
RNAi experiments in culture to repress Wt1 expression at different stages during kidney 
development; early inhibition of Wt1 mimicked the Wt1-/- mouse of Kreidberg’s team. 
When Wt1 was ablated at a later stage, nephrons were incapable of differentiating and 
instead, proliferated aberrantly (Davies et al., 2004). Moreover, a gain of function study 
performed by another group examined the significance of Wt1 during the condensed 
mesenchyme stage in early kidney development; microinjection and electroporation of 
Wt1 in null murine kidney organ cultures resulted in normal nephron growth, highlighting 
Wt1’s importance during nephrogenesis (Gao et al., 2005).  
 
More recently, Kreidberg’s team examined Wt1 and fibroblast growth factor (FGF) 
signalling in nephron progenitor cells (NPC); they concluded that Wt1 controls FGF 
signalling by triggering a downstream target of Wt1, growth arrest-specific 1 (Gas1). 
ChIP-on-chip and ChIP-qPCR analysis revealed that Wt1 binds directly to a conserved 
DNA binding motif within the Gas1 promoter. In situ hybridisation (ISH) showed reduced 
Gas1 expression following oligonucleotide morpholino (MO) inhibition of Wt1. Loss of 
Gas1 expression in vivo resulted in hypoplastic kidneys with decreased nephron number, 
highlighting the requirement of Wt1 for Gas1 expression in the kidneys and its 
significance during kidney development (Kann et al., 2015a). 
 
ChIP and high-throughput sequencing using DNA from mouse glomeruli was performed 
to identify targets of Wt1 during podocyte differentiation. Deletion of Wt1 in a podocyte-
specific Cre-inducible mouse resulted in kidney haemorrhage and death 24 hours post-
birth (Dong et al., 2015b). Functional zebrafish studies identified wt1 targets, including 
nphs2, mafb and magi2 that were necessary for podocyte development (Dong et al., 
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2015b). Moreover, Kreidberg’s team investigated podocyte development and viability by 
performing RNA and ChIP sequencing; WT1 was found to regulate the podocyte 
transcriptome through binding to enhancers and promoters of target genes. Additionally, 
a podocyte transcriptional network between Wt1, Lmx1b, Tcf21, Fox-c and Mafb was 
identified, controlling podocyte gene expression (Kann et al., 2015b). 
 
Three different Cre-inducible systems to knockout Wt1 in transgenic mice were analysed 
before and after MET: 1) Nes-Cre;Wt1co/co ; Nes encodes the intermediate filament 
protein Nestin and is a transcriptional target of Wt1, 2) Pax8+/Cre;Wt1co/co; Pax8  encodes 
the paired box gene 8, which is initially expressed at the renal vesicle stage and 
maintained until the end of nephrogenesis (Bouchard et al., 2004), 3) Cre-GFP fusion 
construct inserted into the endogenous Wnt4 locus (Wnt4-Cre;Wt1co/co) (Shan et al., 
2010); Wnt4 is expressed in epithelial progenitors in the developing kidney. The loss of 
Wt1 at each stage of kidney development resulted in disrupted kidneys and post-natal 
death within 24 hours (Berry et al., 2015). Wt1 transcriptionally activates Wnt4 to induce 
MET, leading to nephron differentiation (Davies et al., 2004, Essafi et al., 2011), and 
deletion of Wt1 prior to MET results in the formation of aberrant kidneys that resemble 
human Wilms’ tumours, emerging from WT1 mutations (Berry et al., 2015). 
 
Mosaic and somatic ablation of Wt1 with constitutive expression of Igf2 were studied in 
mice to mimic a set of human Wilms tumours. H19 and Igf2 are closely linked and are 
from a large group of imprinted genes, located on chromosome 7 (Zemel et al., 1992). 
Their monoallelic expression patterns are conserved between humans and mice. In this 
study, a truncated form of WT1 was produced following Cre-knockout of the endogenous 
gene; mice also contained an H19- allele, resulting in the upregulation of the normally 
silenced copy of the maternal Igf2 known to be a target of WT1 activity (CreERTM;Wt1-
/fH19+/-m). Ablation of Wt1 blocked kidney development, with the formation of Wilms 
tumours at E13.5 following tamoxifen induction in experimental animals, but not controls 
(CreERTM;Wt1+/fH19+/-m, Wt1+/fH19-/-m;Wt1+/fH19+/-m). At E19, mutant kidneys displayed 
complete lack of nephron development with no glomeruli in comparison to the controls 
(Hu et al., 2011). In vivo mouse studies on Wt1 during early nephrogenesis and late 
nephrogenesis are summarised below (Table 1.3). 
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Table 1.3. Early nephrogenesis in transgenic mouse models of Wt1 gene manipulation 
Mouse strain Phenotype Reference 
Wt1-/-  Bilateral renal agenesis, embryonic 
lethality  
(Kreidberg et al., 
1993) 
Wt1R362X/+  DDS: 
Abnormally large capillaries, few 
capillary loops, present but irregular 
FP shape – no adverse effect on 
kidney development (E18) 
(Natoli et al., 2002a) 
Nes-Cre;Wt1Co/Co 
 
Disturbed nephron development, 
inhibited ureteric branching, reduced 
MM condensation; Intermediate cortex: 
reduced formation of RV, comma and 
S-shaped bodies; Inner cortex: 
reduced glomerulogenesis, 
tubulogenesis (E18.5) 
(Essafi et al., 2011, 





MET stage reduced, mesenchyme 
expansion; lack of glomerulogenesis 
and tubular maturation (E18.5); 
Normal levels of condensation, 
epithelisation; lack of 
glomerulogenesis and early 
tubulogenesis (E18.5) 
(Berry et al., 2015) 
 
CreERTM;Wt1-/flH19+/m No glomeruli, no differentiation of 
condensed mesenchyme after comma-
shaped body, block in nephron 
development (E19) 
(Hu et al., 2011) 
*DDS, Denys-Drash syndrome; MM, Metanephric mesenchyme; FP, Foot process; RV, Renal 
vesicle; MET, Mesenchymal to epithelial transition 
 
Hammes et al. studied the KTS domain between zinc fingers 3 and 4 (Hammes et al., 
2001). Heterozygous mutants of the +KTS isoform (+KTS+/-) developed GS and died 3 
months after birth. Homozygous mutants of both +KTS(-/-) and –KTS(-/-) did not survive 
longer than 24 hours post-birth due to a low number of glomeruli, reduced kidney size 
and haemorrhage. Conversely, Natoli et al. showed that no phenotypes were observed 
in mice lacking the 17 amino acid domain of exon 5 (Natoli et al., 2002b). 
 
An early study generated mice with amino acid substitution S395R, within exon 9. This 
resulted in a premature termination within zinc finger 3 of the WT1 protein, where a stop 
codon was introduced at 396, Wt1tmT396 (Patek et al., 1999). The truncated protein lacked 
the KTS insertion and zinc finger 4. Heterozygous mice exhibited global sclerosis and 
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protein casts within the tubules at four months of age compared to the wildtypes (Patek 
et al., 1999). A later study generated transgenic mice that carried the mutant form of Wt1 
in podocytes, where zinc fingers 3 and 4 were deleted (R362X truncation), and the 
constructs either contained or omitted exon 5 (Ex5/or Ex5-). Mice with the mutant form 
of Wt1, lacking exon 5 at E18, demonstrated abnormally large capillaries in the glomeruli 
with irregular shaped FPs (Natoli et al., 2002a). A subsequent study developed a mouse 
strain carrying the missense mutation Wt1 R394W (Wt1+/R394W) to recapitulate the genetic 
defect seen in DDS patients (Gao et al., 2004). By four months of age, all male 
heterozygotes exhibited proteinuria and GS compared to the wildtypes (Wt1+/+). The 
podocyte-specific genes and proteins, nephrin, podocin and podocalyxin were also 
reduced in the mutants compared to the wildtypes, with increased TGFβ1 and IGF1 
expression (Gao et al., 2004). 
 
Induced FSGS was reported in transgenic mice overexpressing the micro-RNA, miR-
193a. Doxycycline induction in 2-month old mice increased the expression of the miRNA 
by ten-fold, which repressed Wt1 expression resulting in FP effacement, glomerular 
lesions and albuminuria at 10 weeks of age. Rapidly progressive FSGS and death was 
observed at 12 weeks of age (Gebeshuber et al., 2013). Next, the investigators deleted 
Wt1 to test whether this excision would result in the same FSGS phenotype as the 
increased miR-193a. A Wt1 floxed gene (flanking exons 2 and 3, resulting in a premature 
stop) was combined with a podocyte-specific doxycycline inducible transcriptional 
activator (rtTA) and an rtTA-inducible Cre (LC1) in the transgenic mice, where Wt1 
deletion was induced by doxycycline treatment (Wt1fl/fl;Nphs2rtTA;LC1). Wt1 deletion at 
12 weeks post-doxycycline led to a downregulation of its target genes, Podxl and Nphs1 
as well as other podocyte-specific genes, and an FSGS phenotype with progressive 
albuminuria similar to that caused by miR-193a overexpression in comparison to the 
controls (Wt1fl/+) (Gebeshuber et al., 2013). Thus, WT1 is a master regulator of podocyte 
differentiation and targeting miR-193a might be a potential therapeutic target in FSGS. 
 
WT1 targets have been investigated in differentiating podocytes by ChIPseq, exon 
arrays and genetic studies in mice (Lefebvre et al., 2015), where FOXC1 (Forkhead box 
C1), a transcriptional activator of WT1, was revealed to possess binding sites in a large 
section of WT1-bound regions. The SD protein, membrane-associated guanylate kinase 
(MAGI2), was also only seen when the +KTS isoform was predominant. Mice lacking this 
isoform resulted in glomerular injury (Lefebvre et al., 2015). This highlights the 
importance of WT1 KTS isoforms in podocyte differentiation and maintenance. In vivo 
mouse studies on Wt1 during late nephrogenesis are summarised below (Table 1.4). 
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Table 1.4. Late nephrogenesis in transgenic mouse models of Wt1 gene manipulation 















Severe mesangial sclerosis, proximal 
tubule dilation, protein casts, death 3 
months after birth 
 
Mildly reduced kidney size, local 
haemorrhage within kidney, less 
developed glomerular tufts, death within 





Severely reduced kidney size, reduced 
number of glomeruli, severe glomerular 
contraction, death within 24hrs after birth 
(Hammes et al., 
2001, Lefebvre et 
al., 2015) 
Wt1ex5n/ex5n No phenotypes reported in adult mice (Natoli et al., 
2002b) 
Nphs2-Cre; Wt1fl/fl Reduced glomeruli, kidney haemorrhage 
and death (24h post-birth) 
(Dong et al., 
2015b) 
Wt1+/R394W Proteinuria and GS (4 months old) (Gao et al., 2004) 
Wt1fl/fl;Nphs2rtTA;LC1 FSGS, albuminuria FP effacement (2 
weeks post-doxycycline) 
(Gebeshuber et al., 
2013) 
Wt1tmT396/+ Global sclerosis, podocyte hyperplasia, 
protein casts in dilated tubules (4 months) 
(Patek et al., 1999) 
Cre-ERTM+/-;Wt1f/f GS, protein casts in tubules, proteinuria, 
gonadal dysgenesis 
(Chau et al., 2011) 
* GS, Glomerulosclerosis; FSGS, Focal segmental glomerulosclerosis; FP, Foot process;  
 
1.3.1.5 Molecular mechanisms of WT1 action  
 
While WT1 acts as a transcriptional regulator by enabling the activation or repression of 
genes, reports have revealed an additional role as a post-transcriptional regulator where 
it can interact with RNA (Morrison et al., 2008). Most research proposes that the WT1  
-KTS isoforms are linked to DNA binding, whilst the +KTS isoforms interact with RNA 
(Toska and Roberts, 2014, Ullmark et al., 2018). That being said, DNA binding has also 
been associated with the +KTS isoforms, and –KTS isoforms can interact with RNA.  
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WT1 transcription and chromatin 
 
WT1 contains both transrepression and transactivation domains, which can repress or 
activate certain gene targets via WT1 dimerisation at the promoters (Toska and Roberts, 
2014) (Figure 1.13A). Wang et al. found that WT1 functioned as a repressor of a PDGFA 
promoter reporter when binding to elements both upstream and downstream of the 
transcription start site (TSS), whereas when it bound to only one of the sites it acted as 
an activator (Wang et al., 1993). WT1 not only self-interacts at its C-terminal region but 
has also been shown to bind via its N-terminus. 
 
 
Figure 1.13. Roles of WT1 in transcriptional and post-transcriptional regulation 
(A) WT1 can either transcriptionally activate or repress target genes depending on its binding 
partners. (B) Post-transcriptional regulation; WT1 can directly bind to mRNA 3’UTR regions, 
regulating RNA stability.  
 
Recent ChIP-ChIP and ChIP-sequencing data have revealed a number of WT1 
transcriptional target genes that interact with its –KTS isoform during kidney 
development, including Mafb, Nphs1, Nphs2 (Motamedi et al., 2014, Kann et al., 2015b, 
Lefebvre et al., 2015, Dong et al., 2015b, Hastie, 2017). Specific domains of WT1 can 
mediate transcriptional regulation or repression by interacting with transcriptional co-
regulators. One example is BASP1, which is expressed during kidney development. The 
interaction of BASP1 with the activator domain of WT1 leads to the formation of a 
repressor complex (Toska and Roberts, 2014). Additionally, WT1 has been shown to be 
sumoylated within its N-terminus, within its transcriptional repression domain. Small 
ubiquitin-related modifier-1 (SUMO-1) and ubiquitin-conjugating enzyme 9 (Ubc9) have 
been shown to interact with WT1. Phosphorylation of WT1 by protein kinase A and C 
(PKA, PKC) have also been identified in zinc fingers 2 and 3, affecting the ability of WT1 
to bind to DNA. WT1 phosphorylation can also influence the localisation pattern of WT1 
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from the nucleus to the cytoplasm, suggesting that WT1 transcriptional regulation can 
be negatively regulated by phosphorylation (Toska and Roberts, 2014). 
 
RNA binding and post-transcriptional regulation 
 
Early studies have shown that the WT1 +KTS isoform can bind to certain RNA 
sequences. Zinc fingers 1 and 4 have been associated with RNA binding. In particular, 
Igf2 has been found to bind to zinc finger 1 (Caricasole et al., 1996) as has Actinin alpha 
1 (Actn1) (Ladomery et al., 2003, Caricasole et al., 1996, Nurmemmedov et al., 2010, 
Bardeesy and Pelletier, 1998). During olfactory development, the proneural transcription 
factor, achaete-scute complex homologue-1 (Ascl1) mRNA is upregulated by WT1 +KTS 
(Wagner et al., 2005), highlighting the role of WT1 +KTS in mRNA regulation. 
Furthermore, the WT1-associated protein, WTAP and RBM4 (RNA binding motif protein 
4) interact with +KTS (Little et al., 2000, Ortega et al., 2003, Markus et al., 2006). UV 
crosslinking and sequencing in M15 kidney cells revealed a group of endogenous mRNA 
binding sites that are regulated by WT1 during kidney and cardiovascular development 
(Bharathavikru et al., 2017) (Figure 1.13B). 
 
1.3.2 Forkhead-box C1/2 (FOXC1/2)  
 
The mesenchyme/mesoderm forkhead 2-transcription factor/Forkhead box protein 2 
(MF2/FOXC2) is a member of the forkhead/winged helix family expressed in various 
embryo tissues (Kume et al., 2000). It is highly expressed during mesenchyme 
condensation and persists within podocytes at the late S-shaped body stage, and 
overlaps with FoxC1 (Kume et al., 2000). 
 
FOXC1 and FOXC2 transcription factors play critical roles in non-renal tissues, including 
the lymphatic system, eye and cardiovascular system (Motojima et al., 2017). 
 
1.3.2.1 Transgenic models of FoxC1/2 mutations 
 
Earlier studies revealed the involvement of FOXC2 in podocyte differentiation and GBM 
development (Takemoto et al., 2006). Former research in Xenopus uncovered a network 
of transcription factors involved in podocyte specification, including foxc2, wt1, hey1, 
tcf21 (pod1), lmx1b and mafb (Carroll and Vize, 1996, Ishibashi and Yasuda, 2001, 
Haldin et al., 2003, Simrick et al., 2005, Taelman et al., 2006). One particular study 
investigated the role of wt1 and foxc2 during podocyte development in Xenopus (White 
et al., 2010). Combined knockdown of wt1 and foxc2 using morpholinos resulted in 
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reduced podocyte gene expression and notch signalling during podocyte development 
was necessary for the accurate spatiotemporal arrangement of podocyte gene 
expression. Glomerular abnormalities have been associated with FoxC2 in FoxC2-null 
murine models (Motojima et al., 2016b). Reduced podocyte number was associated with 
double knockdown of either wt1a/rbpj or wt1a/foxc1a in zebrafish, when compared to 
just single knockdown of the respective genes (O'Brien et al., 2011), demonstrating the 
importance of their interactions in podocyte maintenance. Conditional knockout of Foxc2 
using Pax2-Cre mice results in kidney hypoplasia and glomerular cysts (Motojima et al., 
2016a). While reduced expression of Foxc2 leads to injured podocytes, overexpression 
of the gene results in disrupted SD protein markers, including ZO-1, as well as increased 
β-catenin activity, a pathway related to podocyte dysfunction (Datta et al., 2016). Mice 
carrying null-FoxC1 mutations, where both Foxc1 alleles (Foxc1ch/ch) lead to a truncated 
form FOXC1 protein, displayed hypoplastic kidneys with fewer glomeruli than controls 
(Komaki et al., 2013). Furthermore, increased FoxC2 expression induces EMT within the 
kidney tubular cells (Hader et al., 2010). Deletion of FoxC1/2 in adult mice leads to 
podocyte injury and glomerular sclerosis associated with increased proteinuria, 
proteinaceous casts and dilated tubules (Motojima et al., 2017). Table 1.5 summarises 
nephrogenesis in transgenic models of FoxC gene manipulation. 
 
Table 1.5. Nephrogenesis in transgenic models of FoxC gene manipulation 
Mouse model Phenotype Reference 
Foxc2-/-  Abnormal glomerular 
tufts 
(Takemoto et al., 2006) 
Foxc1ch/ch null  Ectopic budding and 
kidney hypoplasia  
(Komaki et al., 2013) 
Pax2-Cre;FoxC2flox/flox Glomerular cysts and 
kidney hypoplasia 
(Motojima et al., 2016a) 
Foxc1+/-;FoxC2+/- 
Foxc1-/-  
Duplex urinary system 
Hydronephrosis 
megaureter 











Mild tubular dilation 
Died before weaning 
(Motojima et al., 2017) 
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PAX2 (Paired Box 2) is a transcription factor member of the paired box family present in 
the mesoderm, giving rise to the metanephros. Pax2 expression is strong in the nephric 
duct before and during MM induction (Patel et al., 2014). Pax2 is expressed at the RV 
stage, and downregulated at the S-shaped body stage (Eccles, 1998, Sharma et al., 
2015, Dong et al., 2015a, Dressler and Woolf, 1999). 
 
Transgenic mice ubiquitously expressing Pax2 under the control of the cytomegalovirus 
(CMV) promoter show FP effacement and proteinuria (Dressler et al., 1993). 
Homozygous mutants of Pax2 results in a lack of UB development, eventually leading to 
renal agenesis (Patel et al., 2014). Human PAX2 mutations have also been linked to 
kidney abnormalities, including CAKUT (Congenital anomalies of the kidney and urinary 
tract) (Harshman and Brophy, 2012). Frameshift mutations of PAX2 can lead to 
papillorenal syndrome (PRS), an autosomal dominant disorder caused by a truncated 
PAX2 protein. This syndrome results in reduced nephrons and UB branching, leading to 
renal hypoplasia (Dureau et al., 2001). 
 
Both Pax2 and WT1 are believed to regulate one another following induction of the 
condensing MM. This relationship was assessed using mice carrying heterozygous 
mutations in both genes. Hypoplastic kidneys were observed in the compound 
heterozygotes compared to the wildtypes and fewer nephrons developed. Pelletier’s 
group discovered that the compound heterozygous mice, as well as Wt1-null mice, 
resulted in Pax2 phenotypes, suggesting that Wt1 and Pax2 interact with one another to 
form a molecular complex and the Wt1 alleles may be one of the modifiers of Pax2 alleles 
(Discenza et al., 2003). Earlier in vitro work showed that Pax2 contains WT1 binding 
sites and during kidney development, it may be a potential target of WT1 negative 




The basic-loop-helix-loop (bHLH) proteins are another family of transcriptional regulators 
of podocyte development. POD1 (capsulin/epicardin/Tcf21) was the first bHLH protein 
found in the developing kidney (Lu et al., 1998, Robb et al., 1998, Quaggin et al., 1999). 
POD1 is highly expressed during MM condensation and is downregulated in the renal 
vesicles during epithelialisation. It is re-expressed at the S-shaped stage within the 
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podocyte precursors. This gene is continuously expressed in fully differentiated 
podocytes in the adult kidney (Quaggin et al., 1998). Pod1-null mice have major renal 
abnormalities with arrested glomerular differentiation at the capillary loop stage and die 
at birth due to lung and cardiac defects (Quaggin et al., 1999). Selective knockout of 
Pod1 using the Cre-loxP system in mature podocytes in mice results in underdeveloped 
glomerulus with proteinuria and FSGS (Maezawa et al., 2014). 
 
1.3.3.3  Kreisler  
 
Kreisler (MAF-1, MAFB), a member of the basic domain leucine zipper family of 
transcription factors, is significantly expressed in the developing and mature podocytes 
at the capillary loop stage (Imaki et al., 2000). Mice homozygous for Maf1 mutation 
exhibit proteinuria and podocyte FP effacement with reduced Nphs1 and Nphs2 
expression (Sadl et al., 2002). Mafb has been found to be significant for podocyte 
differentiation and FP development (Moriguchi et al., 2006). An in vivo experiment 
overexpressing Mafb in podocytes of mice with diabetic nephropathy ameliorated 
albuminuria and protected podocyte number (Morito et al., 2014). Furthermore, 
transcriptomic analyses identified mafb to be a target gene of wt1 in zebrafish models 
(Dong et al., 2015b). ChIP sequencing data has also revealed strong WT1-associated 
peaks at Mafb, highlighting WT1’s importance in regulating Mafb (Lefebvre et al., 2015, 




LMX1B, a member of the LIM-homeodomain family, is limited to differentiating podocytes 
from the capillary loop stage onwards. It is important during GBM development by 
regulating the type IV collagen gene as well as regulating other genes during podocyte 
maintenance (Morello and Lee, 2002). LMX1B mutations result in nail patella syndrome 
with 30-50% of patients developing kidney disease and around 5% developing ESRD 
(Sweeney et al., 2003). Chen et al. examined Lmx1b’s function in mouse limb and 
kidney, as dorsal-ventral limb patterning is known to be controlled by this gene. They 
showed that Lmx1b is necessary for dorsal limb fate specification and targeted disruption 
of this gene leads to nail and patellae absence, with glomerular proteinuria, GBM 
thickening and convoluted proximal tubules (Chen et al., 1998). LMX1B can interact with 
other podocyte genes to maintain normal podocytes; double knockdown of lmx1b and 
foxc using morpholinos in zebrafish interrupts podocyte development and co-
overexpression of both genes induces nphs2 expression in podocytes, emphasising 
LMX1B’s importance in podocyte integrity (He et al., 2014). 
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1.4 Notch Signalling and glomerulogenesis 
 
The Notch pathway is a highly conserved cell-signalling pathway essential for the spatial 
patterning and homeostasis in embryonic and adult tissues and is important during renal 
organogenesis and podocyte differentiation (Bray, 2006, Bray, 2016). 
 
1.4.1.1 Notch components  
 
In mammals, there are four Notch receptors NOTCH 1-4 (N1-4) which are 
transmembrane type 1 proteins (Kovall and Blacklow, 2010, Kopan and Ilagan, 2009); in 
contrast only one Notch homolog exists in Drosophila (Figure 1.14). The extracellular 
domain of the Notch receptors (NECD) contains around 29-36 EGF-like tandem repeats 
(epidermal growth factor) and is glycosylated by glycosyltransferases in the endoplasmic 
reticulum (ER) post-cleavage of the N-terminus (Rana and Haltiwanger, 2011). Sugar 
modifications include O-fucosylation by Ofut1 (Pofut1 in mammals) followed by Fringe 
elongation with O-GlcNAc in the Golgi complex (Munro and Freeman, 2000, Moloney et 
al., 2000, Bruckner et al., 2000) (Figure 1.15). Receptor activation occurs in the ER by 
Rumi O-glycosylation (Poglut in mammals) (Acar et al., 2008). C-terminal to the ECD is 
a negative regulatory region (NRR) consisting of the Lin-12 Notch repeats (LNR) and HD 
(heterodimeric) motifs (Figure 1.14). The EGF domain of the receptor allows ligand 
interaction to take place between neighbouring cells (trans) and within the same cell 
(cis). 
 
Both proteolytic cleavage sites, S1 and S2, reside in the cysteine-rich LNR within the 
negative regulatory region (NRR). In the absence of the Notch ligand, the proteolytic 
cleavage site (S2) of the receptor is masked by the NRR, preventing activation of the 
Notch pathway (Weinmaster and Fischer, 2011). Cleavage of the S3 site takes place in 
the transmembrane domain (TMD) (Figure 1.14). The intracellular domain of the Notch 
receptor (NICD) consists of the RBPj association module (RAM), and nuclear localising 
sequence (NLS), which links the RAM to seven ankyrin repeats (ANK). Another NLS 
(NLS2) is located after the ANK repeats, followed by a transactivation domain (TAD) 
(Figure 1.14). The stability of the NICD is controlled by proline/glutamic acid/serine/ 
threonine-rich motifs (PEST), located at the C-terminus (Kopan and Ilagan, 2009, 
Yamamoto et al., 2014). The NICD also contains numerous post-translational 
modification sites for phosphorylation and ubiquitination (Fryer et al., 2004). The 
Drosophila NICD contains a poly-glutamine (Q)-rich domain, OPA domain, within the 
TAD (Wharton et al., 1985). 
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Figure 1.14. Notch pathway components 
Notch receptors contain Intracellular (NICD) and extracellular (NECD) domains. NICD: PEST 
(proline, glutamate, serine, threonine rich degradation motif), essential for proteasome-facilitated 
degradation of NICD; OPA (opa repeats); TAD (transactivation domain), involved in recruiting 
additional coactivators; NLS (nuclear localisation signals), ANK, seven ankyrin repeats and RAM, 
RAM domain, which interact with CSL (CBF, suppressor of Hairless, Lag-1) and Mam 
(Mastermind). NECD: NRR (Negative regulatory region) contains three LNR domains and a HD 
motif, where the S1 and S2 cleavage sites reside; TMD (transmembrane domain) is the S3 
cleavage site; EGF (epidermal growth factor) repeats, EGF 11-12 are essential for ligand binding, 
EGF 8 is associated with ligand selectivity, EGF 24-29 (Abruptex domain) negatively regulate 
signalling. The receiving cell contains Notch receptors that bind to Notch ligands. Notch ligands 
also contain EGF repeats; DSL (Delta-serrate-Lag2 domain); CR (cysteine rich region), TMD. 
Adapted from (Schwanbeck et al., 2011, Yamamoto et al., 2014). 
 
The Notch pathway consists of two families of ligands; the Delta-like family members, 
Delta-like 1, 3 and 4 (Dll1, Dll3, Dll4), and Jagged/serrate family members Jagged 1 and 
2 (Jag1, Jag2). The Notch ligands are also transmembrane type 1 proteins, which 
contain a DSL (Delta/serrate/LAG-2) motif at their N-terminus, the DOS domain (Delta 
and OSM-11) and EGF repeats (Kopan and Ilagan, 2009, D'Souza et al., 2010) (Figure 
1.14). Both ligands contain a PDZ (PSD-95/Dlg/ZO-1) binding domain at their C-
terminus, apart from Jag2 and Dll3 (Adam et al., 2013). Jagged ligands contain more 
EGF-like repeats than Delta-like ligands, and a cysteine-rich domain near the 
transmembrane domain (Sjoqvist and Andersson, 2017). 
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1.4.2 Notch signalling activation 
 
The Notch pathway is activated by inter-cellular cross-talk between a signal-sending cell 
and a signal-receiving cell, resulting from initiation of signalling in the Golgi Apparatus 
with eventual translation of Notch to the nucleus (Figure 1.15). The EGF domains of the 
NECD receptors undergo glycosylation by fucosyltransferases, including POFUT1 
(protein o-fucosyltransferase), subsequently followed by Fringe modification in the Golgi 
complex, where specific Fringes (Manic Fringe [Mfng], Lunatic Fringe [Lfng] and Radical 
Fringe [Rfng]) elongate the o-fucose chains, modifying the Notch receptors and allowing 
them to bind their ligands. 
 
 
Figure 1.15. The Notch pathway 
(1) Notch signalling is initiated in the Golgi apparatus where the receptor undergoes proteolytic 
cleavage at its S1 site, facilitated by furin proteases. (2) It is then transported to the cell surface 
membrane, where its extracellular domain binds with Notch ligands from the adjacent cell. (3) The 
Notch receptor is then proteolytically cleaved by ADAM metalloproteases, leading to endocytosis 
of the ECD into the ligand-expressing cell, followed by the release of the NICD with a hitched 
membrane. (4) NICD undergoes cleavage by gamma-secretase, leading to an active NICD. (5) 
Activated NICD translocates to the nucleus, interacting with CSL, forming a complex with MAML, 
RBPJ. (6) The active complex releases canonical Notch targets HES and HEY. Lack of NICD 
binding leads to CSL interacting with co-repressor. Adapted from (Suresh and Irvine, 2015). 
 
The NECD undergoes its first proteolytic cleavage (S1) in the Golgi complex, where the 
LNR is cleaved by furin-like proteases and a heterodimeric receptor with the NECD is 
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formed in the HD (Lake et al., 2009, Gordon et al., 2009) (Figure 1.15). The Notch ligands 
are translated in the ER and travel to the cell surface through the Golgi complex. 
Following Fringe modification, the Notch receptor transfers to the cell surface where it 
interacts with the ligand, and trans-endocytosis is activated into the signal-sending cell. 
Trans-endocytosis is triggered by E3 ubiquitin ligases, Neuralized (Neu), recognising 
delta-ligands or Mindbomb (Mib), recognising jagged ligands, which are necessary for 
ligand endocytosis (Yamamoto et al., 2014). This process creates a conformational 
change in the Notch receptor and reveals its S2 cleavage site, normally masked by NRR, 
which is cleaved by ADAM proteases. This allows Notch extracellular truncation (NEXT) 
to enter the active site where S3, within the TMD, is sequentially cleaved by γ-secretase 
(Jorissen and De Strooper, 2010). This cleavage releases the NICD, which translocates 
into the nucleus and forms a complex with the DNA-binding transcription factor CSL 
(RBP-jk in mammals, Su(H) in Drosophila) and coactivator mastermind (MAML1, 
MAML2, MAML3 in mammals, Mam in Drosophila) through its domains, RAM and ANK  
(Borggrefe and Liefke, 2012, Tanigaki and Honjo, 2010). Downstream canonical 
transcription factors, including Hairy/enhancer of split (HES and HEY) genes are then 
activated (Kopan and Ilagan, 2009, Liu et al., 2013, van Tetering and Vooijs, 2011, 
Yamamoto et al., 2014) (Figure 1.15). NICD absence results in the binding of CSL to its 
analogous sequence, leading to a recruitment of transcription corepressors, including 
Hairless, CtBP (C-terminal Binding Protein), and Groucho. These corepressors 
negatively regulate Notch target gene expression. 
 
Notch receptors are initially cleaved during exocytosis at site 1 (S1), regulating signal 
activity (Figure 1.15). Ubiquitination of the ligand takes place in the ICD and is controlled 
by E3 ubiquitin ligases including Mindbomb and Neuralized (Kopan and Ilagan, 2009). 
Lateral patterning during Notch signalling depends on positive (lateral induction) or 
negative (lateral inhibition) feedback. 
 
1.4.2.1 Notch glycosylation  
 
Notch modification by glycosyltransferases takes place in the Golgi complex where 
glycans are added to the EGF domains of NECD. The addition of glycans can either 
reduce or potentiate Ligand-mediated Notch signalling, depending on which EGF domain 
is being modified (Taylor et al., 2014). Table 1.6 highlights the glycosyltransferases that 
modify the ECD of Notch1. 
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Function EGF modification 
Ofut1/Pofut1 O-fucosyltransferase/ 
Chaperon activity 














O-xylosyltransferase Adds first xylose to xylose on O-glucose 





Notch modification involves addition of O-fucose or O-glucose to the EGF repeats within 
the extracellular domain of the receptor. Enzymes involved in this process include 
POFUT1 (Protein O-Fucosyltransferase 1), which are located and function within the 
Golgi complex (Figure 1.15, Table 1.6). O-glucose addition is carried out by the enzyme 
O-glucosyltransferase, POGLUT, encoded by Rumi, and finally, O-GlcNAc, a type of O-
glycosylation occurring on hydroxyl amino acids of the EGF repeat, is added by Fringe. 
(Rana and Haltiwanger, 2011). O-fucosylation can occur on EGF12 as well as other EGF 
repeats, which may play a vital role in Notch activation (Ge and Stanley, 2008). Amongst 
the 36 EGF repeats of the Notch receptors, 20 of them have O-fucosylation sites, thus 
Fringe modifications can take place in any of these residues. 
 
The Fringe proteins (β3-N-acetylglucosaminyltransferases) 
 
Fringes are β3-N-acetylglucosaminyltransferases that transfer a GlcNAc to O-fucose 
residues in the Golgi complex, and play a crucial role in activating the Notch pathway 
through specific ligand binding (Okajima et al., 2003, Moloney et al., 2000, Taylor et al., 
2014, Bruckner et al., 2000). There are three Fringe proteins that mediate Notch 
signalling; Lunatic (LFNG), Manic (MFNG) and Radical Fringe (RFNG), all of which 
elongate the O-fucose chain of the Notch transmembranes (Table 1.6, Table 1.7). 
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Table 1.7. Fringe-mediated glycosylation of Notch 1 
Fringe 
proteins 
Notch 1 EGF domains 
EGF6 EGF8 EGF12 EGF26 EGF36 
Lfng - Jag1 + Dll1 +Dll1, +Jag1 -Dll1, -Jag1 - Jag1 
Mfng - Jag1 + Dll1 + Dll1, 
+Jag1 




+ Dll1 + Dll1 +Dll1, +Jag1 NM 
(+Jag1, + 
Dll1) 
*NM, not modified by Fringe; +/-, ligand binds/ligand does not bind. Adapted from (Kakuda and 
Haltiwanger, 2017) 
 
1.4.3 Ligand-independent Notch signalling 
 
1.4.3.1 Deltex-induced Notch activation  
 
Notch ligand-independent signalling is activated through the binding of Notch ICD and 
Deltex (Dx), promoting Notch endocytosis (Baron, 2012) (Figure 1.16). Notch 
endocytosis can be blocked by an early endosome component, RAB5, downregulating 
Notch signalling. Dx-induced Notch activation requires assistance of particular 
components to allow Notch trafficking into the late endosome. These components are 
the Adaptor-protein-3 (AP-3) complex and the HOPS (Homotypic fusion and vacuole 
protein sorting); AP-3 transfer NICD to the late endosomal and lysosomal vesicle 
membranes (Peden et al., 2004), HOPS is involved in late endosome maturation and 
fusion to the lysosome (Rink et al., 2005). With the help of these complexes, Notch is 
co-expressed with a constitutively active form of RAB7, allowing Notch to relocate to the 
late endosomes and upregulating Notch activity (Wilkin et al., 2008, Morohashi and 
Tomita, 2013, Baron, 2012). 
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Figure 1.16. Ligand-independent Notch activation 
The Notch pathway can be triggered through ligand-receptor binding (left) or ligand-independent 
activation (right). Ligand-independent activation of Notch involves the binding of Deltex (Dx) with 
NICD, inducing endocytosis of NICD from the early endosome (RAB5) to the late endosome 
(RAB7), promoted by HOPS and AP-3, regulating endosome maturity. The interaction of Dx with 
Su(Dx), Kurtz (Krz), and Shrub localises Notch into internal vesicles of the multivesicular bodies, 
downregulating Notch activity. Notch activity can also be triggered by S3 cleavage by presenilin 
post-NECD removal, where Notch is sorted to the late endosome, further requiring Rab7 and 
HOPs-fusion to the lysosome. During late endosomal maturation, ESCRT complexes are required 
to transfer Notch into multivesicular bodies, downregulating Notch signalling. 
 
1.4.3.2 Notch trafficking destinations associated with up or downregulation of signalling 
 
When Notch is no longer required for cell-to-cell signalling, it is marked for degradation. 
Coexpression of Dx with the suppressor of Deltex (Su(dx)) relocalises Notch into the 
multivesicular body and results in a downregulation of Notch activity (Wilkin et al., 2008). 
Without Su(dx), Dx induces Notch endocytosis and allows it to remain at the periphery 
of the late endosome, preventing it from relocalising to the multivesicular bodies (MVB) 
(Wilkin et al., 2008). Kurtz (Kz) is another protein that downregulates Notch activity 
through its co-expression with Dx. This stimulates receptor poly-ubiquitination of Notch 
and decreases the activity of the ESCRTIII (endosomal sorting complex required for 
transport) complex named Shrub, resulting in Notch downregulation (Mukherjee et al., 
2005). Polyubiquitinated proteins are recognised by the ESCRT complexes, which are 
known to regulate numerous membrane-bound receptors (Palmer and Deng, 2015). The 
distinct ESCRT complexes function in a serial manner to sort Notch into intraluminal 
vesicles (ILVs) of the MVB. Here, the MVB lumen cargo is transported to the lysosome 
lumen, where it becomes degraded (Palmer and Deng, 2015, Hori et al., 2012). 
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1.4.4 Expression of Notch pathway components during kidney development 
 
Notch plays a crucial role in podocyte cell fate induction and is involved in the initial 
patterning of the nephron, determining proximal versus distal fates in both mouse and 
Xenopus (White et al., 2010, Hartwig et al., 2010). 
 
Notch pathway components including NOTCH1-4, HES1 and HEY1 are expressed in 
podocyte progenitors at the S-shaped body stage. All components are no longer 
detected in terminally-differentiated podocytes (McCright et al., 2001) (Figure 1.17). 
Notch homologues and ligands involved in podocyte differentiation are highlighted in 
Table 1.8. 
 
Figure 1.17. Notch expression during podocyte differentiation 
At the S-shaped body of glomerulogenesis, Notch components Notch1 (N1), Notch2 (N2), Hes1, 
Hey1 are expressed. At the capillary loop stage of the differentiating podocytes, N1 and HES1 
become downregulated, while N2 and Hey1 expression remains. When the podocytes are 
terminally differentiated, all Notch components are downregulated. Adapted from (Aoife Waters, 
2009). 
 
During glomerulogenesis, numerous Notch components are expressed, including 
NOTCH1, NOTCH2 and the Notch ligands, DLL1 and JAG1. HES1 and HEY1 are 
expressed in the proximal domain of the S-shaped body and become increasingly 
reduced during terminal podocyte differentiation. NOTCH3 is mainly present in the major 
kidney blood vessels and glomerular tuft, whilst NOTCH4 is found in the vascular 
endothelia. JAG1 is seen in the proximal part of the S-shaped body along with DLL1, 
which is usually restricted to the middle segment (Table 1.8). Notch2 mRNA has also 
been detected in the comma-shaped bodies and tubules (McCright et al., 2001) and 
earlier work revealed that Notch2 was essential for proximal tubule fate during 
nephrogenesis (Cheng et al., 2007). 
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Table 1.8. Expression of the Notch components during glomerulogenesis 
Notch 
component 






Notch 1 Middle + + - 
Notch 2 Proximal + - - 
Notch 3 Proximal - + + 
Notch 4 - - + - 
Jag1 Middle - +  + 
Jag2 - - + - 
Dll1 Middle - + - 
Dll3 - - - - 
Dll4 - - + - 
Hes 1 Middle + + - 
Hes 5 Middle - - - 
Hes 6 - - - - 
Hey 1 Middle + + - 
Hey 2 - - - - 
HeyL Middle - + - 
Lfng Middle - - - 
*Adapted from (Leimeister et al., 2003, Piscione et al., 2004, Chen and Al-Awqati, 2005)  
 
1.4.5 The role of Notch in kidney development 
 
1.4.5.1 Transgenic mouse models of Notch in kidney development and disease 
 
Numerous studies have investigated the role of the Notch pathway in mouse models 
during early (summarised in Table 1.9) and late nephrogenesis (summarised in Table 
1.10). 
 
Cheng et al., demonstrated the significance of Notch expression in the comma- and S-
shaped bodies (Cheng et al., 2003) by blocking the Notch pathway with a  γ-secretase 
inhibitor; UB branching, renal epithelial structures, glomerular podocytes and proximal 
tubules were reduced. Likewise, targeted deletion of the EGF repeat 14 in Notch2 
homozygotes (Notch2del1/Notch2del1) from the MM stage resulted in hypoplastic kidneys 
with no comma- nor S-shaped bodies and lack of mature glomeruli at E16.5 compared 
to wildtype glomeruli (McCright et al., 2001). Subsequent research revealed that 
NOTCH1 and NOTCH2 (N1 and N2) displayed differential expression patterns in the 
developing kidney; NOTCH1 was mainly expressed in the endothelial cells whilst 
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NOTCH2 was largely expressed in the MM, UB and vascular smooth muscle cells (Liu 
et al., 2013). By switching the NICD genomic sequences, new mice were generated 
carrying the genes N12 (N1 locus carrying N2ICD) and N21 (N2 locus carrying N1ICD), 
where they discovered that the ICDs were interchangeable and their ECDs were more 
responsible for the abundance of NOTCH2 during nephrogenesis. NOTCH2 binding 
affinity was higher than NOTCH1 at the cell surface and NOTCH2 ECD produced more 
NICD than NOTCH1 ECD. Heterozygous mice N1+/-;N221/- and homozygous N221/21 
carrying the N2 locus and lacking the N2ICD, still developed nephrons that were 
functional, however, Pax3-Cre;N2f/f;N112/12 mice lacking the N2 locus altogether did not 
develop nephrons and died within 24 hours of birth, suggesting a role for the ECD’s 
rather than ICDs during kidney development (Liu et al., 2013). Notch1 and 2 cleavage 
were further assessed using a Cre reporter mouse line (N1;CreLo and N2;CreLo), where 
the release of Cre depended on the release of the Notch ECD. Epithelial cells in the S-
shaped bodies and RV were detected in N2;CreLo;RosaCAG-EYFP mice, but not seen in 
N1;CreLo;RosaCAG-EYFP mice, indicating that Notch2 ECD is released more efficiently than 
Notch1 in developing nephrons. 
 
Additionally, Tomino’s team investigated the role of NOTCH2 during nephrogenesis in 
ADR-treated mice, representing models of NS and GS. NOTCH2 agonistic monoclonal 
antibody (mAB), NOTCH1 agonistic mAB and JAG1 antagonistic mAB were 
administered independently in mice post-ADR-induction. Proteinuria and GS were both 
improved following Notch2 activation by the mAB but no improvement was seen using 
the NOTCH1 agonistic mAB or JAG1 antagonistic mAB. Likewise, when NOTCH2 
activation was decreased in vitro, apoptosis was increased in the podocytes (Tanaka et 
al., 2014). Similarly, an increase in Notch2 activation has been linked with enhanced 
activation of the transcription factor Mafb (essential for podocyte differentiation), which 
has been shown to ameliorate albuminuria and phenotypes associated with diabetic 
diseases (Morito et al., 2014). NOTCH3 has also been detected in podocyte nuclei of 
patients with FSGS or lupus nephritis (Lasagni et al., 2010). Mice injected with 
nephrotoxic sheep serum (NTS) develop a rapid progressive glomerulonephritis (RPGN) 
with increased expression of Notch3 and its canonical targets. NTS-induced mice lacking 
Notch3 (Notch3-/-) resulted in reduced renal inflammation, proteinuria and uremia 
compared to the NTS/Wildtype mice (El Machhour et al., 2015). 
 
Presenilins (PSEN1 and PSEN2) are transmembrane proteins that are catalytic 
components of γ-secretase, which proteolytically cleave the Notch receptors to regulate 
Notch signalling. Psen1-deletion in mice leads to pre- or perinatal death, with somite 
segmentation defects associated with Notch1 (Wong et al., 1997). Mice with a double 
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knockout of Psen1 and Psen2 die at E9.5, with absence of somite patterning, similar to 
the Notch1 loss of function model and Notch1 and Notch4 double knockout mouse 
phenotypes (Conlon et al., 1995, Donoviel et al., 1999, Herreman et al., 1999, Krebs et 
al., 2000). Double knockout of Psen1 and Psen2 with a human PSEN1 transgene 
introduced into mice (Psen1-/-;Psen2-/-;PSEN1) supported the survival of the null 
embryos up until the perinatal stage, however, the mutant embryos were slightly smaller 
in size. Moreover, no S- or comma-shaped bodies were observed in E13.5 mutant 
kidneys compared to their littermate controls, suggesting that presenilins may play a role 
in the progression of pretubular aggregates towards the S- and comma-shaped bodies. 
By P0, kidneys lacked glomeruli and mice died within 24 hours (Wang et al., 2003). Notch 
signalling is also activated by E3 ubiquitin ligases. Mindbomb is an E3 ubiquitin ligase 
known to promote endocytosis of the Notch ligands during Notch signalling. Inactivation 
of the Mindbomb gene (Mib1) was induced specifically in the renal collecting duct by 
crossing Hoxb7-Cre mice, where Cre recombinase was expressed only in the UB, and 
exons 2 and 3 of Mib1 were floxed (Hoxb7-Cre;Mibf/f). P17 mice showed disrupted Notch 
activation with unilateral or bilateral hydronephrosis that had become more evident at 
P30 (Jeong et al., 2009). 
 
A former study analysed Notch1 and Notch2 function during nephron development and 
showed that Notch2 was more essential than Notch1 for proximal tubule fate (Cheng et 
al., 2007). Cre-mediated knockout of Notch2 in the kidney mesenchyme using a Pax3-
Cre mouse line was used to study the formation of proximal tubules (Pax3-
cretg/+;Notch2f/f). The mutant mice died 48 hours after birth, with smaller kidneys 
compared to the control heterozygote littermates (Pax3-cretg/+;Notch2f/+). Haemorrhage 
was detected in the interstitial spaces of the mutant kidneys, as well as a collapsed renal 
pelvis and flattened papilla. Furthermore, the Notch2-deficient kidneys formed distal 
tubules without developing podocytes or proximal tubules. To examine whether Notch2 
was adequate for nephron segmentation, without Notch1, a mouse model to delete 
Notch1 was generated, using a Pax2-cre;Notchf/∆1 line (where ∆1 represents a null allele). 
Notch1-deficient mice contained normally developed proximal tubules, suggesting that 
Notch1 is not required for proximal patterning of the nephron. Furthermore, Rbpj 
knockouts (Pax2-cre;Rbpjf/f) lacked glomeruli and proximal patterning, mimicking the 
Notch2-deficient mice. Constitutive expression of Notch1 ICD in undifferentiated nephron 
progenitors using Six2GFPcre line, at the cap stage before RV formation 
(RosaNotch/+;Six2-GFP:Cretg/+), was used to test whether Notch1 was able to compensate 
for the loss of Notch2 in the kidneys. Although proximal tubules developed, mice at E17.5 
displayed severely hypoplastic kidneys, with reduced UB branching and repressed distal 
tubule formation (Cheng et al., 2007). Subsequent research was performed on models 
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of DKD to identify the roles of Notch1 and Notch2 during the development of diabetic 
nephropathy (Sweetwyne et al., 2015). Conditional deletion of Notch1 in podocytes of 
NPHS2cre;Notch1fl/f mice protected the kidneys from streptozotocin-induced DKD with 
reduced podocyte dedifferentiation, whereas controls only carrying the Notch1 floxed 
gene (Notch1fl/f) and Notch2 knockout did not rescue DKD (NPHS2cre;Notch2fl/f), 
suggesting a distinctive role for Notch1 in podocytes during DKD progression. This was 
also supported by in vitro deletion of Notch1, resulting in reduced podocyte apoptosis 
and dedifferentiation. Notch1 deletion led to an increase in Notch2 expression, 
highlighting an interaction between both receptors (Sweetwyne et al., 2015). 
 
Recent research reported that the Notch pathway is not only important for proximal 
tubule formation but necessary for proximal-distal segmentation of the nephron (Chung 
et al., 2017). Chung et al. carefully examined the Notch pathway during the late stages 
of nephrogenesis by deleting both exon 1 of Notch1 (Notch1c/c) and exon 3 of Notch2 
(Notch2c/c) using a Wnt4GFPcre-activated Rosa EYFP reporter. The loss of function 
(LOF) experiment revealed a reduction in nephron markers, including the podocyte 
marker, Podocin, and proximal tubule marker, SLC34A1, and all nephron segments 
failed to develop. Although loss of Notch signalling still allowed epithelial cell transition, 
S-shaped bodies were not able to form compared to the controls. Transcription factors, 
LHX1 and HNF1B, both important for correct nephron segmentation, were expressed in 
lower amounts in the LOF mutant cells compared to the controls. A gain of function 
(GOF) experiment was subsequently carried out using the Six2GFPcre-activated Rosa 
EYFP/b-gal where NICD1 was constitutively activated. Following up on this study, Park’s 
team (Chung et al., 2017) used the same reporter line to see whether the nephron 
progenitors would only convert to proximal tubules and no other nephron segment. GOF 
Notch activated SIX2 progenitor cells not only developed into proximal cells, but a 
heterogeneous population of cells, including podocyte marker positive cells (WT1+ and 
MAFB+) were observed. Lhx1 and Hnf1b were ectopically expressed following GOF 
Notch expression, highlighting the importance of Notch signalling for the differentiation 
of nephron progenitors. To conclude, Notch is not only important for proximal tubule 
formation, but is required for the segmentation of the nephron. 
 
Hairy/enhancer of split (HES) play a significant role during early nephrogenesis; they are 
expressed in UB tips, condensed mesenchyme, and the comma- and S-shaped bodies. 
Haematoxylin/PAS-stained kidneys of Hes1 and Hes5 mutant mice (Hes1-/-, Hes5-/-, 
Hes1-/-;Hes5+/-, Hes5-/-;Hes1+/-, Hes5+/-;Hes1+/-) at E15-E17.5 showed no morphological 
difference in the kidneys compared to the wildtype mice. LTA-stained proximal tubules 
and E-cadherin-stained distal tubules/collecting ducts in all the mutants were similar to 
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the wildtypes. Double knockouts (Hes1-/-;Hes5-/-) were not analysed as they did not 
survive past E11.5, i.e. before nephron formation (Chen and Al-Awqati, 2005). 
 
Table 1.9. Early nephrogenesis in transgenic mouse models of Notch gene manipulation  
Mouse model Phenotype  Reference 
Notch2del1/Notch2del1  - UB branching with formation of 
metanephric vesicles (E13.5) 
- Arrested glomerular differentiation, 
absent capillary tuft and disorganised 
clumped cells, capillary tuft replaced by 
capillary aneurysm structure within 





- Normal induction of UB and condensed 
mesenchyme (E12.5) 
- S- and comma-shaped bodies absent, 
only PTA/RV present (E13.5) 
- Absent mature glomeruli (E15.5-P0). 
Death within 2hrs of birth 




Hes1-/-, Hes5-/-, Hes1+/-;Hes+/-  
No obvious morphological difference; 









- No impact on proximal fates; 
histologically normal (E12.5) 
- Failure to produce proximal tubules, 
death (E13.5) 
- Hypoplastic kidneys, reduced UB 
branching  







- Normal RV, SSB, endothelial cells 
(E17.5) 
- Normal RV and SSB development 
(E17.5) 
- Reduced RV and SSB cell expression 
(E17.5) 
(Liu et al., 
2013) 
R26EYFP/+;N1c/c;N2c/c;Wnt4Cre  Failed nephron segment formation, both 
proximal and distal, failed S-shaped 
body formation (E16.5)  
(Chung et al., 
2017, Yang et 
al., 2004b, 
McCright et al., 
2006) 
* UB, Ureteric bud; PTA, Pretubular aggregate; RV, Renal vesicle; SSB, S-shaped body 
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Table 1.10. Late nephrogenesis in transgenic mouse models of Notch gene manipulation 




- Perinatal death, hypoplastic kidneys, 
capillary aneurysms (P0) 
- Hypoplastic kidneys, reduced number of 
glomeruli, absent capillary tufts, capillary 
aneurysms (P6) 
(McCright et al., 
2001) 
Pax3-cretg/+;Notch2f/f Glomeruli and proximal tubules lost. Distal 
tubules lacking podocytes, spotty 
haemorrhage in interstitial space, collapsed 
renal pelvis, flattened papilla (P2) 
(Cheng et al., 
2007) 
NPHS2-rtTA; tetO-ICN1 Podocyte apoptosis, FSGS, proteinuria, 
advanced stage of tubular dilation (4weeks 
old) 




DMS, podocyte proliferation, FP 
effacement, reduced podocyte gene and 
protein expression (P0-P42) 
(Waters et al., 
2008) 
Hoxb7-Cre;Mibf/f Unilateral and bilateral hydronephrosis, 
distal renal tubular defects (P17) 
(Jeong et al., 
2009) 
Pax8-rtTA;tetO-ICN1 Sever tubule degeneration, dilation, 
interstitial fibrosis (10 weeks old) 
(Bielesz et al., 
2010) 
N1+/-;N221/- & N221/21 
Pax3-Cre;N2f/f;N112/12 
- Normal nephron formation (P0) 
- No nephron development, death within 
24hrs of birth 
(Liu et al., 2013) 
Notch3-/- NTS-induced 
nephropathy 
Significant decrease in proteinuria and 
uremia, decreased crescentic glomeruli and 
fibrin deposits, reduced renal inflammation 






-N1 reduction leads to podocyte apoptosis 
and dedifferentiation reduced, mesangial 
expansion ameliorated (20 weeks old) 
- Proteinuria and increased mesangial 




* FSGS, Focal segmental glomerulosclerosis; DMS, Diffuse mesangial sclerosis; FP, Foot 
process; NTS, nephrotoxic sheep serum; STZ, streptozotocin 
 
Overexpression of Notch activity is associated with renal disorders 
 
Ectopically activating Notch in developing and terminally differentiated podocytes in 
murine models can lead to proteinuria and GS (Niranjan et al., 2008, Waters et al., 2008). 
Tubulointerstitial fibrosis has been demonstrated in Pax8rtTA;tetOICN1 doxycycline 
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induced mice, where NOTCH1 ICD was overexpressed in mature tubular epithelial cells. 
Histological analysis revealed severe tubular dilation and degeneration with interstitial 
fibrosis, similar to that of patient TIF phenotypes (Bielesz et al., 2010). Genetic and 
pharmacological inhibition of the Notch pathway has been tested in several models of 
kidney disease (summarised in Table 1.11). 
 
Pharmacological inhibition of the Notch pathway using a γ-secretase inhibitor in PAN-
induced NS rats prevents podocyte apoptosis and albuminuria (Niranjan et al., 2008). 
Additional research however, revealed that γ-secretase inhibition exacerbated GS in 
ADR-induced FSGS mice (Lasagni et al., 2010) instead of ameliorating the disease. 
Niranjan et al. also deleted the canonical Notch target, Rbpj in DN mice and revealed a 
reduction in podocyte injury with less proteinuria (Niranjan et al., 2008). 
 
Immunohistochemistry of human kidney biopsies with proteinuric nephropathy show 
expression of NOTCH1, NOTCH2 and JAG1 expression in the podocytes (Murea et al., 
2010). Patients with HIVAN show an increase in NOTCH1 and NOTCH4 in their kidney, 
and γ-secretase inhibition of this pathway ameliorates kidney injury and hinders podocyte 
proliferation in a Tg26 mouse model of HIVAN (Sharma et al., 2013). Xiao et al. used γ-
secretase inhibition with Dibenzazepine (DBZ) in unilateral ureteral obstructed (UUO) 
C57/Bl6 mice, where upregulation of Notch1, 3, 4, Nicd and the downstream targets 
Hes1 and HeyL were observed (Xiao et al., 2014). DBZ treatment post-UUO significantly 
reduced Notch expression, ameliorated renal fibrosis and inhibited the TGF-β pathway. 
A more recent study conditionally-deleted podocyte-specific Notch1 in mice with DKD 
induced by uninephrectomy and STZ injection. Notch1 deletion protected the mice from 
DKD. Podocyte dedifferentiation was prevented by maintaining Nphs1, as well as 
reducing levels of snai1 observed post-TGFβ1 treatment. Notch2-deleted mice did not 
show improved podocyte dedifferentiation nor apoptosis; on the contrary, Notch2 
deletion enhanced podocyte apoptosis. These results revealed that Notch1 plays a non-
redundant role in podocytes during DKD progression (Sweetwyne et al., 2015). Likewise, 
constitutive activation of Notch1 in the podocytes resulted in albuminuria and GS 
(Niranjan et al., 2008). 
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Table 1.11. Inhibition of Notch signalling in murine glomerular disease 






- Reduced albuminuria, 
mild mesangial expansion, 
reduced diabetic kidney 
injury 
- Reduced albuminuria, 
effaced FPs rescued, 
reduced GS 
(Niranjan et al., 2008) 
GSIXX-treated TG mice 
 
- Improved glomerular 
lesions, reduced scarred 




(Sharma et al., 2013) 
Nphs1-Cre/ROSA26-
loxP/NEP25 (cFSGS)  
DBZ-treated  
- Urinary casts in cortex, 
tubulointerstitial damage, 
increased histological 
damage- worse than 
vehicle 
(Ueno et al., 2013) 
DBZ treatment on UUO-
induced C57BL6  
- Collagen deposition 
decreased in kidney 
tissues; renal fibrosis 
prevented 
(Xiao et al., 2014) 
DBZ treatment on FA- 
induced TIF  
DBZ treatment on UUO- 
induced TIF  
PEPCKcr;Rbpjfl/fl genetic 
deletion in FA-induced  
- Reduced tubular 
dilatation and TIF  
- Less severe fibrosis, 
attenuated TIF 
- Reduced TIF 
(Bielesz et al., 2010) 
 
ADR- induced nephropathy  
J1 antagonistic mAb and N1, 
N2 agonistic mAb 
- Reduced proteinuria, 
glomerulosclerosis, and 
podocyte apoptosis 
(Tanaka et al., 2014) 
* FP, Foot process; GS, Glomerulosclerosis; TIF, Tubulointerstitial fibrosis; FA, Folic acid; ADR, 
Adriamycin; PAN, Puromycin aminonucleoside; STZ, Streptozotocin; DBZ, Dibenzazepine; GSI, 
γ-secretase inhibitor; UUO, Unilateral ureteral obstruction 
 
Morrissey et al. showed an upregulation of Jag1/Notch1 in CKD and fibrosis through 
early gene expression profiling in mice (Morrissey et al., 2002). Folic Acid (FA) 
administration into mice causes acute renal failure and tubulointerstitial fibrosis (Bielesz 
et al., 2010). Jag1 and Notch1 transcripts were upregulated in FA-treated mice. Notch 
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target, HeyL, was reduced following  γ-secretase inhibition using DBZ. To validate the 
effect of DBZ, another tubulointerstitial model was tested UUO, resulting in increased 
Notch pathway transcript levels. DBZ again reduced Notch target expression and 
tubulointerstitial fibrosis. They followed this up by looking at tubular epithelial cell (TEC)-
specific Rbpj deletion, where floxed Rbpj mice were crossed with PEPCK Cre mice in 
order to knockout Rbpj in TECs (PEPCKcr;Rbpjfl/fl). After FA treatment, tubulointerstitial 
fibrosis was ameliorated in Rbpj knockout mice compared to FA-treated wildtype controls 
(Bielesz et al., 2010). Further research discovered that NOTCH1 expression was 
amplified in hyperplastic parietal epithelial cells (PECs) of human collapsing FSGS 
(cFSGS) and in mouse models of cFSGS (Nphs1-Cre/ROSA26loxp/NEP25). Transgenic 
mice expressing human CD25 on the podocyte (NEP25) develop progressive proteinuria 
and GS following administration of the immunotoxin (LMB2). Pharmacological inhibition 
of Notch with γ-secretase inhibitors did not influence disease (Ueno et al., 2013). 
 
1.5 Interplay between WT1 and Notch in vertebrate nephrogenesis 
 
Notch and WT1 both play a vital role during spatiotemporal kidney development and 
temporal deletion of these genes can severely impact the kidney. The expression of the 
Notch signalling genes, notch1, serrate1, and delta1 has been examined in developing 
pronephros of Xenopus (McLaughlin et al., 2000). Overexpression of Notch signalling in 
the pronephric anlage disrupts tubule formation and results in an increase of both pax2 
and wt1 expression (McLaughlin et al., 2000), highlighting the relationship between 
Notch signalling and WT1 expression. 
 
Davidson’s team (O'Brien et al., 2011) examined the correlation between transcription 
factors wt1 and hes1 during podocyte differentiation in the zebrafish pronephros. Whole 
mount in situ revealed an expression pattern of both genes at different stages of 
development; an increase in wt1 was associated with a downregulation of hey1 (O'Brien 
et al., 2011). Moreover, the significance of Notch during early kidney development was 
demonstrated in the Xenopus pronephros. Xenopus hairy-related transcription factor 
(xhrt) and xhes genes had distinct dynamic patterns during glomerulus development. 
xwt1 antisense morpholinos (MO) in the Xenopus resulted in reduced levels of xhrt1 
expression in the pronephros, highlighting the relationship between WT1 and Notch 
signalling during glomerular development (Taelman et al., 2006). Furthermore, as 
previously cited, earlier work in mice investigated the role of Notch in podocytes at 
various stages of development by inducing the Notch1 ICD in mature and embryonic 
podocytes at the capillary loop stage (NPHS2-rtTA;tetO-ICN1 and Nphs1-Cre(+);Notch-
IC). Depending on the time-point, either FSGS (mature podocytes) or DMS (capillary 
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loop) manifested in the kidney, which was caused by podocyte apoptosis or 
dedifferentiation (Niranjan et al., 2008, Waters et al., 2008). These mice also showed a 
downregulation of podocyte genes, Wt1, Nphs1 and Nphs2. Wt1 knockdown in 
embryonic mouse kidney explants results in a significant reduction of HeyL transcript, 
highlighting the association between Wt1 and the Notch pathway (Hartwig et al., 2010). 
Xenopus morpholino studies demonstrating spatiotemporal expression through the 
systemic elimination of podocyte transcription factors (wt1, foxc2, hey1, mafb, lmx1b) 
discovered that podocyte maturation required three main participators, wt1, foxc2 and 
Notch signalling (White et al., 2010). Likewise, WT1 and the Notch homologue, along 
with sonic hedgehog (SHH) and Wnt pathways, have been shown to function as part of 
a molecular network during nephrogenesis (Dormoy et al., 2012). Figure 1.18 illustrates 
the interplay between the Notch pathway and WT1 during podocyte differentiation. 
 
 
Figure 1.18. Transcriptional regulation of podocyte development 
Podocyte progenitors express high levels of Notch signalling components including Rbpj and 
NICD, as well as Wt1 and FoxC1/2, which induce Hey expression. Notch signalling decreases as 
podocytes mature, whilst Wt1 expression levels increase. Higher levels of Wt1 complexing with 
FoxC1/2 trigger the activation of Podocalyxin. Wt1 expression may regulate the Notch pathway 
by sequestering Rbpj, inhibiting downstream expression of Notch signalling. Adapted from 
(O'Brien et al., 2011). 
 
Valsartan, an angiotensin II type 1 receptor antagonist, was investigated on STZ-induced 
diabetic mice, where Notch signalling was upregulated (Gao et al., 2016). Following 
Valsartan treatment, podocyte injury was ameliorated with reduced expression of the 
Notch signalling genes and increased Wt1 gene expression (Gao et al., 2016). Opposing 
findings recently revealed that overexpression of Notch activity during pronephros 
development in Xenopus increased wt1 expression (Katada and Sakurai, 2016). Further 
research examined Notch signalling during zebrafish kidney development and identified 
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that jag1b, rbpj, jag2b, notch1a and notch3 are necessary to control the separation of 
wt1 expressing podocytes and interrenal cells (Chou et al., 2017). 
 
1.6 Scope of the thesis 
 
Reciprocal interaction between WT1 and Notch has been documented during kidney 
development. Moreover, specific mutations in the WT1 gene cause SRNS in humans 
and manifest as glomerular damage characterised by two distinct histological patterns – 
FSGS and DMS. Studies have also shown that ectopic activation of Notch in both mature 
and differentiating podocytes can also lead to FSGS and DMS in animal models.  
 
As such, the aim of this study was to investigate whether podocyte Notch activation 
participates in Wt1 glomerulopathy in both early and late stages of glomerulosclerosis. 
An inducible mouse model whereby podocyte-specific deletion of Wt1 occurred following 
Tamoxifen administration was used for experiments. 
 
The objectives were to:  
 
• Establish and characterise the histological and biochemical phenotype of a Wt1-
deleted model at different stages of disease; 
• Functionally characterise Notch pathway expression in the inducible model of 
glomerulosclerosis; 
• Determine the underlying mechanisms of podocyte injury; 
• Determine whether pharmacological inhibition of Notch could abrogate GS in the 
inducible Wt1-floxed model; and 
• Characterise Notch activation in human NS. 
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Chapter 2 – Materials and Methods 
2.1 Transgenic mouse strains 
 
Breeding and maintenance 
 
Breeding pairs were set up once mice reached sexual maturity; females at 6 weeks of 
age and males at 8 weeks. Pups were then ear clipped 10 days post-birth and 
genotyped. 
 
CAGG promoter-driven Cre-ERT2TM mice (Cre-ERTM+/-, MGI 2182767) were crossed with 
homozygous Wt1 conditional mice, where the first exon of Wt1 is flanked by loxP sites 
(Wt1loxp/loxp, MGI 4849364) (Chau et al., 2011). Following tamoxifen induction, the Wt1 
gene is excised through the Cre-recombinase mechanism and the kidneys are 
examined. 
 
Frozen embryos were sent from Professor Hohenstein’s group and were re-derived at 
the Kathleen Lonsdale Building (KLB), UCL. Cre-ERT2;Wt1 mice were from a C57Bl/6j 
background. 
 
Nphs2;rtTA transgenic mice were used for primary podocyte cultures and Hes1 
overexpression experiments. These mice carry the reversed tetracycline transactivator 
under the human Podocin (NPHS2) promoter, which targets expression in the podocytes 
of the kidney. Nphs2;rtTA transgenic mice (MGI 3629962) were given to us from Dr. 
David Long’s group in the Nephro-Urology Unit, Institute of Child Health, Great Ormond 
Street Hospital. 
 
Nphs2;rtTA mice were also crossed with the transgenic mice carrying the tetracycline-
responsive promoter element (tetO) achaete-scute family BHLH Transcription Factor 
(Ascl1), which was kindly sent to us from Professor Thomas Reh’s group, University of 
Washington (Ueki et al., 2015). 
 
All animal work was carried out under the permission of the Home Office project license 
2518, PIL 70/23192. After the mice were re-derived at the KLB, UCL, Mice were housed 
and bred in the animal facilities at the Western Labs, UCL Institute of Child Health, Great 
Ormond Street. 
 Page 65 of 214 
 
Wt1 deletion in Cre-ERTM+/-;Wt1loxp/loxp transgenic mice 
 
In vivo Wt1 deletion was achieved through tamoxifen induction (1mg/40g body weight 
for 3 days; Sigma) using 21G syringe needles in 5-week-old mice. Following tamoxifen 
induction, Cre-recombinase induced site-specific recombination between the loxP sites 
of the Wt1 gene, resulting in a ubiquitous Wt1 null allele. Recombination PCR was 
carried out in order to confirm successful Wt1 deletion (Figure 2.1). Mice were sacrificed 
at days (D) 4, 5, 6, 8 and 12 post-tamoxifen induction (P.I.) and both kidneys were 
removed under sterile conditions. Mice were injected for three consecutive days with a 
low dose of tamoxifen in order to facilitate recombination of Wt1 and to minimise 
tamoxifen toxicity and maximise survival. This time-course was established following a 
careful examination of the phenotype at every time-point until D12 P.I. Mice were too 
sick to be examined after D12 P.I., therefore were sacrificed at this time-point for humane 
reasons. Urine was collected at each time-point in order to measure albumin/creatinine 
protein levels at the pre-proteinuric, proteinuric and GS stages. 
 
 
Figure 2.1. Wt1 exon 1 deletion. 
Following tamoxifen I.P., the floxed Wt1 exon 1 is deleted by Cre-recombinase binding with loxP 
sites, resulting in a 400bp fragment. Primers F2 and R4 span loxP at 5’ site of the conditional Wt1 
exon 1, giving a 327bp size. Pre-Tamoxifen, F2 and R1 display the full 2110bp. Post-tamoxifen, 
F2 and R1 result in 400bp. 
 Page 66 of 214 
 
GSI-IX treatments in Cre-ERTM+/-;Wt1loxp/loxp transgenic mice 
 
In this study, podocyte Notch activation has been shown to be a feature of early disease, 
therefore, γ-secretase inhibitor was introduced to mice to prevent Notch signalling at the 
onset of GS. IP treatments of γ-secretase inhibitor, GSI IX (N-[N-(3,5-difluorophen-
acetyl-L-alanyl)]-S-Phenylglycine t-butyl ester (DAPT) (Sigma-Aldrich D5942) were 
given late D4 P.I. in 5-week old Cre-ERTM+/-;Wt1loxp/loxp (Cre-ER+/-;Wt1f/f) mutants as a 
prophylactic intervention (100μg GSI IX/40g body weight) and again the next morning 
(16 hours later). Vehicle controls were treated with Dimethyl sulfoxide (DMSO, W387520 
Sigma-Aldrich) administered by IP (100μg GSI IX/40g body weight) at the same time 
point (D4 P.I.) to Cre-ER+/-;Wt1f/f mutants as controls. For late treatments, an IP injection 
with the γ-secretase inhibitor-GSI-IX DAPT was given to Cre-ER+/-;Wt1f/f mutants 
(100μg/40g mouse body weight) on the evening of day 7 post-tamoxifen induction (D7 
P.I.) and treated again with DAPT the next morning (16hrs later). Urine was collected 
from the metabolic cages at least 8 hours post-second DAPT treatment and mice were 
then sacrificed. PAS-stained specimens were scored for severity of glomerulosclerosis 
following nephrectomy. GSI-DAPT and vehicle-treated Cre-ER+/-;Wt1f/f transgenic mice 
were compared. 
 
Overexpression of Ascl1 in TetOAscl1;NPHS2;rtTA transgenic mice 
 
Doxycycline treatment was achieved orally by either water or chow (2mg/ml in 5% 
sucrose water, 4mg in chow) in 4 week-old mice. The aim was to overexpress Ascl1 in 
the podocytes (podocin-specific) by using a nuclear mCherry reporter under the 
tetracycline-responsive element (tetO-Ascl1-ires-mCherry) (Ueki et al., 2015) to 
investigate whether overexpression of Ascl1 induces a glomerular phenotype. Following 
doxycycline treatment, the NPHS2-rtTA system stimulates Ascl1 expression in the 
podocytes. Mice were treated with 2mg/ml doxycycline in 5% sucrose water for 2 weeks 
and sacrificed. Urine and nephrectomies were collected to examine the phenotype. 
Furthermore, 4 week-old mice were treated with 4mg doxycycline in chow for 2, 4 and 6 
weeks and then sacrificed. It was hard to control the amount of doxycycline intake in 
each mouse, however, to ensure that all mice were receiving doxycycline, levels of water 
and chow were checked daily and replaced every other day. Urine and kidneys were 
then collected and examined for a phenotype. Ex vivo experiments were also performed 
where podocytes from the doxycycline-treated mice were isolated following kidney 
harvest (described later in this chapter). Following 6 days of podocytes in culture, cells 
were treated with doxycycline (4µg/ml) to overexpress Ascl1. RNA and protein analyses 
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were performed to confirm overexpression. The schematic of the experiment is 








To confirm Wt1 floxed genotypes, mice were ear-clipped 10 days post-birth and earclips 
were incubated in tail lysis buffer (Table 2.1) + 400 µg/ml proteinase K (Sigma P6556-
500mg) overnight at 56ºC, followed by enzyme inactivation at 95°C for 5 minutes. 
Isopropanol was then added at equal volumes for precipitation and centrifuged at 4°C 
for 25 minutes at 16,000xg. The supernatant was discarded and 70% ice-cold ethanol 
was added to each sample and centrifuged at 4°C for 5 minutes at 16,000xg. The 
supernatant was carefully removed and the DNA were air-dried for one hour at room 
temperature (RT) upside down. 150µl Milli-Q H2O was added to each pellet. Samples 
were genotyped using polymerase chain reaction (PCR). The remaining samples were 
stored at 4˚C. 
 
Genotyping post- in vivo treatments 
 
Mouse tail tips were collected and lysed (Table 2.1) to determine recombination and Wt1 
deletion using the genomic primers (Table 2.2) and the same PCR programme as 
genotyping (Table 2.3). A combination of 3 primers were used to amplify the floxed region 
of Wt1 and to highlight Cre-recombination and Wt1 excision following tamoxifen 
induction (Figure 2.1). 
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Table 2.1. Tail lysis buffer 
Tail lysis buffer Total 500ml Final conc. 
1M Tris pH 8.0 5ml 10mM 
5M NaCl 10ml 100mM 
0.5M EDTA pH 8.0 10ml 10mM 
10% SDS 25ml 0.5% 
ddH2O 450ml 450ml 
 500ml  
 
Polymerase Chain Reaction (PCR) and genotyping 
 
The Illustra beads kit (GE Healthcare; 27-9559-01) was used to genotype the conditional 
Wt1 floxed alleles (Table 2.2) with a final concentration of 1µM primers and <100ng 
genomic DNA in a total volume of 25µl. Primers were used to amplify CreERT2 DNA 
sequence using the BIOTAQ DNA polymerase kit (Bioline, BIO-21040) containing 
<100ng genomic DNA, 0.4µM primers, 1XNH4 buffer, 1.5mM MgCl2, 0.8mM dNTP, 
0.2µ/µl Taq DNA polymerase in a total volume of 25µl. PCR reactions were run using a 
thermocycler with the programme shown in Table 2.3 and products were run on a 2% 
agarose gel to identify their sizes. TetOAscl1;rtTANPHS2 mice were genotyped using 
genomic primers amplifying Nphs2rtTA and IRES-Ascl1 (Table 2.2) and the PCR 
programme shown in Table 2.4. 
 
Table 2.2. Genomic primers for genotyping 
Gene Primer Sequence (5’-3’) Target Size (bp) 
Cre_F GCATTACCGGTCGATGCAACGAGTGATGAG  Cre expressing 
300 Cre_R GAGTGAACGAACCTGGTCGAAATCAGTGCG  
Nphs2;rtTA F CGCACTTCAGTTACTTCAGGTCCTC  455 
Nphs2;rtTA R GCTTATGCCTGATGTTGATGATGC  
hAscl1 F CATCTCCCCCAACTACTCCA  Ascl1 IRES 400 
IRES R GAGGAACTGCTTCCTTCACG  
Wt1_F  TGGGCATTTCTGCTAAGCG   
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Table 2.3. PCR programme for genotyping Cre-ERT2 and Wt1 floxed alleles 
Cycle Step Temp Time No. cycles 


















Table 2.4. PCR Programme for genotyping TetOAscl1;rtTANPHS2 transgenic mice 
Cycle Step Temp Time No. cycles 












Final Extension 72°C 10 minutes 1 
 
2.3 Glomerular isolation 
 
Four week-old mice, both male and female from available litters (controls, heterozygotes 
and mutants), were sacrificed. Dissected fresh kidney cortices were decapsulated and 
minced in ice-cold Hank’s balanced salt solution (HBSS; Gibco/Invitrogen 24020-133). 
Following a thorough rinse with fresh HBSS, they were filtered through a 100μm cell 
strainer (BD Falcon 352360) into a chilled 50ml falcon tube in order to remove any large 
tubular fragments from passing through. HBSS was added to a total of 6mls, which was 
then divided amongst 2 chilled 15ml falcon tubes. Each tube contained 2.2ml Percoll 
(Amersham 17-0891-02) and was mixed thoroughly. Glomeruli were separated across 
the Percoll gradient by centrifugation at 200xg for 10 minutes at 4°C (Johns et al., 1987). 
The top layer of the gradient contained glomeruli, which was verified microscopically. 
The top 1-2mls of the gradient was passed again through a 100μm cell strainer to prevent 
any large tubule fragments from filtering through in order to achieve pure glomeruli. The 
filtrate was then passed through a 40μm cell strainer (BD Falcon 352340) to trap the 
glomeruli. Glomeruli were either lysed on the cell strainer to collect RNA and protein, or 
used to isolate primary podocytes. 
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2.4 Primary podocyte culture 
 
For podocyte culture, minced cortices were digested in 1mg/ml collagenase A (Sigma 
C2674) in HBSS medium for 30 minutes at 37°C. Glomeruli were obtained following the 
above protocol. Harvested glomeruli were placed onto culture dishes coated with 
Matrigel (Corning; 35423) Culture medium was RPMI 1640 containing 15% foetal bovine 
serum (FBS; Atlanta Bio), 1% penicillin/streptomycin (P/S), 1% Insulin, transferrin, 
selenium (I/T/S) and amphotericin B. On day 3 of culture, unattached glomeruli were 
washed away and fresh medium was added. Podocytes were examined on day 6 of 
culture post-harvest and were verified by immunofluorescence using the podocyte 
marker, Nestin. 
 
2.5 RNA extraction  
 
RNA was extracted using the RNeasy mini kit for cells or RNeasy Micro Kit for glomerular 
isolates (Qiagen; 74104). Total RNA was isolated following the manufacturer’s 
instructions. Podocyte cell RNA concentrations from both kidneys/mouse gave a good 
yield of around 100-300ng/µl whilst glomerular isolates (from two kidneys) gave between 
20-100ng/µl eluted in 50µl water and an optical density of 1.8-2.0, measured by the 
Nanodrop spectrophotometer ND1000 (Lab Tech). 
 




cDNA was generated from the total RNA using the high capacity cDNA synthesis kit 
(Thermo Fisher 4387406). RNA was normalised before synthesising cDNA, where 
approximately 1µg RNA was added to the 2X RT buffer and 20X RT enzyme in a total 
volume of 20µl. cDNA synthesis ran for one hour at 37°C followed by 95°C incubation 




Real-time qPCR primers were designed using the NCBI primer blast website 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). To ensure pure cDNA amplification, 
primers designed spanned the exon-exon junction, and product size was set to a 
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maximum 150bp. Primers for qPCR were also taken from published papers, where their 
efficiency had been tested. 
 
To ensure maximum efficiency of the primers designed, a relative standard curve method 
was carried out where all the cDNA samples were pooled together and diluted in a 10-
fold dilution series to generate the standard curve (y=mx+c). The efficiencies of each 
primer were analysed relative to GAPDH. This particular method is useful as the 
housekeeping control gene, (GAPDH in this case), is only required once if running 
multiple plates and the efficiency of the primers is measured relative to GAPDH. Due to 
low yields of cDNA and already optimised primers, the ΔΔCT Livak method was also 
used to analyse qPCR data. In this case, the efficiency is approximately 100% between 
the genes and the housekeeping control gene, and the control gene is required each 
time a plate is run. 
 
Real-time qPCR was carried out using the SYBR Green PCR mix (BIORAD 1708882) 
on the CFX96 touch thermal cycler (BIORAD) machine. Samples were analysed on a 
96-well plate in the SYBR Green Master Mix volumes (Table 2.5) using the programme 
illustrated in Figure 2.3. Real-time qPCR primers are summarised in Table 2.6. Primers 
that are not referenced in the table were designed in-house using Ensembl blast, 
Primer3Plus or the NCBI primer design tool, primer-BLAST. These were tested for 
efficiency using the standard curve method. 
 
Table 2.5. qPCR reagents 
SYBR Green Mastermix Total 24µl 
cDNA 2μl 
20uM Primer F 1μl 








Figure 2.3. Real-time qPCR protocol 
 
Table 2.6. Real-time qPCR primers 
Gene Primer sequence (5’-3’) Reference 
Apaf1 F GGGTGGGTCACCATCTATGG (Niranjan et al., 2008) 
Apaf1 R TTCCGCAGCTAACACAGACTTG 
Bax F CCAAGAAGCTGAGCGAGTGTCT 
Bax R AGCTCCATATTGCTGTCCAGTTC 
Bcl2 F TGGGATGCCTTTGTGGAACT 
Bcl2 R CAGCCAGGAGAAATCAAACAGA 
Cdkn1c F CAATCAGCCAGCAGAACAGC 
Cdkn1c R CAGCTCCTCGTGGTCTACAG 
Dll1 F CATGAACAACCTAGCCAATTGC 
Dll1 R GCCCCAATGATGCTAACAGAA 
Dll4 F GACCTGCGGCCAGAGACTT 
Dll4 R GAGCCTTGGATGATGATTTGG 
Hes1 F CCCCAGCCAGTGTCAACAC 
Hes1 R TGTGCTCAGAGGCCGTCTT 
Hes3 F AAGGGAGCAGAAAAGCATCA 
Hes3 R CTATGGCAGGGAGCTTTGAG 
Hes5 F TGGGCACATTTGCCTTTTGT 
Hes5 R CAGGCTGAGTGCTTTCCTATGA 
Hes6 F GAAGTGGCCAATCTTGAGACTGA 
Hes6 R GGATTGCTGTGGCCTGTGT 
Hey1 F GGGAGGGTCAGCAAAGCA 
Hey1 R GCTGCGCATCTGATTTGTCA 
Hey2 F CACATCAGAGTCAACCCCATGT 
Hey2 R GTGAGGAGAGCAGAGCCATGA 
HeyL F AGATGCAAGCCCGGAAGAA 
HeyL R CGCAATTCAGAAAGGCTACTGTT 
Jag1 F ACACAGGGATTGCCCACTTC 
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Gene Primer sequence (5’-3’) Reference 
Jag1 R AGCCAAAGCCATAGTAGTGGTCAT (Niranjan et al., 2008) 
Jag2 F CGACTCACACTGCGCTTCA 
Jag2 R TCGGATTCCAGAGCAGATAGC 
Notch1 F CCAGCAGATGATCTTCCCGTAC 
Notch1 R TAGACAATGGAGCCACGGATGT 
Notch2 F TCTATCCCCCGTCGATTCG 
Notch2 R GATGTGATCATGGGAGAGGATGT 
Notch3 F CCAGGGAATTTCAGGTGCAT 
Notch3 R GCCGTCGAGGCAAGAACA 
Nphs1 F GCCAATCAATGACAGGAGGT 
Nphs1 R GTCAGGTTGTTGGGCTTGTT 
Nphs2 F AGGGATGACAAGAAGGCAAA 
Nphs2 R ACCTCGTCCACGTCCACTAC 
p53 F CTCTCCCCCGCAAAAGAAA 
p53 R CGCCCGCGGATCTTG 
Rbpsuh F GCGGATAAAGGTCATCTCCA 
Rbpsuh R TTCCTGAAGCAATGCACAAG 
Trp53 F AGCGCTGCTCCGATGGT 
Trp53 R TTCCTTCCACCCGGATAAGA 
Wt1 F GGTGGCACAGTTGTCAGAAA 
Wt1 R GGTGAGTGGGAGGAATTTCA 
Ascl1/Mash1 
F 




Gapdh F AGGTCGGTGTGAACGGATT 
Gapdh R TCTAGACCATGTAGTTGAGGTCA 
Lfg F CGAGCACAAAGTGAGACCTG 
Lfg R TGCCGTGCTCATGAAGTGTC 
Mfg F AGACTACCTGGGCCTTCCAT 
Mfg R TGAATGTCTGTTGCCTGATCCT 
Mib2 F CTAGGATGGCAGAGATGGGC 
Mib2 R ACCCAGAAGCTGTTGTGCTT 
Neurb1 F AATCGTCTCTGGTGACAGCC 
Neurb1 R GTGCACTCTCCATTCCTGCT 
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2.7 Phenotype analysis 
 
2.7.1 Renal histology 
 
Histomorphometrical semi-quantitative analysis of glomerulosclerosis from 0-3 was 
achieved (Score 0-3, 0, < 25%, 1, 25-50%, 2, 50-75%, 3,>75% sclerosis) by scoring the 
severity of 30 PAS-stained glomeruli/sample where Cre-ERTM-/-;Wt1fl/fl and Cre-ERTM+/-
;Wt1fl/+ controls were compared to Cre-ERTM+/-;Wt1fl/fl mutants. Scoring was based on 
formed adhesions, mesangial expansion and capillary obliteration in one segment. 
 
2.7.1.1 Paraffin and cryo- tissue preparation 
 
Mouse kidneys were dissected, cut in half lengthwise, and fixed overnight in 4% 
paraformaldehyde (PFA, Sigma 158127) in PBS. For paraffin-embedding, kidneys were 
dehydrated through different Ethanol (EtOH) concentrations reaching 100% EtOH and 
then transferred to Histo-Clear (National Diagnostics). Kidneys were then infiltrated with 
paraffin for 3 hours, overnight at 60°C, then embedded sagittally in paraffin. Kidneys 
were sagittally sectioned using a microtome at 5-10µm thickness and transferred onto 3-
(Triethoxysilyl)propylamine (TESPA)-coated SuperFrost® microscope slides (VWR) 
overnight to dry. Paraffin embedding and sectioning was also carried out by the 
Histopathology Unit, GOSH, who also performed Periodic acid-Schiff (PAS) and 
Haematoxylin & Eosin (H&E) staining were performed for phenotype analysis. 
 
For cryo-preparation, 4% PFA-fixed kidneys were placed in 30% sucrose overnight at 
4°C. Kidneys were then moved from 30% sucrose to 1:1 30% sucrose:OCT embedding 
matrix (Fisher) for 30 minutes on a shaker to gradually remove all sucrose from the 
sections, and then into 100% OCT. Kidneys were moulded in OCT on dry ice with ethanol 
to snap freeze the sections. Tissues were stored at -80°C. Serial sections of the kidneys 
were cut at 10µm on SuperFrost® Plus glass slides (VWR) using the cryostat and stored 
at 80°C until staining. 
 
2.7.2 Urine protein analysis 
 
Urinary albumin and creatinine levels were determined using the mouse albumin ELISA 
quantitation set (Bethyl Laboratories, E90-134) and R&D systems creatinine assay 
(KGE005) kits respectively. For Albumin ELISAs, mouse albumin serum of 0-500ng/ml 
through to Blank (1:2 dilution series) were used to set the standard curve and urine was 
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diluted between 1:1,000–20,000 due to differing concentrations of albumin in each 
sample. Absorbance was measured on a plate reader at 450nm and concentrations were 
analysed using the 4-parameter curve method. Creatinine assay standards were 
prepared from 0-20mg/dl (1:2 dilution series) and most urine samples were diluted 1:20. 
Absorbance was measured on a plate reader at 490nm and measured using a log/log 
curve fit. Concentrations of albumin and creatinine were multiplied by their dilution and 
units were converted to µg/ml (albumin) and mg/ml (creatinine) in order to calculate a 
final ratio of albumin/creatinine (µg/mg). The results were analysed using Prism 
GraphPad 6. 
 
Furthermore, albuminuria was determined by using Western blot analysis with the 
albumin antibody (Bethyl laboratories, E90-134; 1:1,000 dilution). Urine samples were 
diluted 1:100 and loaded 10µl/lane. Urine samples were collected from Cre-ERTM-/-;Wt1f/f 
and Cre-ERTM+/-;Wt1f/f mice at D4, 5, 6, 8, and 12 P.I. to test for albumin. 
 
2.7.3 Immunohistochemistry and immunofluorescence multi-labelling 
 
2.7.3.1 Immunofluorescence on paraffin sections (IHC)  
 
A list of antibodies used can be found in Table 2.7. 
 
Sections were deparaffinised in Histo-Clear and rehydrated through a series of graded 
EtOH washes and then rinsed with H2O. For antibody staining, microwave antigen 
retrieval was performed in citrate buffer (pH6) for 15 minutes on a high heat setting 
(Panasonic NN-S758WC, 950W max. output), followed by a 20 minute cooling period at 
room temperature (RT). Slides were incubated in blocking buffer (PBS + 15% BSA + 
Goat Serum) or Universal Blocking Reagent (DAKO) in a humidified chamber for one 
hour at RT to prevent drying of sections. Sections were probed with primary antibodies 
diluted in incubation buffer (PBS+30% BSA+Goat serum+ 0.1% Tween-20) or DAKO 
buffer overnight at 4°C. The following day, sections were washed three times in PBS for 
10 minutes, and incubated with Alexa Fluor-conjugated secondary antibodies for one 
hour at RT. Slides were then washed in PBS, counterstained with DAPI (Sigma) and 
mounted using VECTASHIELD mounting medium (Vector laboratories H-1000). 
 
2.7.3.2 Immunofluorescence on cryosections  
 
Sections were brought to room temperature, washed in PBS and permeabilised in 0.5% 
Triton X-100 (Sigma) for 5 minutes, followed by 3x5 minute PBS washes. Sections were 
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incubated in blocking buffer (10% goat serum (Sigma), 1% BSA (Sigma), 0.1% Triton X-
100, PBS) in a humidified chamber for one hour, then incubated in primary antibody 
diluted in blocking buffer overnight at 4°C. The following day, slides were washed in PBS 
3x5minutes and incubated with Alexa Fluor-conjugated secondary antibodies for one 
hour at RT. Slides were then washed in PBS, counterstained with DAPI and mounted 
with coverslips using VECTASHIELD mounting medium. 
 
2.7.3.3 Cellular immunofluorescence 
 
For all cellular immunostaining, approximately 1x105 podocytes were seeded on 
Matrigel-coated (Corning 354234) chamber slides (Millipore Cat no. PEZGS0816) in 
RPMI (supplemented with 10% FBS, 1% ITS, 1% P/S). 
 
Cells were fixed in 4% PFA for 15 minutes at room temperature, washed three times in 
PBS and incubated in blocking solution (10% goat serum (Sigma), 1% bovine serum 
albumin (BSA, Sigma-Aldrich, 0.1% Triton X-100, PBS) for one hour at RT. Cells were 
then probed with the selected primary antibodies diluted in blocking solution overnight at 
4°C. A day later, cells were washed twice in PBS and probed with Alexa Fluor-conjugated 
secondary antibodies for one hour at RT. Slides were then washed in PBS, 
counterstained with DAPI and mounted with coverslips using VECTASHIELD mounting 
medium. 
 
Electron Microscopy (EM) and imaging were performed at the Histopathology Unit, 
GOSH. 
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Table 2.7. Antibodies for IHC, ICC, IFC 
Antibody Isotype Species 
reactive 
Dilution Use Company 
B-Actin (13E5) Rabbit mAB 
IgG 
H, M, R, 
Mk, Pg, B 
1:1,000 Western Cell Signalling 
CD13 (553370) Rat IgG2a M 1:100 IHC BD Biosciences 
NICD1(Val1744) Rabbit mAB H, M, R, 
Mk 
1:50 IHC Cell Signalling  
Notch1 (D1E11) Rabbit mAB H, M, R 1:1,000 Western Cell Signalling 
Cleaved Notch2 
(Ala1734) 
Rabbit H, M, R 1:150 IHC Thermo Fisher 
Cleaved Notch2 
(07-1234) 





Jagged 1(C20) Goat H, M, R 1:100 IHC Santa Cruz 
Jagged 1 (H114) Rabbit H, M 1:1,000 Western Santa Cruz 
Podoplanin 
(811) 
Hamster mAB M 1:100 IHC Novus 
Biologicals 







Mouse IgG1 H, M, R, 
GP, B 




Rabbit H, M, R 1:100 IHC Sigma Aldrich 
LTL biotinylated 
(B1325) 





Rabbit H, M, R, 
Mk 
1:400 IHC Cell Signalling  
Slug (C19G7) Rabbit H, M 1:1,000 Western Cell Signalling 
Delta-like1 
(HMD1-5) 
Hamster M 1:1,000 Western ThermoFisher 
WT1 (C-19) Rabbit H, M, R 1:250 IHC Santa Cruz 
POFUT1 (PA5-
31357) 
Rabbit H, M 1:1,000 Western Invitrogen 
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Antibody Isotype Species 
reactive 
Dilution Use Company 
PSMAD2 
(D27F4) 
Rabbit mAB H, M, R, 
Mk 
1:100 IHC Cell Signalling 
Nestin (NB100-
1604) 















Guinea Pig H, M 1:50 IHC Fitzgerald 








M 1:10,000 IHC ThermoFisher 
 
2.8 Apoptosis Assays 
 
2.8.1 Cleaved caspase 3 analysis  
 
Cleaved caspase-3 antibody staining was carried out on cryosections using the same 
method as described in section 2.7.3.2. 
 
2.8.2 DeadEnd Fluorometric TUNEL assay  
 
Cells were fixed in 4% PFA for 15 minutes at RT and washed three times in PBS. The 
DeadEnd Fluorometric TUNEL (Terminal deoxynucleotidyl transferase dUTP nick-end 
labelling) assay (Promega G3250 l) was used to assess apoptosis in the podocytes at 
different stages post-tamoxifen induction. Following fixation, cells were permeabilised 
with 0.2% Triton X-100 in PBS for 5 minutes, washed in PBS for 5 minutes and 
equilibrated in Equilibration TdT Buffer for 5-10 minutes at RT. rTdT [Terminal 
Deoxynucleotidyl Transferase, recombinant enzyme] incubation buffer (45µl 
Equilibration buffer + 5µl Nucleotide mix + 1µl rTdT enzyme) was then added to the cells 
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for one hour at 37°C. To ensure even distribution of the buffer, the slides were covered 
with plastic cover slips. Plastic coverslips were removed by immersing the slides in 
2XSSC (Saline-sodium citrate: 3M NaCl, 0.3M trisodium citrate pH7.0) for 15 minutes at 
RT. Slides were then washed twice in PBS at RT. VECTASHIELD with DAPI mounting 
medium (Vector Laboratories H-1200) was added to stain the nuclei and slides were 
mounted. For double staining with antibodies, cells were blocked following rTdT 
incubation and probed with the desired antibody for one hour at RT or overnight at 4°C. 
The next day, cells were washed twice in PBS and probed with Alexa Fluor-conjugated 
secondary antibodies for one hour at RT. Slides were then washed in PBS and mounted 
as previously described. 
 
2.8.3 Caspase 3/7 immunostaining  
 
Podocytes were incubated in 5µM Cell Event caspase 3-7 green detection reagent 
Green (prepared in complete RPMI - Life Technologies, C10423) for 30 minutes at 37°C. 
Cells were then fixed with 4% PFA, for 15 minutes at RT, washed in PBS, counterstained 
with DAPI and mounted with VECTASHIELD mounting medium. Caspase 3/7- and 
DAPI- positive cells were quantified in 10 different fields for each sample. 
 
2.8.4 Annexin V staining 
 
Following podocyte isolation and culture of six days, cells were collected and analysed 
at the FACS facility, Moorfields Eye Hospital. The samples were spun down at 320xg for 
5 minutes and washed with Annexin V Binding Buffer (ThermoFisher Scientific, 88-8103-
74). The cells were then stained with Annexin V-PE-Cy7 (ThermoFisher) for 30 minutes 
on ice, in the dark. Following incubation, the samples were washed again and re-
suspended in the Annexin V Binding Buffer. Samples were stained with SYTOX Blue at 
a final concentration of 0.3 mM (Thermo Fisher Scientific, Cat. No. S34857). Before cell 
acquisition, the cells were filtered through a 35mm cell strainer, preventing cellular 
aggregation during sample acquisition. The cells (control and mutant) were acquired 
using a 5-laser BD LSRFortessa X-20 Analyser, equipped with 355nm (UV), 405nm 
(violet), 488nm (blue), 561nm (yellow) and 640nm (red) lasers.  
 
2.8.5 Fluorescence microscopy 
 
All cellular and tissue sections were imaged in the laboratory using a Zeiss upright 
microscope with an AxioCam MRm camera and UV lamp. Confocal imaging was also 
performed using a Zeiss LSM-710 system with an upright DM6000 compound 
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microscope and images were processed with Zen software suite. Z stacks were acquired 
at 0.5μm intervals and converted to single planes by maximum projection with Fiji 
software. 
 
All images were processed using ImageJ/Fiji. 
 




2x105 podocytes were seeded in 100mm Matrigel-coated dishes overnight and lysed the 
following day with RIPA lysis buffer (50 mM Tris–HCL [pH 7.5], 150 mM NaCl, 0.5% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate), 
supplemented with phosphatase and protease inhibitors (Sodium orthovanadate and 
protease inhibitor cocktail, Sigma P8340) for one hour on ice. Lysis was completed by 
shearing through a 26-gauge syringe needle and samples were spun at 10,000xg for 
one minute at 4°C. The supernatant was collected and protein concentration was 
measured using the BCA protein assay kit (Thermo Scientific, 23225) where absorbance 
at 562nm was measured on a plate reader and concentrations were calculated using the 
standard curve log/log curve fit. 
 
Western Blot Analysis 
 
Samples were denatured with 10% β-Mercaptoethanol (Sigma) in 4X Laemmli sample 
buffer at 95°C for 10 minutes. 15µg protein was loaded per lane. Primary and 
immortalized podocyte lysates were run on 4–15% SDS-PAGE gradient gels (Bio-Rad 
Laboratories). Prepared 10X Running buffer (30g Tris base, 144g glycine, 10g SDS, 1L 
H2O, [pH 8.3]) was diluted to 1X Running buffer for sample running and separation. All 
gels were transferred onto polyvinylidene fluoride (PVDF, Bio-Rad) membranes using 
1X Transfer buffer (Diluted from 10X Transfer; 30 g Tris, 144g glycine, 1L H2O), blocked 
in 5% non-fat milk in PBS+ 0.5% Tween-20 before being probed with primary antibodies 
(overnight at 4°C) and secondary antibodies (one hour at RT) in blocking buffer (2.5% 
non-fat milk in PBS+ 0.5% Tween-20). Blots were developed with Pierce ECL Western 
Blotting Substrate (Thermo Scientific; 32106) and images were collected by film. 
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2.10 Glomerular RNA sequencing 
 
Mouse glomeruli were isolated at day 4 post-tamoxifen induction and RNA was extracted 
using the QIAGEN RNeasy mini kit (74104) for whole transcriptome sequencing. 
Samples were processed by UCL Genomics, where pair end reads were produced using 
the Illumina TruSeq stranded assay. BAM files were generated and analysed using the 
Strand NGS 2.5 software. This software uses DESeq algorithm, incorporating additional 
downstream analysis including Gene Ontology (GO) and pathway analysis. A Mann-
Whitney test was performed to analyse differential gene expression with a 2-fold change 
and p value of <0.5 to filter genes. GO and pathway analysis were used to understand 
the function and relationship between the identified genes of interest. 
 
2.11 Podocyte shRNA experiments 
 
Transformations and plasmid purifications 
 
shRNA GIPZ hairpin plasmids (provided by UCL Cancer Institute) were obtained as 
bacterial agar stab cultures. The stab cultures were streaked onto a Lysogeny broth (LB) 
agar plate (with 100µg/ml ampicillin) under sterile conditions and incubated at 37°C 
overnight. The following day, colonies from each shRNA plasmid were picked and 
inoculated in 3ml LB with 100µg/ml ampicillin in 15ml falcon tubes. These were incubated 
at 37°C overnight in a shaking incubator (300rpm). The bacterial cells were then 
harvested and the plasmids were purified using the Qiagen miniprep kit (Qiagen 27104) 
according to the manufacturer’s protocol. Purified plasmids were sent off to the 
Cambridge Source Bioscience facility for Sanger sequencing using the GIPZ sequencing 
primer (5' - GCATTAAAGCAGCGTATC - 3') and analysed by Sequencher. Plasmids 
were used to knock down Manic Fringe (GE Dharmacon V3LMM_20363) and Rbpsuh 
(GE Dharmacon V3LMM_437682) genes from D6 P.I. Cre-ERTM+/-;Wt1fl/fl primary 
podocytes, and non-silencing vectors (RHS4346) were used as controls. 
 
For Nphs2;rtTA podocyte transfection, Tet-O-Hes1 plasmids [Addgene 6154, (Cassady 
et al., 2014)] and control GFP only plasmids were purchased and grown using Stbl3 
chemically-competent cells (Thermo Fisher C737303). Colonies were grown on LB agar 
plates as mentioned above and plasmids were purified using the Qiagen miniprep kit. 
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shRNA transient transfections 
 
On the day before transfection, 1x105 cells/well were seeded in 6-well plates in RPMI 
medium (15% FBS, 1% P/S, 1% I/T/S) to allow between 70-90% confluency at the time 
of transfection. Cells were Cre-ERTM+/-;Wt1f/f mutants at D6 post-tamoxifen induction. 
Transfection was carried out using the Lipofectamine 2000 protocol (ThermoFisher, 
11668019). On the day of transfection, 4µg plasmid was diluted in 250µl Opti-MEM and 
mixed gently. 10µl Lipofectamine 2000 was diluted in 250µl Opti-MEM and incubated for 
5 minutes. The diluted plasmid and diluted Lipofectamine 2000 were then combined, 
mixed and incubated at RT for 20 minutes. 500µl of the mixture was then added to each 
well containing the medium and cells and gently mixed by rocking (according to the 
manufacturer’s protocol). Cells were then incubated at 37°C, 5% CO2 and RNA was 
extracted after 24, 48, 72 and 96 hours post-transfection. RNA was collected using the 
Qiagen RNeasy Micro Kit to examine gene expression using real-time qPCR (sections 
2.5 and 2.6). 
 
Primary transgenic murine Nphs2;rtTA podocytes were transfected with Tet-O-Hes1 
plasmid or control-GFP only plasmid with Lipofectamine 3000 kit (Thermo Fisher 
Scientific, L3000001). Cells were transfected at 70% confluency. After 24 hours, both 
Tet-O-Hes1- and control plasmid-transfected cells were treated with Doxycycline [2 and 
4 µg/ml] for 72 and 96 hours. RNA was extracted according to the manufacturer’s 
instructions using the Qiagen microRNA extraction kit. Protein was extracted as per 
section 2.9. 
 
2.12 Statistical analysis 
 
GraphPad Prism V.7 (GraphPad Prism Software, USA) was used to perform statistical 
analyses. Depending on the availability of the mice, between 3-10 mice per experimental 
group were used for each analysis. For qRT-PCR analysis, the average of duplicate 
reactions was used as the value of that sample. Normally distributed data was expressed 
as means ± SD (Standard deviations) or SEM (Standard error of the means) relative to 
the specified controls; non-normally distributed data was reported as medians with 
respective interquartile ranges (IQR). A two-tailed, unpaired student’s t-test or Mann-
Whitney test were used for statistical analysis between two groups and the Bonferroni 
correction and two-way ANOVA tests were used when more than two groups were 
compared. Values were regarded as significant if p<0.05 was calculated; error bars 
represent SEM, SD or IQR. 
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Chapter 3 - Podocyte Notch activation coincides 
with the onset of Wt1 Glomerulopathy 
3.1 Introduction 
 
Notch is a highly conserved pathway that mediates cell-to-cell signalling during 
organogenesis and is essential during podocyte development (Cheng et al., 2003, 
Piscione et al., 2004, Cheng and Kopan, 2005, Chen and Al-Awqati, 2005). Podocytes 
are terminally differentiated visceral epithelial cells crucial for glomerular permselectivity 
(Pavenstadt et al., 2003, Reiser et al., 2000, Fukasawa et al., 2009) and mutations in 
podocyte genes can result in various events including EMT, apoptosis, podocyte 
dedifferentiation and proliferation (Niranjan et al., 2008, Waters et al., 2008). As 
previously mentioned, the WT1 gene is key not only to podocyte development but also 
essential for podocyte homeostasis throughout adult kidney life (Guo et al., 2002, 
Kreidberg et al., 1993, Kreidberg, 2010, Dong et al., 2015a). Thus, the rationale for this 
study was that manipulating WT1 would allow further investigation of pathways 
secondary to podocyte injury. In order to examine the molecular mechanisms and 
pathways underlying WT1 glomerulopathy, a transgenic mouse line was established 
whereby Wt1 could be deleted and any glomerular phenotype examined. Temporal 
deletion of Wt1 was investigated using a ubiquitously expressed Cre-driver mouse line 
crossed to mice with a conditional floxed allele of Wt1, which allowed ubiquitous deletion 
including in podocytes following tamoxifen induction. 
 
The importance of the Notch pathway during kidney development is established in 
kidney-related diseases including GS (Cheng and Kopan, 2005, Piscione et al., 2004). 
Notch was shown to be essential at the early stages of podocyte development but 
detrimental during podocyte differentiation and in mature podocytes (Waters et al., 2008, 
Niranjan et al., 2008). Waters et al. reported that when cleaved Notch1 was activated in 
the developing podocytes, podocyte proliferation with DMS resulted (Waters et al., 
2008); Niranjan et al. reported that activating Notch at the capillary loop stage led to 
podocyte apoptosis with FSGS (Niranjan et al., 2008) as well as a reduction in podocyte 
markers, including Wt1. 
 
In view of this existing data supporting interaction between WT1 and NOTCH, I tested 
the following hypothesis:  
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3.2.1 Wt1 deletion leads to glomerulosclerosis (GS) 
 
To establish a transgenic mouse line of Wt1 glomerulopathy, Cre-inducible mice carrying 
the Wt1 exon 1 floxed gene were tamoxifen-induced to delete Wt1 and a glomerular 
phenotype was examined. 
 
3.2.1.1 Temporal Wt1 deletion is observed in Cre-ERTM+/-;Wt1f/f mutants post-tamoxifen  
 
Tamoxifen induction in Cre-ERTM+/-;Wt1f/f transgenic mice has previously been reported 
to result in Wt1 deletion and GS at day 7 P.I. (post-induction) (Chau et al., 2011). In this 
project, earlier time-points of Wt1 deletion were explored to investigate the molecular 
mechanisms prior to and during the manifestation of GS. Day 4 P.I. was the earliest 
stage examined, allowing 3 days of tamoxifen to facilitate Wt1 deletion. Animals were 
very sick, showing signs of oedema at D12 P.I. This was therefore the latest time-point 
to examine due to humane reasons. 
 
Genetic deletion of Wt1 was supported by immunohistochemical findings with WT1 
protein expression significantly downregulated in Cre-ERTM+/-;Wt1f/f mutants compared 
to Cre-ERTM-/-;Wt1f/f controls at day 4 P.I. (Figure 3.1A, A’), day 5 P.I. (Figure 3.1B, B’) 
and absent by day 12 P.I. (Figure 3.1C, C’). Only non-specific autofluorescence was 
seen in figure 3.1C’ that did not co-localise with Dapi. Wt1 deletion was also validated 
on a molecular level through PCR at D4 and D5 P.I., where the recombination of Cre-
LoxP spanning exon 1 was detected post-tamoxifen induction. An amplicon size of 
400bp was observed, presenting the deletion of exon 1, only seen in Cre-ERTM+/-;Wt1f/f 
mutants compared to Cre-ERTM-/-;Wt1f/f controls, where no recombination was observed 
(Figure 3.1D, E). The floxed Wt1 amplicon was faintly present in the mutant, but evidently 
less than the Cre-ERTM-/-;Wt1f/f control at all time-points. Moreover, real-time qPCR 
analysis at D12 P.I. demonstrated a highly significant reduction in Wt1 gene expression 
in the Cre-ERTM+/-;Wt1f/f mutants compared to Cre-ERTM-/-;Wt1f/f controls (Figure 3.1F). 
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Figure 3.1. Temporal Wt1 deletion in Cre-ER TM+/-;Wt1f/f mutants. 
Illustrative images of WT1 protein in glomeruli following immunofluorescence labelling with WT1 
antibody of Cre-ERTM-/-;Wt1f/f control mouse kidney tissue sections, n=6 vs. Cre-ERT+/-;Wt1f/f 
mutants, n=6 (scale bars, 50μm). counterstained with DAPI. (A, A’) D4 P.I. controls show WT1 
protein expression (red arrows) (A) compared to mutants, where there’s reduced WT1 protein 
expression (A’). (B, B’) D5 P.I micrographs highlighting WT1 protein expression in controls as 
indicated by arrows (B) vs. mutants, where no WT1 protein is observed (B’). (C, C’). 
Representative micrographs of glomeruli following immunofluorescent labelling of podocytes with 
WT1 in D12 P.I. sections. WT1 protein is present in controls (red arrows) (C) vs. mutants, where 
WT1 is absent (C’). (D) DNA expression of Wt1 post-tamoxifen induction following PCR analysis 
at D4 P.I.; Recombination is seen in the mutants vs. controls. (E) PCR analysis of Wt1 genotyping 
post-tamoxifen induction at D5 P.I. in mutants vs. controls. The quantity of the Wt1 amplicon is 
reduced and recombination is shown in the mutant. (F) Quantitative real-time qPCR showing 
mRNA expression of Wt1 relative to Gapdh at D12 P.I., where Wt1 expression is reduced in the 
mutant vs. control (n=6 vs n=6 for each time-point). Analysed by Livak, ∆∆CT method. (Asfahani 
et al., 2018) 
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3.2.1.2 Early manifestation of GS is evident at day 5 post-tamoxifen induction in Cre-
ERTM+/-;Wt1f/f mutants 
 
To begin to address the underlying mechanisms and pathways following Wt1 deletion, it 
was important to confirm a phenotype of Cre-ERTM+/-;Wt1f/f mutants in comparison to Cre-
ERTM-/-;Wt1f/f and Cre-ERTM+/-;Wt1f/+ controls post-tamoxifen induction. This was achieved 
through PAS staining on paraffin-embedded kidney sections to assess the temporal 
induction of GS post-tamoxifen induction. Cre-ERTM-/-;Wt1f/f and heterozygote Cre-
ERTM+/-;Wt1f/+ controls did not exhibit any GS at any time-point (Figure 3.2A-D, Figure 
3.3A-F). To categorise glomerular morphology, the severity of GS was assessed based 
on the proportion of glomeruli analysed by extent of intra-GS (Score 0, <25% of 
glomerulus sclerosed; Score 1: 25-50% sclerosed, score 2: 50-75% sclerosed 
glomerulus, Score 3: >75% sclerosed glomerulus) in transgenic mice. 
 
At D4 P.I., some mutant glomeruli exhibited early segmental GS with higher urinary 
albumin/creatinine (UA/UC) ratios, however these were not statistically significant 
(p=0.21) between mutants and controls (Figure 3.2A, A’). At D5 P.I., the proportion of 
mutant glomeruli exhibiting segmental GS was significantly higher than the controls 
(>50% GS, ≥ score 2, p<0.05), (Figure 3.2B). UA/UC ratio was significantly increased in 
the mutants compared to the controls (*p=0.01) (Figure 3.2B’). By D6 P.I., hyaline-filled 
tubules were observed in the mutant kidneys with more extensive GS associated with 
significant albuminuria relative to the controls (Figure 3.2C, C’). Global GS was evident 
by D12 P.I. in the mutants with a significant increase in albuminuria compared to the 
controls (***p<0.0001 GS, *p=0.04 urine albumin/creatinine ratio) (Figure 3.2D, D’). 
Temporal induction of albuminuria in mutant mice from D4 to D12 P.I. was seen by 
Western blot analysis, where no albumin was present in the controls (Figure 3.2E). Due 
to limited availability of the mice, mouse numbers varied for each time-point. 
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Figure 3.2. Temporal increase of GS in Cre-ERTM+/-;Wt1f/f mutants post-tamoxifen induction 
(A) Glomeruli of Cre-ERTM+-/-;Wt1f/f transgenic mutant mice are morphologically similar to their 
controls, at D4 P.I. (A’) Quantitative graph displaying mean urine albumin/creatinine ratio (μg/mg) 
at D4 P.I. controls vs. mutants (n=14 vs n=10); 104.4±25.71 vs. 563.5±443, p=0.21, Student t-
test. (B) At D5 P.I., mutant mice reveal segmental GS compared to control mice. (B’) Graph 
showing mean urine albumin/creatinine ratio (μg/mg) at D5 P.I in controls vs. mutants (n=14 vs 
n=14); 217±157.5 vs. 11654±4304, *p=0.01, Student t-test. (C) More extensive GS is evident at 
D6 P.I. in mutants with hyaline filled tubules vs. control mice. (C’) Graph presenting mean urine 
albumin/creatinine ratio (μg/mg) at D6 P.I. in controls vs. mutants (n=5 vs n=6); 79.8±29.8 vs. 
15202±7210, **p=0.004, Student t-test. (D) Mutant mice glomeruli exhibit global GS at D12 P.I., 
with hyaline-filled tubules and pyknotic podocyte nuclei. (D’) Graph showing mean urine albumin/ 
creatinine ratio (μg/mg) at D12 P.I. controls vs. mutants (n=7 vs. n=7); 76.8±13.9 vs. 9469 ±4279, 
*p=0.04, Student t-test (E). Western blot analysis from D4, D5 and D6 D12 P.I. reveals increased 
albumin levels in the mutants vs. controls. (Scale bars=50 μm). (Asfahani et al., 2018) 
 
Heterozygotes (Cre-ERTM+/-;Wt1f/+) analysed at D4 (Figure 3.3A, A’) , D8 (Figure 3.3B, 
B’) and D12 P.I. (Figure 3.3C, C’) were no different to Cre-ERTM-/-;Wt1f/f controls. WT1 
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was observed in the glomeruli of these mice (Figure 3.3A, B, C). A normal phenotype 
was seen at all time-points (Figure 3.3A’, B’, C’) with no hyaline tubules or GS. 
 
 
Figure 3.3. WT1 is expressed Cre-ERTM+/-;Wt1f/+ hets transgenic mice post-tamoxifen 
induction 
Representative micrographs of murine glomeruli labelling podocytes with immunofluorescent anti-
WT1 antibody in D4 (A), D8 (B), D12 P.I. (C) Cre-ERTM+-/-;Wt1f/+ heterozygotes P.I. reveal WT1 
expression (Red arrow), Scale bar 50µm. (A’-B’) H&E stained glomeruli at D4, D8 and D12 P.I, 
Scale bar 25µm. (A’) No histological abnormalities exhibited at D4 P.I. (B’) D8 P.I.; intact 
glomeruli (C’) D12 P.I.; healthy glomeruli with no hyaline material in tubules (D) Graph presenting 
mean urine albumin/creatinine ratio (µg/mg) in D4 P.I controls vs. heterozygotes vs. mutants 
(n=14 vs. n=8 vs. n=10); 104.4±25.7 vs. 174.9±27.0 vs. 563.5±443.9, p=0.21, Student t-test. (E) 
Graph displaying mean urine albumin/creatinine ratio (µg/mg) in D12 P.I controls vs. 
heterozygotes vs. mutants (n=8 vs. n=3 vs. n=7); 76.8±13.9 vs. 223.5±93.8 vs. 9469±4279 (p= 
0.21, mutants vs controls), (*p=0.05, mutants vs hets), student t-test. (F) Immunoblot analysis of 
Cre-ERTM-/-;Wt1f/f, Cre-ERTM+/-;Wt1f/+ and Cre-ERTM+/-;Wt1f/f urine samples at D8 P.I. probed with 
anti-albumin [MW of albumin, 66.5kDa]. (Asfahani et al., 2018) 
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The manifestation of GS was first observed at D5 P.I. with a significant increase in 
proteinuria in the mutants compared to the controls. This temporal model of GS allowed 
us to further explore the fundamental mechanisms and pathways, which may be 
associated with Wt1 glomerulopathy at the early and late stages of the disease; 
proteinuria and global GS. 
 
3.2.1.3 Podocyte FP effacement prior to the manifestation of GS 
 
Podocyte FP effacement was evident at D4 P.I. in Cre-ERTM+/-;Wt1f/f mutants compared 
to controls (Figure 3.4A, B).  
 
 
Figure 3.4. FP effacement at D4 P.I. in Cre-ERTM+/-;Wt1f/f transgenic mice 
Electron micrographs exhibiting focal FP effacement in Cre-ERTM+/-;Wt1f/f mutants (B) at D4 P.I. 
compared to control mice (A). (Asfahani et al., 2018) 
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Interestingly, PAS staining revealed no morphological difference between both controls 
and the mutants at this time-point (Figure 3.2A); however, albumin/creatinine ratio was 
higher in the mutants, although not significant compared to the controls (Figure 3.2A’). 
TEM highlights the early stages of glomerular disease, prior to GS, indicating that the 
deletion of Wt1 at an early time creates defects in the normal charge barrier, causing a 
leak of larger proteins, including albumin into the urine. This could be an indication of 
MCD, rather than FSGS or DMS, where the glomeruli show noticeable phenotypes. 
 
3.2.1.4 Tubulointerstitial disease is evident by D12 P.I. 
 
GS can lead to tubulointerstitial disease, causing tubular atrophy and fibrosis or 
inflammation of the interstitium, resulting in reduced renal function. Tubulointerstitial 
fibrosis is associated with an increased build-up of fibroblasts in the tubules expressing 
α-smooth muscle actin (α-SMA) and can lead to CKD. 
 
In order to confirm tubulointerstitial fibrosis in the Wt1-deleted mutants, glomeruli were 
marked with vascular α-SMA and the tubule marker LTL at D12 P.I. due to the high levels 
of proteinuria and GS at this time-point. Mutant mice showed evidence of the disease 
with increased vascular α-SMA expression within the glomeruli and peritubular cells 
(Figure 3.5A bottom panel, B bottom panel, green arrows). Control mice, on the other 
hand displayed insignificant levels of α-SMA within the kidney interstitium and glomeruli 
(Figure 3.5A top panel, B top panel). Thus, in addition to GS, SMA protein expression 
suggested that there was a progression towards CKD, a leading cause of ESRD. 
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Figure 3.5. Vascular SMA expressed in Cre-ERTM+/-;Wt1f/f mutants 
(A-B) Representative micrographs of double immunofluorescent labelled glomeruli and tubules 
of transgenic mouse kidney tissue sections at D12 P.I; anti-α smooth muscle actin (Alexa Fluor 
488-conjugated) and Lotus tetragonolobus, LTL (Alexa Fluor 594-conjugated). tissues were 
counterstained with DAPI (scale bars, 50µm). (A) α-smooth muscle actin expansion is expressed 
in tubulointerstitial compartment in mutants (Green arrows, SMA) (A, bottom panel) vs. controls 
(red arrows, LTL) (A, top panel). SMA is not expressed within LTL-tubules of controls (A, top 
panel: merge) vs. mutants (A, bottom panel: merge, green arrows) (B) High power images of 
glomeruli and tubulointerstitium. α-SMA expression (green arrows) is stimulated in peritubular 
cells and in the glomerulus in the mutants (B, bottom panel) that is not seen in control Cre-ERTM-
/-;Wt1f/f transgenic mice (B, bottom panel). SMA is not expressed within LTL-tubules of controls 
(B, top panel: merge) vs. mutants (B, bottom panel: merge, green arrows). Scale bars 50µm. 
(Asfahani et al., 2018) 
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3.2.1.5 Podocin is detected within the tubular lumens of Cre-ERTM+/-;Wt1f/f mutants  
 
Due to the evidence of albuminuria and GS in the tamoxifen-induced Cre-ERTM+/-;Wt1f/f 
mutants, further investigation was carried out to determine whether podocyte depletion 
was taking place outside of the GBM. Under extreme stress, podocytes are in danger of 
detaching from the GBM causing disruption, and eventually leading to proteinuria (Kriz 
et al., 2013). TEM revealed that podocyte FP effacement was occurring as early as D4 
P.I. in the tamoxifen-induced mutants (Figure 3.4), which explained proteinuria at this 
time-point. This evidence drove us to investigate podocyte detachment further. 
 
Podocin is important for the glomerular SD and absence of this protein can lead to 
albuminuria and NS (Mollet et al., 2009). Following immunohistochemical findings of 
tamoxifen-induced D8 Cre-ERTM-/-;Wt1f/f controls and Cre-ERTM+/-;Wt1f/f mutants, Podocin 
was seen in the glomeruli of the controls with little expression in the tubules (Figure 3.6A-
F). 
 
Podocin staining of glomeruli in controls was weak (Figure 3.6E), but was completely 
absent from mutant glomeruli (Figure 3.6H, I). In the mutants, Podocin was seen in the 
kidney tubular lumen (Figure 3.6K, L), further supporting FP effacement and podocyte 
injury in the mutants, with podocyte detachment leading to GS. Research on animal 
models of progressive GS have reported that podocytes are undergoing apoptosis (Hara 
et al., 1998, Niranjan et al., 2008). GS, proteinuria and podocyte detachment led us to 
investigate the mechanisms of podocyte injury, namely apoptosis. 
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Figure 3.6. Podocin-positive cells in kidney tubules of D8 P.I Cre-ERTM+/-;Wt1f/f mutants 
Representative micrographs of kidney tubules and glomeruli in Cre-ERTM-/-;Wt1f/f controls (A-F) 
vs. Cre-ERTM+/-;Wt1f/f mutants (G-L), marked with the tubule marker, biotinylated Lotus 
tetragonolobus lectin (LTL, Alexa Fluor 488) and podocin (NPHS2, Alexa Fluor 594). Cre-ERTM-/-
;Wt1f/f controls exhibit low NPHS2 protein in the tubules, whilst NPHS2 is seen in the glomeruli, 
although faint (B, C, E, F). Cre-ERTM+/-;Wt1f/f mutants show loss of NPHS2 protein in the 
glomerulus and NPHS2 is seen in the tubules, indicated by red arrows (H, K, Alexa Fluor 594) 
and white arrows (I, L, merged). Scale bar 25µm. 
 
3.2.2 Apoptosis is evident in Cre-ERTM+/-;Wt1f/f mutants 
 
Due to the terminally differentiated nature of the podocytes, loss or injury of these cells 
can lead to GS. Although cell death can occur in three different forms: apoptosis, 
autophagy, and necrosis (Galluzzi et al., 2018, Elmore, 2007), given the evidence that 
apoptosis is a key mechanism in the pathogenesis of GS (Niranjan et al., 2008), this was 
an important mechanism to investigate following Wt1 deletion. Apoptosis is recognised 
by a compression of nuclei, along with cell shrinkage, plasma membrane blebbing and 
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cell detachment (Brauchle et al., 2014). Initial histological investigation of the glomeruli 
of Wt1 deleted mice led us to believe that podocyte apoptosis may be taking place in the 
mutant transgenic mice. 
 
One of the key components of apoptosis are the activated proteases, caspase-3 and 
caspase-6, which are the hallmark of apoptosis, triggering the “death cascade” (Crowley 
and Waterhouse, 2016). Caspases are usually inactive under normal conditions, 
however, become activated once cleaved. Upstream caspases, including caspase-8 and 
caspase-9 are the main components of triggering caspase-3 activation. In these 
experiments, cleaved caspase-3 was a major marker in detecting apoptosis at different 
time-points following Wt1 deletion. 
 
Additional apoptosis markers were explored with TUNEL assay to detect DNA 
fragmentation in the podocytes. Real-time qPCR was used to identify apoptotic genes 
expressed in the podocytes of the mutants compared with controls, and flow cytometry 
to detect Annexin V-positive podocytes in D8 P.I. mutants compared with controls. 
Annexin V staining detects translocated phosphatidylserine, identifying early actions of 
apoptosis. Together, these experiments enabled us to confirm podocyte apoptosis in the 
Wt1-deleted mice. 
 
3.2.2.1 Cleaved caspase-3 and caspase-3/7 protein expression support apoptosis in 
mutant podocytes from D4 P.I. 
 
At D4 P.I., cleaved caspase-3 protein was observed in vivo within the mutant glomeruli 
but quantitatively, was not significantly different compared to the controls, p=0.06 (Figure 
3.7A, A’, D). However, cleaved caspase-3/DAPI-positive cell numbers were significantly 
higher in the mutants by D5 P.I. compared to the controls, coinciding with the early 
manifestation of GS, ***p<0.0001 (Figure 3.7B, B’, E). Moreover, a significant increase 
of cleaved caspase-3/DAPI-positive cells was observed by D8 P.I., where severe GS 
was detected by PAS, ***p<0.0001 (Figure 3.7C, C’, F). Cleaved caspase-3 protein, 
however, was not colocalised with DAPI in all places. DAPI was evidently more 
condensed and pyknotic in the mutants in comparison to the controls, highlighting 
degeneration of the nuclei at this time-point. Podoplanin protein expression was severely 
reduced in the mutants at D8 P.I. compared to the controls, indicating a loss of 
glomerular architecture (Figure 3.7C), supporting the PAS histology analysis at D6 and 
D12 P.I. 
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Figure 3.7. Temporal increase in podocyte apoptosis in Cre-ERTM+/-;Wt1f/f mutants  
(A-F) Double immunofluorescence labelling of mouse of glomeruli; anti-cleaved caspase-3 (Casp-
3) (Alexa Fluor 594–conjugated secondary antibody) and anti-Podoplanin (Pdpn) (Alexa Fluor 
488–conjugated secondary antibody) at day 4, 5 and 8 P.I. counterstained with DAPI. Casp-3 
(red arrows) and Podoplanin-positive cells observed in DAPI-positive cells in mutant glomeruli 
(inset, white arrows) (A’, B’, C’) and not in control glomeruli (A, B, C). Scale bars 25 µm. (D) 
Graph mean percentage of DAPI-positive, Casp-3–positive cells per glomerulus at D4 PI in 
control and mutant mice. Bars represent mean and error bars specify the SEM. The number of 
DAPI-positive, Casp-3–positive glomerular cells were increased in mutant vs. control mice at D4 
PI: Controls vs. mutants (n=79 vs. n=80 glomeruli from n=3 per genotype); 1.6±0.3% vs. 
3.0±0.4%, p=0.06, not significant (NS). Student’s t-test. (E) Graph mean percentage of DAPI-
positive, cleaved caspase-3–positive, Podoplanin-positive cells per glomerulus at D5 PI in control 
and mutant mice: controls vs. mutants (n=98 vs. n=107 glomeruli from n=3 per genotype); 
0.8±0.2% versus 3.6±0.4%, ***p<0.0001, Student’s t-test. (F) Graph mean percentage of DAPI-
positive, Casp-3–positive, Podoplanin-positive cells per glomerulus at D8 PI in control and mutant 
mice: controls vs. mutants (n=30 vs. n=56 glomeruli from n=3 per genotype); 0.1±0.1% vs. 
9.5±6.4%, ***p=0.0005, Student’s t-test. (Asfahani et al., 2018) 
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In addition to this staining, D6 P.I. cellular immunostaining of cleaved caspase-3/7/DAPI 
positivity was also assessed and quantified in primary podocyte cultures (Figure 3.8). 
We observed increased cleaved caspase-3/7 positivity in the mutant podocytes (Figure 
3.8B) compared to the controls (Figure 3.8A), providing further evidence of podocyte 
apoptosis in early Wt1 glomerulopathy. 
 
 
Figure 3.8. Cleaved-caspase-3/7 is activated in primary Cre-ERTM+/-;Wt1f/f podocytes 
(A-B) Representative micrographs of D6 P.I. primary podocytes (cultured for 6 days) showing 
immunofluorescent labelling of anti-cleaved caspase-3/7 (Alexa Fluor 488-conjugated secondary 
antibody, green arrows) in control (A) and mutant mice (B). Dot plot showing the median number 
of cleaved caspase-3/7- positive podocytes in mutants vs. controls (C). Bars denote the median 
per group. Error bars symbolise the interquartile ranges (IQR). Median percentage of DAPI-
positive, cleaved caspase 3/7-positive podocytes in controls (n=9) vs. mutants (n=15): 0 (IQR: 0, 
6.56) % vs. 6.8 (IQR: 0, 16.7) % p=0.19 (n.s.), Mann-Whitney test. (n=number cells 
counted/sample). (Asfahani et al., 2018) 
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3.2.2.2 TUNEL expression coincides with the early manifestation of GS 
 
Apoptosis was further assessed using in vitro TUNEL analysis in D6 P.I. primary 
podocytes, and TUNEL-positive podocytes were apparent in the mutants (Figure 3.9D-
G) compared to the controls (Figure 3.9A-C). Quantification of TUNEL/DAPI-positive 
cells was significantly higher in the mutants vs. controls, *p=0.04 (Figure 3.9H).  
 
 
Figure 3.9. TUNEL-positive primary podocytes in D6 P.I. Cre-ERTM+/-;Wt1f/f mutants 
D6 P.I. Labelling of terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL)–
positive primary podocytes (Alexa Fluor 488–conjugated secondary antibody, green arrows) 
isolated from control and mutant mice (A-G) Sections counterstained with DAPI. (G) Higher-
power image displaying cell nucleus expressing TUNEL-positive signal. (H) Graph of apoptotic 
cells showing the proportion of TUNEL-DAPI–positive podocytes at D6 P.I. in vitro. Bars represent 
the mean, and error bars denote the SEM. Cre-ERTM-/-;Wt1f/f (n=2 samples, number of cells 
quantified per sample) versus Cre-ERTM+/-;Wt1f/f (n=2 samples, number of cells quantified per 
primary podocyte line per mouse); 1.4±0.2% versus 6.3±1.0%, *p=0.04, Student t-test. Scale bar 
25µm. (Asfahani et al., 2018) 
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Moreover, TUNEL-positive mutant podocytes were detected in vivo in D5 P.I. glomeruli 
(Figure 3.10A’), but not in controls (Figure 3.10A). There was a significant increase 
TUNEL/DAPI-positive cells in the mutants vs. controls, **p<0.0001 (Figure 3.10B). In 
vivo TUNEL analysis was further analysed at D12 P.I., where there were obvious 
TUNEL-positive podocytes in the mutants (Figure 3.11B, C, D) compared to the controls 
(Figure 3.11A). The increase in significance by D12 P.I. correlated with its phenotype of 
global GS and proteinuria, supporting apoptosis as a mechanism linked to the 
development of GS and potentially secondary tubulointerstitial fibrosis. 
 
 
Figure 3.10. TUNEL-positive glomeruli in D5 P.I. of Cre-ERTM+/-;Wt1f/f mutants 
Representative images of D5 P.I cryosections, TUNEL-positive and DAPI-positive cells [inset] in 
Cre-ERTM+/-;Wt1f/f mutants (A’) compared to Cre-ERTM-/-;Wt1f/f controls (A). Scalebar, 50µm. (B). 
Graph demonstrating increased proportion of median number of TUNEL-positive podocytes in 
Cre-ERTM-/-;Wt1f/f controls (n=2, 30 glomeruli counted/sample) vs Cre-ERTM+/-;Wt1f/f mutants (n=3, 
30 glomeruli counted/sample). Bars display the median of each group. Error bars represent 
interquartile ranges, **p<0.0001, Mann-Whitney test. (Asfahani et al., 2018) 
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Figure 3.11. TUNEL-positive cells in Cre-ERTM+/-;Wt1f/f glomeruli at D12 P.I. 
(A-D) D12 P.I. micrographs of glomeruli of transgenic mouse kidney tissue sections marked with 
TUNEL (Green arrows) and counterstained with DAPI (Scale bars, 25µm). (A) In the glomerulus 
of Cre-ERTM-/-;Wt1f/f controls, no TUNEL-positive cells are detected. (B-D) D12 P.I. Cre-ERTM+/-
;Wt1f/f mutants exhibit TUNEL/DAPI-positive cells in the glomeruli. (Asfahani et al., 2018) 
 
3.2.2.3 Early and late apoptosis is evident in the late stages of GS 
 
In vitro detection of apoptosis was also investigated along with cell necrosis through 
Annexin V/SYTOX Blue staining of D8 P.I. podocytes. Annexin V is a marker of early 
apoptosis and it identifies changes in the plasma membrane due to membrane 
externalisation of phosphatidylserine (Crowley et al., 2016). It is a useful assay to detect 
the development of apoptosis but it cannot identify which cells are undergoing late 
apoptosis or are early necrotic cells. For this reason, double staining of Annexin 
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V/SYTOX Blue was carried out to determine which cells were apoptotic and which were 
necrotic. 
 
Annexin V/SYTOX Blue positive (late apoptotic/necrotic, Figure 3.12A, C) and Annexin 
V/SYTOX Blue negative (early apoptosis, Figure 3.12B, D) expression were higher in 
the primary mutant podocytes than the control podocytes, but not significantly so. The 
increase in Annexin V expression in the mutants vs. controls at D8 supported the 
previous findings of increased cleaved caspase-3 expression at this time-point, but at a 
less significant level. 
 
 
Figure 3.12. Apoptosis is increased at D8 P.I. in Cre-ERTM+/-;Wt1f/f mutant podocytes 
(A, B) Flow cytometry analysis of primary podocytes from Day 8 P.I. Cre-ERTM-/-;Wt1f/f control and 
Cre-ERTM+/-;Wt1f/f mutant transgenic mice. The abscissa and ordinate represent the fluorescence 
intensity of Annexin V Cy7 and SYTOX Blue, respectively. (C) Dot plot showing podocyte cell 
death. Bars display the median percentages of Annexin V–positive/SYTOX Blue–positive (late 
apoptotic/necrotic) podocytes. Cre-ERTM-/-;Wt1f/f controls (n=2) vs. Cre-ERTM+/-;Wt1f/f mutants 
(n=2): 2.1% versus 3.9%, p=0.33 (n.s). (D) Dot plot showing median percentages of Annexin V-
positive cells (early apoptosis); 1.6% versus 5.0%, p=0.33 (n.s). Mann-Whitney test. (Asfahani et 
al., 2018) 
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3.2.2.4 Increased apoptotic gene transcript levels in the mutants  
 
In addition to the detection of apoptosis on a protein level, further markers of apoptosis 
were investigated on an RNA level, including Bcl2 and Bax. Both genes are regulators 
of apoptosis, involved in either inducing or inhibiting the pathway (Hardwick and Soane, 
2013); Bcl2 is anti-apoptotic, inhibiting cell death and promoting cell survival, whilst Bax 
is pro-apoptotic, and both are involved in the intrinsic apoptosis pathway, affecting the 
mitochondria. 
 
Real-time qPCR data revealed an increase in apoptosis in the mutants compared to 
controls. Expression of apoptosis-related genes was carried out on D4, D5, and D6 P.I. 
glomerular isolates. The trend of the anti-apoptotic marker, Bcl2, was not significant in 
the mutants compared to the controls at D4 and D5 P.I. (Figure 3.13A). The pro-apoptotic 
marker, Bax, was also increased in the mutants at these time-points, but failed to reach 
statistical significance (Figure 3.13B). Interestingly, both Bcl2 and Bax were slightly 
increased in the mutants vs controls at these time-points (D4 and D5 P.I.), suggesting 
that the apoptotic pathway may be activated. Bcl2 transcript levels were at approximately 
equivalent levels in both the mutants and controls at both time-points; however, Bax 
transcript levels had increased by D5 P.I. in the mutants. This corroborated my findings 
of the activation of apoptosis using cleaved caspase-3 and TUNEL at D5 P.I. By D6 P.I. 
on the other hand, the anti-apoptotic transcript, Bcl2 was lower in the mutants compared 
to the controls, but again failed to reach statistical significance (Figure 3.13A). This 
correlates with my earlier findings of increased TUNEL and caspase-3 expression. While 
this was the case, Bax transcript levels were lower in the mutants vs. controls at D6 P.I., 
however were not significant (Figure 3.13B). D6 P.I. sample numbers were less than D4 
and D5 P.I., thus may be impacting the final result. It is also important to note that this 
experiment was done in the early stages of the project, where RNA transcripts were 
analysed from glomerular isolates that were not cultured. These isolates were not only 
podocytes, but were also mesangial and endothelial cells. Bcl2 and Bax2 transcript 
levels would have therefore been analysed from a heterogenous population. This may 
explain the lower expression of Bax transcript levels in the mutants in comparison to 
other apoptosis assay markers, such as cleaved caspase-3 and TUNEL, as the latter 
experiments (figures presented earlier) were focused on podocyte cells undergoing 
apoptosis. Moreover, limited sample numbers for real-time qPCR may also be impacting 
our final results. 
 
 Page 102 of 214 
 
 
Figure 3.13. Podocyte apoptosis in pre-proteinuric and GS Cre-ERTM+/-;Wt1f/f mutants. 
Representative dot plot analyses showing the median mRNA levels of apoptosis at D4, 5 and 6 
P.I. Error bars represent IQR. (A) Bcl2; D4 P.I. Cre-ERTM-/-;Wt1f/f controls (n=3) vs. Cre-ERTM+/-
;Wt1f/f mutants (n=3), 0.6 (IQR: 0.5, 1.5) vs. 0.9 (IQR: 0.5, 1.3), p=0.9; D5 P.I. Cre-ERTM-/-;Wt1f/f 
controls (n=6) vs. Cre-ERTM+/-;Wt1f/f mutants (n=5), 0.6 (IQR: 0.3, 1.6) vs. 0.7 (IQR: 0.5, 1.4), 
p=0.77; D6 P.I. Cre-ERTM-/-;Wt1f/f controls (n=2) vs. Cre-ERTM+/-;Wt1f/f mutants (n=3), 1.0 (IQR: 
0.7, 1.3) vs. 0.6 (IQR: 0.5, 0.7), p=0.2 (B) Bax; D4 P.I. Cre-ERTM-/-;Wt1f/f controls (n=3) vs. Cre-
ERTM+/-;Wt1f/f mutants (n=3), 0.7 (IQR: 0.6, 1.3) vs. 1.2 (IQR: 0.9, 1.7), p=0.4; D5 P.I. Cre-ERTM-/-
;Wt1f/f controls (n=6) vs. Cre-ERTM+/-;Wt1f/f mutants (n=6), 1.2 (IQR: 06, 1.9) vs.1.2 (IQR: 0.8, 2.6), 
p=0.6; D6 P.I. Cre-ERTM-/-;Wt1f/f controls (n=2 mice) vs. Cre-ERTM+/-;Wt1f/f mutants (n=3 mice), 1.0 
(IQR: 0.8, 1.1) vs. 0.7 (IQR: 0.5, 0.9), p=0.4. Mann-Whitney test. (n= number of mice). 
 
3.2.3 Podocyte Notch activation precedes GS in Cre-ERTM+/-;Wt1f/f mutants  
 
As previously mentioned, the Notch pathway is highly relevant during the early stages of 
kidney development and is activated following glomerular injury (Niranjan et al., 2009, 
Cheng and Kopan, 2005, Barak et al., 2012, Sirin and Susztak, 2012, Barisoni, 2008). 
Studies revealed that ectopically inducing cleaved Notch1 during the late stages of 
kidney development resulted in DMS and FSGS with reduced expression of podocyte 
markers, including Wt1, Nphs1, Nphs2 as well as increased podocyte apoptosis and 
dedifferentiation (Niranjan et al., 2008, Waters et al., 2008). Thus, we postulated that 
deleting Wt1 would trigger the Notch signalling pathway in the mutants, causing GS. 
 
3.2.3.1 Notch components are activated following Wt1 deletion 
 
Cleaved NOTCH1 is a transmembrane protein involved in the Notch pathway, which is 
cleaved following γ-secretase activation post-ligand binding (Jorissen and De Strooper, 
2010). As stated previously, the Notch pathway consists of 2 ligand family members 
including the Dll and Jag families. Upon binding with the Notch receptors, the Notch cell 
signalling pathway is activated, cleaving the intercellular domains of the Notch receptors, 
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thus finally activating the downstream transcription factors, including HES1 and HEYL, 
which are important for organogenesis and tissue patterning (Kopan and Ilagan, 2009, 
Bray, 2006, Bray, 2016, Hori et al., 2013). 
 
After detecting increased podocyte apoptosis in Cre-ERTM+/-;Wt1f/f transgenic mice, we 
postulated that podocyte Notch activation may be a factor in early Wt1 glomerulopathy. 
The Notch pathway was analysed using real-time qPCR at D4 and D5 P.I. (Figure 3.14). 
At D4 P.I., the bHLH transcription factor, Hes6, was significantly reduced in the mutants 
compared to controls (*p=0.03) (Figure 3.14A, Appendix B [figure B.1 A-S, individual dot 
plots]). Hes6 has been shown to promote neuronal differentiation by negatively 
regulating Hes1 activity (Gratton et al., 2003, Carvalho et al., 2015).  
 
The current data shows that Hes1 transcript was increased in D4 P.I. mutants, however, 
this was not significant (p=0.53) (Figure 3.14A). There was an increase in HeyL transcript 
levels, however the increase was not significant (Figure 3.14A). Interestingly, the β3-N-
acetylglucosaminyltransferase, Lfng, was significantly lower in the mutants compared to 
the controls at this time-point (**p=0.008) (Figure 3.14A). Lfng has been reported to 
inhibit Notch1 activity from Jag1 and enhance its activity from Dll1 by modifying Notch1 
EGF6 and 36 (Kakuda and Haltiwanger, 2017). At D4 P.I, Notch signalling was activated 
by showing increased transcript levels of bHLH transcription factors Hes1, Hes3, Hes5, 
Hey1, Hey2, HeyL in the mutants, although these were not significant (Figure 3.14A). 
Notch signalling was indeed activated at D4 P.I., however, sample sizes were quite low 
(n=5/group) due to the availability of mice. 
 
At D5 P.I., bHLH transcription factors, Hes3 (*p=0.01) and Hey1 (*p=0.03) were 
significantly lower in the mutants compared to controls (Figure 3.14B, Appendix B [figure 
B.2 A-R, individual dot plots]). Dll4 transcript levels were reduced in the mutants 
compared to the controls, however, these were not significantly different (Figure 3.14B). 
There was an outlier in the control group, showing a reduction in Dll4 mRNA levels. Mfng 
transcript levels were increased in mutant podocytes, however, not significantly (p=0.45, 
Figure 3.14B). Although Mfng was not significantly increased in the mutants, we were 
keen to explore whether there was a link between increased Mfng transcript and Notch 
activity in our mice. Manic Fringe is a β3-N-acetylglucosaminyltransferase that facilitates 
NECD glycosylation during signal transduction (Kakuda and Haltiwanger, 2017). Sample 
numbers for Neur were not equal between control and mutants due to availability of the 
samples. Due to apoptosis being significantly increased at D6 P.I., we were specifically 
interested in analysing the Notch pathway at this time-point. Individual dot plots for the 
genes at D4, D5 and D6 P.I. are shown in Appendix B. 




Figure 3.14. Podocyte Notch pathway gene expression in pre-proteinuric Cre-ERTM+/-;Wt1f/f 
primary podocytes  
(A) Notch pathway transcripts in D4 P.I. Cre-ERTM+/-;Wt1f/f mutants compared to Cre-ERTM-/-;Wt1f/f 
controls. Box and whisker plots showing relative mRNA levels of Notch pathway components in 
primary podocytes of Cre-ERTM-/-;Wt1f/f vs. Cre-ERTM+/-;Wt1f/f. Horizontal lines within the box show 
medians. The boundaries of the box nearest zero mark the 25% percentile, the boundaries 
farthest from zero mark the 75% percentile (IQR). Whiskers indicate outliers outside the 10% and 
90% percentiles. Notch1 (n=5 vs n=5): 1.1 (IQR: 0.8, 1.6) vs. 0.8 (IQR: 0.5, 1.4), p=0.53; Notch2 
(n=5 vs. n=5): 1.3 (IQR: 0.7, 1.9) vs. 1.8 (IQR: 1.1, 4.3), p=0.31; Notch3 (n=5 vs. n=5): 1.2 (IQR: 
0.7, 1.5) vs. 1 (IQR: 0.5, 1.6), p=0.94; Jag1 (n=5 vs. n=5): 1 (IQR: 0.8, 1.4) vs. 1 (IQR: 0.5, 1.3), 
p=0.94; Jag2 (n=5 vs. n=5): 1 (IQR: 0.7, 1.4) vs. 0.8 (IQR: 0.5, 0.8), p=0.22; Dll3 (n=5 vs. n=5): 
0.8 (IQR: 0.6, 1.9) vs. 1.2 (IQR: 0.6, 1.9), p>0.99; Dll1(n=5 vs. n=5): 1.9 (IQR: 0.2, 4.2) vs. 1.3 
(IQR: 0.2, 2.2), p=0.67; Dll4 (n=5 vs. n=5): 0.9 9IQR: 0.3, 3.5) vs. 0.6 (IQR: 0.4, 2.7), p=0.67;  
Hes1 (n=5 vs. n=5): 3 (IQR: 1.5, 4) vs. 4 (IQR: 2.5, 4.3), p=0.53; Hes3 (n=5 vs. n=5), 0.8 (IQR: 
0.7, 1.6) vs. 1.2 (IQR: 0.7, 1.6), p=0.94; Hes5 (n=5 vs. n=5), 1.1 (IQR: 0.7, 1.5) vs. 1.2 (IQR: 1, 
3.8), p=0.31; Hes6, (n=5 vs. n=5), 1 (IQR: 0.8, 1.3) vs. 0.4 (IQR: 0.4, 0.8), *p=0.03; Hey1, (n=5 
vs. n=5), 1 (IQR: 0.5, 2.3) vs. 1 (IQR: 0.7, 1.1), p=0.94; Hey2, (n=5 vs. n=5), 0.8 (IQR: 0.6, 1.9) 
vs. 1.2 (IQR: 0.9, 1.6), p=0.8; HeyL, (n=5 vs. n=5), 0.9 (IQR: 0.5, 2.7) vs. 1.9 (IQR: 1.5, 18.9), 
p=0.15; Mfng, (n=4 vs. n=5), 0.8 (IQR: 0.3, 6.1) vs. 1.4 (IQR: 0.5, 1.5), p=0.68; Lfng (n=5 vs. n=5), 
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1 ( IQR: 0.8, 1.2) vs. 0.4 (IQR:0.3, 0.5), **p=0.008; Mb (n=5 vs. n=5), 1.3 (IQR: 0.6, 1.7) vs. 1.3 
(IQR: 0.7, 2.7), p=0.8; Neur (n=5 vs. n=5), 1 (IQR: 0.7, 1.5) vs. 0.5 (IQR: 0.5, 1.6), p=0.22. Mann-
Whitney U test. (B) Notch pathway transcripts in D5 P.I. Cre-ERTM+/-;Wt1f/f mutants compared to 
Cre-ERTM-/-;Wt1f/f controls. Box and whisker plots showing relative mRNA levels of Notch pathway 
components in primary podocytes of Cre-ERTM-/-;Wt1f/f vs. Cre-ERTM+/-;Wt1f/f. Horizontal lines 
within the box show medians. The boundaries of the box nearest zero mark the 25% percentile, 
the boundaries farthest from zero mark the 75% percentile (IQR). Whiskers indicate outliers 
outside the 10% and 90% percentiles. Notch1 (n=6 vs n=6), 1.3(IQR:1, 1.5) vs. 1.1(IQR: 0.4,2.1), 
p>0.99; Notch2 (n=6 vs. n=6), 1.5 (IQR: 1.2, 1.7) vs. 2 (IQR: 1, 2.7), p=0.33; Notch3 (n=6 vs. 
n=7), 1.3(IQR: 1.1, 1.5) vs. 1 (IQR:0.4, 1.7) p=0.36; Dll1 (n=6 vs. n=8), 1 (IQR: 0.8, 1.3) vs. 0.9 
(IQR: 0.03, 1.4), p=0.84; Dll4 (n=6 vs. n=7), 0.8 (IQR: 0.5, 2.9) vs. 0.4 (IQR: 0.04, 0.8), p=0.18; 
Jag1 (n=6 vs. n=8), 1.1 (IQR: 0.9, 1.3) vs. 0.6 (IQR: 0.5, 1.1), p=0.08; Jag2 (n=2 vs. n=2), 1.3 
(IQR: 0.6, 1.9) vs. 1 (IQR: 0.9, 1.1), p>0.99; Hes1 (n=7 vs. n=8), 2.2 (IQR: 1.4, 3.9) vs. 1.5 (IQR: 
1.4, 3.1), p=0.39; Hes3 (n=9 vs. n=11), 1.3 (IQR: 0.9, 1.5) vs. 0.8 (IQR: 0.6, 1.2), *p=0.01; Hes5 
(n=6 vs. n=7), 1 (IQR: 0.7, 2) vs. 1.4 (IQR: 0.7, 2.1), p=0.7; Hes6, (n=8 vs. n=8), 1.6 (IQR: 1, 2.1) 
vs. 1.1 (IQR: 0.4, 1.8), p=0.41; Hey1, (n=6 vs. n=8), 1.5 (IQR: 0.9, 2.1) vs. 0.7 (IQR: 0.5, 1.1), 
*p=0.03; Hey2, (n=6 vs. n=8), 1.2 (IQR: 0.7, 1.4) vs. 1.2 (IQR: 0.6, 1.5), p>0.99; HeyL, (n=6 vs. 
n=7), 2.2 (IQR: 0.3, 4.8) vs. 2.8 (IQR: 0.3, 4.4), p=0.8; Mfng, (n=12 vs. n=10), 0.8 (IQR: 0.6, 3.1) 
vs. 1.4 (IQR: 0.6, 9.4), p=0.45; Lfng (n=6 vs. n=8), 0.6 ( IQR: 0.5, 1.3) vs. 0.6 (IQR:0.2, 0.7), 
p=0.49; Mb (n=6 vs. n=5), 0.6 (IQR: 0.4, 1.2) vs. 0.8 (IQR: 0.7, 1.5), p=0.33; Neur (n=2 vs. n=4), 
1.4 (IQR: 0.9, 1.8) vs. 0.4 (IQR: 0.3, 0.7), p=0.13. Mann-Whitney U test. Individual dot plots are 
shown in Appendix B. 
 
Double immunofluorescence labelling at D4 P.I. between the controls and mutants 
(Figure 3.15A-H) showed increased cleaved Notch1 (Val1744) protein expression in the 
mutant nuclei of Nestin-positive podocytes, with a loss of podocyte glomerular 
architecture (Figure 3.15E-H). We observed no cleaved Notch1 (Val1744) protein in the 
podocyte nuclei of the controls, labelled with the podocyte marker, synaptopodin (Synpo) 
at D5 P.I. (Figure 3.15I-L). In the mutants, however, cleaved Notch1 protein was seen in 
the podocytes (Figure 3.15M-P). Podocyte markers, Podoplanin at D4 P.I, and 
Synaptopodin at D5 P.I. were used due to the lack of availability of one or the other 
during the experiment.  
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Figure 3.15. Activated cleaved Notch1 at the early onset of disease in Cre-ERTM+/-;Wt1f/f 
mutants 
Representative micrographs of glomeruli in D4 P.I., stained with the glomerular marker, 
podoplanin (PDPN, Alexa Fluor 488, green), and cleaved notch 1 (Val1744, Alexa Fluor 594, red), 
counterstained with the nuclear marker, DAPI (A-H) NICD protein expression is not evident in the 
control Cre-ERTM-/-;Wt1f/f mice (C, D) in comparison to the Cre-ERTM+/-;Wt1f/f mutants, where NICD 
appears to be expressed in the podocytes, indicated by red and white arrows (G, H) 
Representative micrographs of mouse glomeruli at D5 P.I. stained with the podocyte marker, 
Synaptopodin (SYNPO, Alexa Fluor 488, green) and NICD (Alexa Fluor 594, red), counterstained 
with DAPI (I-P). Control Cre-ERTM-/-;Wt1f/f mice display no NICD protein in the glomerulus (K, L) 
compared to Cre-ERTM+/-;Wt1f/f   mutants, where NICD protein expression is revealed in the 
podocytes, indicated by red and white arrows (O, P). Scale bar, 25 µm. 
 
Next, we examined the Notch pathway at the onset of GS, D6 P.I. Concomitant with early 
GS and albuminuria, Notch transcripts, Notch1, Hes1, 3, 5 and Hey2 were increased in 
primary mutant podocyte lysates compared to controls (Figure 3.16A, Appendix B 
[Figure B.3 A-R, individual dot plots]). FoxC2 transcript was repressed in the mutants, 
with increased Nrarp expression (Figure 3.16A). Notch regulated ankyrin repeat protein 
(NRARP) is a downstream effector of Notch signalling (Zhang et al., 2017). Earlier 
studies showed that Nrarp is regulated by Notch signalling and is highly expressed in 
mouse tissues where Notch1 is expressed (Krebs et al., 2001). Our data reveals a 
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significant increase in Notch1 (*p=0.04), Nrarp (**p=0.0087), Hes5 (**p=0.005), and 
Hey3 (*p=0.03) transcripts in the mutants. This data suggests that the increased Nrarp 
transcript is regulated by Notch activity. Repression of FoxC2 coincides with the 
upregulation of the Notch components and onset of GS in the mutants (Figure 3.16A). 
 
Immunofluorescence labelling at D6 P.I. validated these results, where cleaved Notch1 
protein (Val1744) was seen in the mutant podocytes compared to controls (Figure 
3.16B). Western blot analysis further validated this data, where Notch1 protein was 
increased in primary mutant podocyte lysates relative to controls (Figure 3.16C). 
Supporting activation of a pathogenic Notch signal was further observed in increased 
podocyte Mfng transcript (Figure 3.16A). Pofut1 protein was also observed in primary 
mutant podocytes at D6 P.I. (Figure 3.16D). Fucosylation of the extracellular domain of 
the Notch protein is mediated by Pofut1, an O-fucosyltransferase 1 enzyme (Rana and 
Haltiwanger, 2011). 
 
A role for ligand-dependent activation of podocyte Notch1 was suggested by the 
observation of a striking upregulation of Jag1 in the parietal epithelium of mutants 
compared to controls (Figure 3.17 A, B). Mutant glomeruli fragments revealed Jag1 
expression in foci of Podocin-positive cells (Figure 3.17a, b, insets). At D6 P.I., Jag1 
protein expression was evident in the primary mutant lysates compared to controls 
(Figure 3.17C). Increased transcript levels of Mfng, as well as increased Jag1 and Pofut1 
protein expression in the mutants led us to hypothesis that Jag1 may be activating 
Notch1 signalling via Mfng and Pofut1 modification in our disease model. These data 
support a role for the potentiation of Notch1 signalling in early Wt1 glomerulopathy.  
 
To further validate Notch activation following Wt1 deletion, immortalised podocytes of 
DDS and FS patients were analysed. DDS patients carried C1096T mutations in WT1, 
(p.Arg366Cys) and FS patients carried mutations at intron 9 of WT1, affecting the ratio 
of +/-KTS. There was an increase in transcript levels of Notch pathway components, 
NOTCH1, NOTCH2, HES1, HEYL, JAG1 (Figure 3.18A). PCR data showed no WT1 
amplicon in the DDS and FS patients compared to the control sample, where WT1 was 
expressed (Figure 3.18B). While this corroborates our in vivo findings, patient sample 
numbers were very low. Therefore, increasing sample sizes will provide us with a more 
accurate result. 
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Figure 3.16. Notch activation coincides with onset of GS in Cre-ERTM+/-;Wt1f/f mutants  
(A) At D6 P.I.; Box and whisker plots showing relative mRNA levels of Notch pathway components 
in primary podocytes of mutants vs controls. Horizontal lines within the box show medians. The 
boundaries of the box nearest zero mark the 25% percentile, the boundaries farthest from zero 
mark the 75% percentile. Whiskers indicate outliers outside the 10% and 90% percentiles. Cre-
ERTM-/-;Wt1f/f  vs. Cre-ERTM+/-;wt1f/f: Wt1 (n=6 vs. n=6), 1 (IQR: 0.7, 1.8) vs. 0.2 (IQR: 0.2, 0.6), 
*p=0.02; FoxC2 (n=5 vs. n=6), 1.5 (IQR: 0.4, 1.7) vs. 0.1 (IQR: 0.1, 0.7), *p=0.03; Notch1 (n=6 vs 
n=11), 0.9(IQR:0.7, 1.5) vs. 2.9(IQR: 0.9, 3.5), *p=0.036; Notch2 (n=6 vs. n=10), 0.9 (IQR: 0.9, 
1.2) vs. 1.2 (IQR: 0.8, 1.8), p=0.41; Dll1 (n=6 vs. n=10), 1.2 (IQR: 0.4, 2.9) vs. 0.3 (IQR: 0.1, 2.8), 
p=0.3; Dll4 (n=5 vs. n=5), 2.3 (IQR: 0.3, 2.5) vs. 0.1 (IQR: 0.04, 1.6), p=0.15; Jag1 (n=6 vs. n=10), 
1.1 (IQR: 0.6, 1.7) vs. 0.9 (IQR: 0.7, 1.2), p=0.71; Jag2 (n=5 vs. n=5), 0.8 (IQR: 0.5, 2.2) vs. 0.5 
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(IQR: 0.4, 0.7), p=0.15; Nrarp (n=5 vs. n=5), 0.8 (IQR: 0.3, 1.8) vs. 3.8 (IQR: 3.1, 4.2), **p=0.0087; 
Rbpj (n=7 vs. n=10), 1 (IQR: 0.8, 1.3) vs. 1.5 (IQR: 1, 2.1), p=0.05; Hes1 (n=6 vs. n=11), 1 (IQR: 
0.7, 1.3) vs. 1.3 (IQR: 1, 2.2), p=0.12; Hes3 (n=6 vs. n=11), 0.9 (IQR: 0.7, 1.7) vs. 1.3 (IQR: 0.9, 
3.4), p=0.17; Hes5 (n=6 vs. n=11), 0.9 (IQR: 0.7, 1.4) vs. 2.3 (IQR: 1.3, 6.2), **p=0.005; Hey1, 
(n=4 vs. n=5), 1.2 (IQR: 0.5, 1.8) vs. 2 (IQR: 1.2, 2.6), p=0.29; Hey2, (n=4 vs. n=5), 1.4 (IQR: 0.6, 
1.5) vs. 3.9 (IQR: 2.1, 6), *p=0.03; HeyL, (n=5 vs. n=5), 1.1 (IQR: 0.6, 1.6) vs. 1.7 (IQR: 0.9, 4.8), 
p=0.31; Mfng, (n=9 vs. n=10), 0.9 (IQR: 0.5, 2.3) vs. 2.3 (IQR: 0.7, 5.7), p=0.21; Lfng (n=5 vs. 
n=5), 0.8 ( IQR: 0.7, 1.6) vs. 0.8 (IQR:0.5, 1.9), p=0.8; Mb (n=5 vs. n=5), 0.6 (IQR: 0.6, 2.3) vs. 
1.3 (IQR: 0.6, 3.8), p=0.53. Mann-Whitney U test. Individual dot plots are shown in Appendix B. 
(B) Representative image of D6 P.I. glomeruli following double immunofluorescence labelling of 
mouse kidney sections with anti-cleaved Notch1 (Val1744, Alexa Fluor 594-conjugated 
secondary antibody) and anti-Nestin (demarcates podocytes, Alexa Fluor 488-conjugated 
secondary antibody) in Cre-ERTM-/-;Wt1f/f (controls) and Cre-ERTM+/-;Wt1f/f (mutants) 
counterstained with DAPI. Arrows indicate positive Cleaved Notch1 nuclear staining in mutant 
glomeruli within Nestin-positive cells, which are not detected in control glomeruli. Scale bar 50 
μm. Inset display high power image of same cell, scale bar 10 μm. (C, D) western blot images of 
protein derived from primary podocytes isolated from mutant and control mice. Immunoblots show 
that (C) cleaved Notch1 [Val1744] and Pofut1 (D) are expressed at D6 P.I. in mutant podocytes 
and not in controls (Asfahani et al., 2018). 
  




Figure 3.17. JAGGED 1 is expressed in Cre-ERTM+/-;Wt1f/f glomeruli at disease onset 
Representative images showing glomeruli double immunofluorescence labelled with anti-JA1 
(Alexa Fluor 594–conjugated secondary antibody) and anti-Podocin (demarcates podocytes; 
Alexa Fluor 488–conjugated secondary antibody) in D6 P.I. mouse kidney sections of Cre-ERTM-
/-;Wt1f/f (control) and Cre-ERTM+/-;Wt1f/f (mutant) mice. Sections are counterstained with DAPI. 
Positive Jagged1 staining in the parietal epithelium (red arrows), areas of podocyte adhesion (on 
the surface of Podocin-positive podocytes, green arrows, [B]; white arrows in merged image) to 
Bowman’s capsule and in the glomerular stalk of mutant glomeruli that are not evident in control 
glomeruli. Scale bar 50µm. (A, B) Higher-power views showing perimembranous expression of 
Jagged1 (green) in Podocin-positive podocytes (red) in controls (a) compared to mutants (b). (C) 
Western blot analyses of protein derived from primary podocytes isolated from mutants and 
control mice. Jagged1 is shown to be increased at D6 P.I. in mutant podocytes but not in controls. 
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Figure 3.18. Increased Notch pathway transcripts in primary mutant WT1 podocytes 
(A) WT1 is absent in patients carrying WT1 mutations compared to control DNA. GAPDH 
expression is equal amongst all groups. (B) Relative transcript levels of the Notch pathway in 
controls lacking WT1 mutations vs. DDS (exon 8 C1096T mutation) and FS (intron 9 splice site 
mutation) patients. Bars represent the median, error bars represent the IQR; Ctrl (n=3) vs. DDS 
(n=3): NOTCH1, 1±0 (IQR: 1, 1) vs. 2.9 (IQR: 2.5, 2.9), p=0.1; NOTCH2, 1±0 (IQR: 1, 1) vs. 1.1 
(IQR: 1.1, 1.3), p=0.1; HES1, 1 (IQR: 1, 1) vs. 1.8 (IQR: 1.1, 1.8), p=0.1, HEYL, 1 (IQR: 1, 1) vs. 
0.9 (IQR: 0.6, 1), p=0.7; JAG1, 1 (IQR: 1, 1) vs. 0.7 (IQR: 0.7, 0.8), p=0.1. Ctrl (n=3) vs. FS (n=3): 
NOTCH1, 1 (IQR: 1, 1) vs. 1.3 (IQR: 1.2, 1.5), p=0.1; NOTCH2, 1 (IQR: 1, 1) vs. 1.7 (IQR: 1.3, 
1.9), p=0.1, HES1, 1 (IQR: 1, 1) vs. 1.3 (IQR: 1.3, 1.5), p=0.1, HEYL, 1 (IQR: 1, 1) vs. 1.2 (IQR: 
1, 1.3), p=0.1, JAG1, 1 (IQR: 1, 1) vs. 1.1 (IQR: 0.9, 1.1), p=0.7. DDS (n=3) vs. FS (n=3): 
NOTCH1, p=0.1; NOTCH2, p=0.2; HES1, p=0.7; HEYL, p=0.1; JAG1, p=0.1. Mann-Whitney U 
test. DDS, Denys-Drash syndrome; FS, Frasier syndrome 
 
3.2.3.2 HES1 is apparent at the onset of GS and is associated with podocyte EMT  
 
We next investigated the activation of Hes and Hey in early disease. 
Immunofluorescence revealed expression of Hes1 in Synaptopodin-positive podocytes 
at the onset of GS in mutants compared with controls (Figure 3.19A, B). Hes1-positive 
glomerular epithelial cells exhibited Hes1 protein distinctive from Hes1-positive LTL-
positive tubules, indicating Notch activation specifically in the podocytes (Figure 3.19B, 
B’). Hes1 protein was also revealed as clusters in the Synaptopodin-positive podocytes 
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compared to PECAM-positive glomerular endothelial cells of the mutants (Figure 3.19 D, 
D’). Hes1 was absent in the Synaptopodin-positive cells of controls (Figure 3.19C). 
 
 
Figure 3.19. Podocyte Hes1 expression coincides with onset of GS in Cre-ERTM+/-;Wt1f/f 
mutants 
(A, B, B’) D5 P.I. glomeruli following double immunofluorescence labelling of mouse kidney 
sections with anti-Hes1 (Alexa Fluor 594–conjugated secondary antibody), anti-Synaptopodin 
(SYNPO, demarcates podocytes (Alexa Fluor 647–conjugated secondary), and LTL, demarcates 
tubules (Alexa Fluor 488–conjugated secondary antibody) of Cre-ERTM-/-;Wt1f/f (control) and Cre-
ERTM+/-;Wt1f/f (mutant) transgenic mice. Sections are counterstained with DAPI. Scale bar, 50 µm. 
(B, B’) Hes1-positive, SYNPO-positive glomerular epithelial cells were observed in regions 
distinct from LTL-positive tubules in the mutants. Scale bar, 50 µm. (B’) 10 µm. (C, D, D’) 
Segmental clusters of nuclear Hes1 expression in Synpo-positive, PECAM-negative podocytes 
detected in glomeruli of the mutants and not in the control glomeruli. Scale bar, 50 µm. (Asfahani 
et al., 2018) 
 
Due to HES1’s association with EMT (Wang et al., 2015), we tested whether there was 
an upregulation of Snail and Slug mRNAs in D6 P.I. mutant podocytes compared to 
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controls (Figure 3.20A). Both EMT transcript levels were significantly increased in the 
mutants compared to controls, suggesting a role for Hes1 inducing EMT gene 
expression. To examine this, primary podocytes were isolated from Nphs2;rtTA mice, 
cultured, and transfected with constructs expressing either Tet-O-Hes1 or GFP. Hes1 
was not detected in untreated Tet-O-Hes1 nor doxycycline-treated GFP transfected 
Nphs2;rtTA podocytes (Figure 3.20B). Dose-dependent doxycycline treatment led to an 
increase in podocyte Hes1 mRNA and protein expression (Figure 3.20B, C, Figure 3.21). 
Induction of Hes1 expression led to a 3-fold upregulation of Snail and Slug mRNAs 
compared to untreated TetO-Hes1 transfected and doxycycline-treated GFP transfected 
Nphs2;rtTA podocytes (Figure 3.20C). Thus, the induction of Hes1 in podocytes could 
facilitate manifestation of GS by controlling expression of EMT genes in podocytes. 
 
 
Figure 3.20. Upregulation of podocyte EMT genes in TetOHes1-induced podocytes 
(A) Graph at D6 P.I. showing an upregulation of podocyte Snail and Slug EMT transcripts. Median 
Snail mRNA expression at D6 PI in control vs mutant mice: 1.1 (interquartile range [IQR]: 0.9, 
1.2) vs. 2.7 (IQR:1.8, 2.8), *p=0.045, Mann-Whitney. Median Slug mRNA expression at D6 PI in 
control vs. mutant mice: 1.2 (IQR: 0.6, 1.5) vs. 2.8 (IQR: 1.4, 3.7), *p= 0.03, Mann-Whitney. (B) 
Hes1 mRNA expression is increased in doxycycline-treated primary Nphs2;rtTA podocytes 
transduced with TetOHes1 plasmid vs. untreated TetOHes1 and treated green fluorescence 
protein (GFP)-transduced primary Nphs2;rtTA podocytes. Mean Hes1 mRNA expression relative 
to Gapdh (±SD): untreated control (GFP) vs. untreated TetOHes1 vs. treated control (doxycycline 
2 µg/ml) vs. treated TetOHes1 (2 µg/ml) vs. treated TetOHes1 (4 µg/ml): 1.15±0.66 vs. 1.26±1.13 
vs. 1.21±0.88 vs. 54.56±44.24 (**p<0.004) vs. 42.78±33.07 (**p<0.008). No significant difference 
in dose-response was observed, p=.045 (n.s.). (C) EMT genes, Snail and Slug are upregulated 
in doxycycline-treated primary Nphs2;rtTA podocytes transduced with TetOHes1 plasmid vs. 
untreated TetOHes1 and treated GFP-transduced primary Nphs2;rtTA podocytes. Untreated 
control (GFP) vs. untreated TetOHes1 vs. treated TetOHes1 (4 µg/ml): mean Snail mRNA 
expression relative to Gapdh (±SD): 1.76±2.1 vs. 1.01±0.31 vs. 4.82±3.94, *p< 0.05. Mean Slug 
mRNA expression relative to Gapdh (±SD): 0.95±1.12 vs. 0.31±0.26 vs. 5.10±0.3, *p<0.05. 
(Asfahani et al., 2018) 
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Figure 3.21. Hes1 is increased post-doxycycline treatment in Nphs2;rtTA-transduced 
podocytes 
Western blot analysis showing a representative image of protein lysates from doxycycline-treated 
primary Nphs2;rtTA podocytes transduced with TetoHes1 (t-o-Hes1) and GFP plasmids. 
Increased Hes1 protein expression was detected following a dose increase of doxycycline in the 
tetoHes1 transduced podocytes. No Hes1 protein expression was observed in GFP-transduced 
Nphs2;rtTA podocyte lysates post-doxycycline treatment (Asfahani et al., 2018). 
 
In addition to analysis of Notch activation in Wt1 glomerulopathy in mice, we examined 
biopsy samples from an FSGS patient with the mutation WT1c.1390G>T. JAGGED1 
protein was detected in cells with focal NEPHRIN staining in the patient but was 
predominantly in the parietal epithelium (Figure 3.22A, bottom panel). The control 
samples, which were non-diseased time-zero renal transplant biopsies, showed 
JAGGED1 expression in regions distal to NEPHRIN suggesting that there was 
endothelial JAGGED1 expression (Figure 3.22A, top panel). JAGGED1 was not 
observed in the control parietal epithelium to the extent that was seen in the mutant WT1 
patient tissue. The bHLH transcription factor, HES1 was also examined by 
immunofluorescence staining on the patient tissue and was detected in the podocytes 
(Figure 3.22B, bottom panel) compared to the control biopsy tissue (Figure 3.22B, top 
panel). 
 
The data above has highlighted an increase in the Notch pathway components in Wt1 
glomerulopathy in both murine and patient samples, supporting a role for Notch 
activation in human WT1-mediated glomerular disease. A recent study has shown that 
both Jag1 and Notch2 are associated with kidney fibrosis in mouse models of folic-acid 
(FA)-induced nephropathy, UUO and apolipoprotein L1 (APOL1)-associated kidney 
disease (Huang et al., 2018). Similarly, our immunohistochemistry and Western blot 
findings show that Jag1 may be playing a role in the activation of Notch1 in Wt1 
glomerulopathy. 
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Figure 3.22. JAGGED1 and HES1 are expressed in WT1 c.1390G>T (p.Asp464Asn) human 
glomeruli 
(A, B) Representative micrographs of glomeruli following double immunofluorescence labelling 
of human kidney sections from control (time-zero renal allograft biopsy) and WT1 
c.1390G>T mutant patient with anti-JAGGED1 (A) or anti-HES1 (B) antibodies (Alexa Fluor 594) 
and anti-Nephrin antibody (demarcates podocyte slit diaphragm, Alexa Fluor 488). (A) JAGGED1 
is upregulated in parietal epithelium of WT1 c.1390G>T glomeruli vs. controls (red arrows) and is 
also expressed in a linear pattern associated with focal NEPHRIN staining in podocytes. 
JAGGED1 expression is also detected in the endothelium of time-zero allograft glomeruli, which 
do not exhibit GS. Scale bars, 50 μm. (B) Increased HES1 expression is observed in nuclei of 
cells adjacent to NEPHRIN-positive podocytes of WT1 c.1390G>T glomeruli with advanced GS. 
Scale bars, 50 μm (Asfahani et al., 2018). 
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3.2.4 Notch inhibition ameliorates disease severity in Wt1 glomerulopathy 
 
Finding that there was an activation of the Notch pathway in early disease, we next 
determined the consequences of γ-secretase inhibition in Cre-ERTM+/-;Wt1f/f mutant mice 
to inhibit Notch during disease manifestation. Mice were given an intraperitoneal injection 
of the γ-secretase inhibitor, GSI-IX (DAPT), at late D4 P.I. and a second dose was given 
16 hours later (D5 P.I.). Mice were then sacrificed at least 8 hours following the second 
treatment. Paraffin-embedded PAS-stained tissue sections were examined using a light 
microscope to score the severity of GS in the GSI-IX-treated vs. vehicle (DMSO only)-
treated mutants, treated at the same time. Hyaline-filled tubules were observed in the 
vehicle-treated mutants, showing evidence of proteinaceous material in the tissues. 
Sclerotic glomeruli with mesangial proliferation were also evident in the vehicle-treated 
mutants (Figure 3.23B), whilst these features were not exhibited in the GSI-IX-treated 
mutants (Figure 3.23C). GS was significantly higher in the vehicle-treated mutant 
glomeruli compared to the GSI-IX-treated mutants (**p=0.008) (Figure 3.23D). 
 
The hypothesis that podocyte Notch activation is likely a ligand-dependent event is 
supported by the efficacy of GSI inhibition in manifestation of early glomerulopathy. GSI-
IX-treated mutants showed improved urine albumin/creatinine ratio in contrast to the 
vehicle-treated mutants (*p=0.02) (Figure 3.23F). Notch transcript levels were reduced 
post-GSI treatment compared to the vehicle-treated mutants (Figure 3.23E). Wt1 
transcript levels and protein expression were verified by real-time qPCR and 
immunofluorescence in both GSI-IX- and vehicle-treated mutants to confirm whether any 
alteration of Wt1 expression was observed following treatment (Figure 3.24). There was 
no significant difference of Wt1 transcript levels between the vehicle- and the GSI-IX-
treated mutant mice (Figure 3.24B) as well as no difference in WT1 protein expression. 
Cre-ERTM-/-;Wt1f/f controls were used for comparison of Wt1 levels post-tamoxifen 
induction, and it was evident that Wt1 expression was reduced in the mutants vs. Cre-
ERTM+/-;Wt1f/f controls on an mRNA and protein level. To examine urine albumin levels 
further, Western blot analysis revealed absence of albuminuria in the GSI-IX-treated 
mice compared to vehicle-treated mutants at D5 P.I. (Figure 3.23G). 
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Figure 3.23. γ-secretase inhibition of Notch ameliorates early Wt1 glomerulopathy 
(A) PAS-stained sections of D5 P.I. Cre-ERTM-/-;Wt1f/f mutants. (B) Vehicle-treated Cre-ERTM+/-;Wt1f/f 
mutants. (C) GSI-IX-treated Cre-ERTM+/-;Wt1f/f mutants. Scale bar, 50 µm. (A, B) GS with hyaline 
material in the tubules in mutants and vehicle-treated mice. (C) Glomeruli of GSI-IX–treated mutants 
present lower levels of GS vs. vehicle-treated mutants. (D) Graph showing proportion in glomeruli per 
genotype with different levels of GS (score 0: <25% sclerosis; score 1: 25%–50% sclerosis; score 2: 
50%–75% sclerosis; score 3: >75% sclerosis). Bars show mean percentage of scores, error bars show 
SEMs. Normal glomerular morphology was present in a higher proportion of GSI-IX–treated Cre-
ERTM+/-;Wt1f/f transgenic mice (n=52 glomeruli, n=5 mice) compared with vehicle-treated Cre-ERTM+/-
;Wt1f/f (mutants) at D5 P.I. (n=52 glomeruli, n=4 mice): vehicle-treated Cre-ERTM+/-;Wt1f/f vs. GSI-IX–
treated Cre-ERTM+/-;Wt1f/f transgenic mice: score 0: 18 0.9% vs. 59 1.0%, *p<0.02, Student’s t-test; 
score 2: 39 5% vs. 8 3%, *p<0.008, Student’s t-test. (E) Graph showing reduced mean relative Rbpsuh, 
HES1, Hes3, and HES5 mRNA expression from cultured podocytes from GSI-IX–untreated vs. 
untreated mutant mice: Rbpsuh, 1.2±0.2 vs. 0.6 0.03, *p=0.01; Hes1, 1.1±0.1 vs. 0.6±0.01, p=0.05; 
Hes3: 1.4±0.3 vs. 0.5±0.1, p=0.05; Hes5: 3.1 0.9 vs. 2.0±0.4, P=0.1. Bars represent means and error 
bars represent SEMs. (F) Graph illustrating median urine albumin-creatinine ratio in vehicle-treated vs. 
GSI-IX–treated mutant mice. Bars represent the median of each group. Error bars represent the 
interquartile ranges (IQRs): Cre-ERTM+/-;Wt1f/f vs. GSI-IX–treated Cre-ERTM+/-;Wt1f/f mice: 35,836 (IQR: 
21,304, 46,371) vs. 6657 (IQR: 1337, 10,565), *p=0.02, Mann-Whitney test. (G) Western blot analysis 
reveals albumin in urine samples of vehicle-treated vs. GSI-IX–treated mutant mice (MW albumin, 66.5 
kDa), n=3 mice/group (Asfahani et al., 2018). 
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Figure 3.24. Wt1 transcript and protein levels are comparable in Cre-ERTM+/-;Wt1f/f mutants 
post-γ-secretase inhibition and vehicle treatment 
(A) Representative images of glomeruli following immunofluorescence labelling of kidney 
sections: Cre-ERTM-/-;Wt1f/f (control), Cre-ERTM+/-;Wt1f/f (mutant), vehicle-treated Cre-ERTM+/-;Wt1f/f 
and GSI-IX-treated Cre-ERTM+/-;Wt1f/f transgenic mice with anti-WT1 (Alexa Fluor 594-conjugated 
secondary antibody). WT1 is evident in control and reduced in the mutants. (B) Quantitative graph 
illustrating relative transcript levels of Wt1 in primary podocytes of Cre-ERTM-/-;Wt1f/f (control), Cre-
ERTM+/-;Wt1f/f (mutant), vehicle-treated Cre-ERTM+/-;Wt1f/f and GSI-IX treated Cre-ERTM+/-;Wt1f/f 
transgenic mice. Bars signify the mean, error bars denote the standard error of the mean, (SEM). 
Cre-ERTM-/-;Wt1f/f vs. Cre-ERTM+/-;Wt1f/f: 1.1±0.2 vs. 0.4±0.4, *p=0.03; Cre-ERTM-/-;Wt1f/f vs. 
vehicle-treated Cre-ERTM+/-;Wt1f/f mice: 1.1±0.2 vs. 0.4±0.2, p=0.07; vehicle-treated Cre-ERTM+/-
;Wt1f/f vs. GSI-IX treated Cre-ERTM+/-;Wt1f/f: 0.4±0.2 vs. 0.4±0.3, p=0.93, Student t-test, n=6 
mice/group (Asfahani et al., 2018). 
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We next tested the effects of GSI-IX treatment in established disease by inhibiting γ-
secretase at D7 P.I. in Cre-ERTM+/-;Wt1f/f mutant mice. Mice were treated with the 
compound twice and late D8 P.I. kidney histology analysed by PAS staining using a light 
microscope (n=2 mice) following tissue harvest. There was no significant difference in 
the severity of GS or albumin levels between the GSI-IX- and vehicle-treated mutants at 
this time-point (Figure 3.25A, E). In fact, a scoring of 3 for GS was relatively high in both 
groups (Figure 3.25C). Albumin/creatinine levels were lower in the GSI-IX-treated 
mutants; however, the difference did not reach statistical significance (Figure 3.25D). 
Furthermore, immunofluorescence revealed no difference in tubulointerstitial expression 
of vascular smooth muscle actin between both groups (Figure 3.25B).  
 
These data illustrate that the activation of Notch in podocytes occurs in early Wt1 
glomerulopathy. Additional mice need to be analysed to further establish the effect of 
GSI-inhibition at later time-points. 
  




Figure 3.25. γ-secretase inhibition in Cre-ERTM+/-;Wt1f/f at D8 P.I. does not rescue GS  
(A) Representative images of H&E stained kidney sections of GSI-IX-treated Cre-ERTM+/-;Wt1f/f 
and vehicle (DMSO)-treated Cre-ERTM+/-;Wt1f/f mutant mice treated at D8 P.I. Global GS with 
hyaline material in the tubules is observed in vehicle-treated mice (top panel). A lower power 
image of glomeruli and tubules is presented in the top left, with hyaline material in the tubules 
(indicated by white arrows, Scale bar 50μm); A high-power image of the glomerulus is shown in 
the top right panel exhibiting global glomerulosclerosis (indicated by white arrows, scale bar 
25μm). The same level of GS is displayed in glomeruli of GSI-IX treated mice (bottom panel) 
and vehicle-treated mice, with global GS. Bottom left image shows a lower power image of the 
glomeruli and tubules, with hyaline-filled tubules (indicated by white arrows, Scale bar 50μm); 
Bottom right panel displays a high-power image of the glomerulus, with severe glomerulosclerosis 
(indicated by white arrows, Scale bar 25μm). (B) Merged images of kidney sections following 
double immunofluorescence labelling of vehicle- and GSI-IX-treated Cre-ERTM+/-;Wt1f/f kidney 
tissue sections with α-SMA (Alexa Fluor 488-conjugated secondary antibody) and LTL (Alexa 
Fluor 594-conjugated secondary antibody) (scale bars, 50μm). Top panel represents lower power 
image (left) of the tubules and glomeruli in vehicle-treated mutants, highlighting α-SMA between 
the tubules (green arrows), indicating tubulointerstitial disease; higher power (right) shows α-
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SMA- positive staining in dilated capillary loop (green arrow). Bottom panel; low power image 
(left) of the tubules and glomeruli in GSI-IX-treated mutants, showing α-SMA in peritubular 
interstitium (green arrows); higher power (right) images highlights the glomerulus with α-SMA 
expression within the glomerular tuft (green arrows). (C) Graph illustrating semi-quantitative GS 
scoring (Score 0-3, 0, < 25%, 1, 25-50%, 2, 50-75%, 3,>75% sclerosis). Vehicle-treated mutants 
(n=62 glomeruli, n=2 mice) vs. GSI-IX-treated mutants (n=66 glomeruli, n=2 mice): Bars 
symbolise the mean of each group, error bars display the standard error of the mean (SEM). 
Score 0: 0% vs. 8.5±8.5% (p=0.42); Score 1: 9±5% vs. 28.5±3.5% (p=0.09); Score 2: 20.5±1.5% 
vs. 28±11% (p=0.57); Score 3: 72.5±8.5% vs. 49±9% (p=0.20) Student t-test. (D) Quantitative 
graph showing mean urine albumin/creatinine ratio in vehicle- (n=3) vs. GSI-IX-treated (n=1) Cre-
ERTM+/-;Wt1f/f transgenic mice. Bars represent the mean; error bars represent the standard error 
of the mean (SEM). (E) Albuminuria is detected by Western blot analysis in D8 P.I., Cre-ERTM+/-
;Wt1f/f (mutant), vehicle-treated Cre-ERTM+/-;Wt1f/f and GSI-IX treated Cre-ERTM+/-;Wt1f/f 
transgenic mice but not in Cre-ERTM-/-;Wt1f/f control mice [MW of albumin, 66.5kDa] (Asfahani et 
al., 2018). 
 
3.2.5 Podocyte epithelial-mesenchymal transition (EMT) in Cre-ERTM+/-;Wt1f/f 
mutants at the onset of Wt1 glomerulopathy 
 
As previously mentioned, the Notch pathway consists of ligand binding, which is affected 
by the glycosyltransferases; Manic, Lunatic and Radical Fringe, located in the Golgi 
(Okajima et al., 2003, Bray, 2006, Kakuda and Haltiwanger, 2017). The Fringes bind to 
the EGF domains of the extracellular domain of the Notch receptors, affecting which 
ligands the Notch receptors bind to prior to the activation of the Notch pathway (Kopan 
and Ilagan, 2009, Taylor et al., 2014, Kakuda and Haltiwanger, 2017). Studies have 
shown that when Fringe proteins bind to different parts of the EGF domains of the 
receptors, the affinity of binding with either the Dll or Jag families gets influenced (Kakuda 
and Haltiwanger, 2017). 
 
As Mfng and Rbpj transcript levels were upregulated at D6 P.I. (Figure 3.26A, C), we 
sought to determine the influence of knockdown of both transcripts on podocyte EMT 
and apoptotic gene expression. Although both Mfng and Rbpj levels were reduced 
following knockdown, with repression of the Notch bHLH transcripts, there was no sign 
of a significant decrease of the EMT genes, Snail and Slug, nor a significant upregulation 
of podocyte-specific transcripts including Nphs1 and Nphs2 (Figure 3.26). Sample 
numbers were very low (n=2 mice/group), therefore we could not draw final conclusions 
for this data. Podocytes that were transfected were the only available D6 P.I. cells. This 
was due to slow growth, apoptosis, and the viability of the primary mutant podocytes. In 
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future, higher sample numbers of podocytes that show increased transcript levels of the 
bHLH transcription factors would be selected. 
 
Figure 3.26. Mfng/Rbpj shRNA knockdown in Cre-ERTM+/-;Wt1f/f podocytes repress Notch 
bHLH transcripts  
(A) Dot plot analysis showing the median relative transcript mRNA levels of Rbpj (canonical Notch 
target) in D6 P.I. primary podocytes of Cre-ERTM-/-;Wt1f/f controls cultured for 6 days (n=7) vs. 
Cre-ERTM+/-;Wt1f/f mutants (n=10). Error bars represent the interquartile range (IQR). Rbpsuh 
expression is increased in D6 P.I. Cre-ERTM+/-;Wt1f/f vs. Cre-negative controls: 0.95 (IQR: 0.79, 
1.27) vs. 1.45 (IQR: 1.01, 2.09), p=0.05. Mann-Whitney test. (B) Relative transcript levels of Rbpj, 
Notch bHLH components, Hes1, 3 and 5, Snail, Slug (markers of EMT), podocyte-specific 
transcripts Wt1, Nphs1 and Nphs2 and apoptosis components, Apaf1, Bax and p53 following 48 
hours of Rbpj shRNA knockdown. Bars represent the median, error bars represent the IQR. 
Scrambled shRNA (SCR) Cre-ERT+/-;WT1f/f mutants (n=2), vs. shRNA Rbpj-Cre-ERTM+/-;Wt1f/f 
mutants (n=2); Rbpj, 1.0 (IQR: 0.9, 1.2) vs. 0.6 (IQR: 0.5, 0.7), p=0.33; Hes1, 1.0 (1, 1) vs. 0.6 
(IQR: 0.5, 0.6), p=0.33; Hes3, 1.0 (IQR: 1, 1) vs. 0.7 (IQR: 0.7, 0.7), p=0.33; Hes5, 1.0 (IQR: 0.8, 
1.3) vs. 0.4 (IQR: 0.1, 0.7), p=0.33; Wt1, 1.0 (IQR: 1,1) vs. 0.8 (0.7, 0.9), p=0.33; Snai, 1.0 (IQR: 
0.8, 1.2) vs. 1.0 (IQR: 1, 1), p>0.99; Slug, 1.0 (IQR: 0.8, 1.2) vs. 0.9 (IQR: 0.9, 0.9), p>0.99; Apaf1, 
1.0 (IQR: 0.9, 1.1) vs. 0.71 (IQR: 0.5, 0.9), p=0.67; Bax, 1.1 (IQR: 0.7, 1.4) vs. 0.8 (IQR: 0.6, 1), 
p=0.67; p53, 1.0 (IQR: 1, 1) vs. 0.7 (IQR: 0.5, 0.9), p=0.33. Mann Whitney U test. (C) 
Representative dot plot analysis showing the median relative transcript mRNA levels of Manic 
Fringe in Cre-ERTM-/-;Wt1f/f controls vs. Cre-ERTM+/-;Wt1f/f mutants at D4, D5 and D6 P.I. Error bars 
represent the IQR. D4: Mfng: 0.8 (IQR: 0.3, 6.1) vs. 1.4 (IQR: 0.5, 1.5), p=0.68; D5 Mfng: 0.8 
(IQR: 0.6, 3.1) vs. 1.4 (IQR: 0.6, 9.4), p=0.45; D6: Mfng: 0.9 (IQR: 0.5, 2.3) vs. 2.8 (IQR: 0.8, 7), 
p=0.15. Mann Whitney U test. (D) Relative transcript levels of Mfng, Notch bHLH components, 
Hes1, 3 and 5, Snail, Slug (markers of EMT) and podocyte-specific transcript Wt1 following 48 
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hours of Mfng shRNA knockdown. Scrambled shRNA transfected (Scr) Cre-ERT+/-;Wt1f/f (n=2) vs. 
Manic Fringe shRNA (ShMfng) transfected Cre-ERTM+/-;Wt1f/f (n=2). Bars display the median, 
error bars present the IQR, Mfng expression is reduced following shRNA knockdown. Scr vs. 
ShMfng: Mfng: 1.3 (IQR: 0.6, 1.9) vs. 0.1 (IQR: 0.1, 0.1), p=0.33. Wt1 transcript levels are equal 
in both groups post-transfection, 1.0 (IQR: 0.9, 1) vs. 1.1 (IQR: 0.7, 1.5), p>0.99; Hes1: 0.8 (IQR: 
0.4, 1.3) vs. 0.5 (IQR: 0.3, 0.7), p=0.67; Hes5: 1.5 (IQR: 0.1, 2.9) vs. 0.2 (IQR: 0.1, 0.3), p=0.67; 
EMT marker, Snail is reduced: 4.4 (IQR: 1.6, 7.1) vs. 3.2 (IQR: 0.9, 5.5), p=0.67; Slug: 1.1 (IQR: 




This project demonstrates that our inducible model of Wt1 deletion shows activation of 
the Notch pathway in the pathogenesis of Wt1 glomerulopathy. A temporal rise in urine 
albumin/creatinine urine levels was seen in our mutants with FP effacement and 
development of GS. PAS staining of tissue sections revealed FSGS as early as D5 P.I. 
in our mutants. All together, these results support the view of podocyte apoptosis 
contributing to the development of Wt1 glomerulopathy. Likewise, tubulointerstitial 
disease was evident at D12 P.I., which may be a result of glomerular injury and podocyte 
apoptosis. This corroborates earlier findings of podocyte apoptosis leading to GS 
(Niranjan et al., 2008). Thus, investigating podocyte apoptosis was an obvious 
mechanism to pursue in our inducible model of Wt1 deletion. 
 
Due to the terminally differentiated nature of podocytes, previous studies have shown 
that apoptosis of these cells contributes to disorders that lead to ESRD, including FS, 
DDS, NS and diabetic nephropathy (DN) (Wang et al., 2014, Niranjan et al., 2008). Loss 
of podocytes and tubular injury have been linked to podocyte apoptosis (Chang et al., 
2012) leading to FSGS and DMS (Shankland, 2006). An earlier study introduced high 
doses of Diphtheria toxin (dT) in a rat model, which led to a reduced number of podocytes 
and FSGS. This work demonstrated the importance of podocytes in glomerular 
selectivity and maintenance (Wharram et al., 2005). Here, we present data from 
numerous apoptosis assays to validate this mechanism in our inducible model. Podocyte 
apoptosis occurs as early as D4 P.I. in the mutants, before GS is evident. Apoptosis is 
significantly increased in the mutants at D5-D12 P.I. and is associated with increased 
albuminuria and the progression of GS. 
 
Temporal Wt1 deletion leads to proteinuria and GS 
 
Despite the accumulated research of Wt1 being vital during the early stages of kidney 
development, it has not been studied in depth in the mouse adult kidneys. Various 
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studies have shown that Wt1 mutations in mice can lead to aberrant kidney 
morphogenesis, kidney failure, and embryonic lethality (Davies et al., 2004, Kreidberg et 
al., 1993, Hammes et al., 2001). Wt1 deletion in Cre-inducible adult mice results in 
glomerulopathy with tubule casts and FP effacement (Chau et al., 2011). While detailed 
analysis of temporal Wt1 deletion has been performed by Chau and colleagues, their 
main focus was to examine multiple organs affected by Wt1 deletion, and the tissues 
analysed were no later than D10 P.I. (Chau et al., 2011). This therefore provided us with 
a great platform to investigate different stages of NS, including pre-proteinuric, 
proteinuric and GS following temporal deletion of Wt1. 
 
Our findings demonstrate a key role for Wt1 in maintaining kidney homeostasis and 
podocyte morphology in adult kidneys. Cre-ERTM+/-;Wt1f/f mutants showed FP effacement 
as early as D4 P.I., with proteinuria at D5 P.I. Glomeruli of D6-D12 P.I. mutants 
presented with either FSGS or DMS, with severe proteinuria and tubulointerstitial 
fibrosis. There was progressive loss of Wt1 in the mutants following tamoxifen induction, 
which was supported by DNA and protein findings. The temporal loss of Wt1 is 
associated with the progression of GS and proteinuria, supporting earlier connections of 
Wt1 with renal disorders (Gessler et al., 1990, Orloff et al., 2005). 
 
Numerous mutations of WT1, including missense, nonsense and splice site-mutations 
have been variously associated with DDS, FS, and SRNS, leading to ESRD (Orloff et 
al., 2005, Benetti et al., 2010, Hall et al., 2015, Ruf et al., 2004, Topaloglu et al., 1999). 
The majority of the mutations lie within exon 8 and 9, which have been linked to DDS 
and FS, mainly due to the disruption of the KTS isoforms (Patek et al., 1999, Barbaux et 
al., 1997, Barbosa et al., 1999, Saylam and Simon, 2003, Hashimoto et al., 2016). 
Additionally, deletion of this gene has given rise to glomerulopathies linked to DDS, FS 
and SRNS. Our data illustrates that time-point analysis following Wt1 deletion in adult 
kidneys show a striking deterioration of the glomerulus and proteinuria, with rapid 
progression towards GS, as early as day 5 P.I.  
 
Podocyte architecture was altered in the Cre-ERTM+/-;Wt1f/f mutants at D4 P.I., where FP 
effacement was seen. Wt1 has been reported to be a master regulator of numerous 
genes associated with podocyte integrity. Target genes include, Itga3, which is 
associated with podocyte adherence to the GBM (Dong et al., 2015b). Mutations in Itga3 
have been linked to FP effacement and proteinuria. Wt1 has been reported to bind to the 
proximal promoters of Nphs1, Nphs2 and Magi2 DNA, regulating their expression within 
the kidney (Lefebvre et al., 2015). Injury to the SD can lead to proteinuria (Grahammer 
et al., 2013, Dong et al., 2015b). The polarity and cytoskeleton of the podocytes are 
 Page 125 of 214 
 
regulated by WT1 where it binds the cis-regulatory elements of genes specific to 
cytoskeletal features of the podocytes (Kann et al., 2015b, Dong et al., 2015b). 
Therefore, direct target genes of WT1 are necessary for the integrity of podocyte 
architecture and maintaining an intact GFB. 
 
Human FSGS and DMS can be caused by mutations in podocyte-specific genes, 
including, WT1, NPHS1, NPHS2, LAMB2, PAX2, which lead to SRNS and ESRD (Chen 
and Liapis, 2015, Lipska et al., 2014). Clinical research has demonstrated the 
importance of podocyte-specific genes in maintaining podocyte integrity (Chen and 
Liapis, 2015, Kaverina et al., 2017). Here, we show that Wt1 deletion leads to FSGS and 
DMS in the mutants from D5 to D12 P.I. Expansion of the mesangial space was observed 
in the glomeruli at D6, D8 and D12 P.I. with fragmented podocyte nuclei in the mutants 
compared to the controls. Hypercellularity and basement membrane thickening was 
detected, possibly due to the increase in protein components following podocyte injury 
as well as the proliferation of endothelial and mesenchymal cells. Extensive hyaline 
material was also noted in the tubules and was associated with tubular dilatation. 
Hyalinosis is a result of capillary wall injury, leading to plasma protein leakage in the 
filtration system, resulting from podocyte injury. Glomerular global scarring was seen at 
D12 P.I., with thickening of the capillary walls, where podocyte and parietal epithelial 
cells were on some occasions, confluent. This may be due to podocytes re-entering the 
cell cycle in order to adhere to the denuded glomeruli (Wiggins et al., 2005). However, 
due to the nature of the terminally differentiated podocytes, their lack of proliferation 
contributed to the manifestation of GS. As a result, hypercellular glomeruli with collapsing 
lesions were observed with proliferation of endothelial and mesangial cells, and 
basement membrane thickening. 
 
Wt1 deletion led to podocyte depletion, GS and tubulointerstitial fibrosis by D12 P.I., 
showing αSMA protein in the mutants’ tubules and glomeruli. The development of GS 
initiates with an adhesion of the tuft and Bowman’s capsule, eventually affecting the 
parietal epithelial membrane and glomerulotubular junction. This leads to the obstruction 
of the urinary opening. Due to the reduced filtrate release, tubules no longer function 
appropriately and degenerate (Kaissling et al., 2013). This disease progression was 
revealed from D4 to D12 P.I. in Wt1 mutants. Proteinuria and FP effacement were signs 
of podocyte injury at D4 P.I., and global GS and tubulointerstitial fibrosis developed by 
D12 P.I. Apoptosis was explored as an important mechanism underlying podocyte loss. 
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Podocyte apoptosis is a mechanism of podocyte injury in Wt1 glomerulopathy 
 
Podocyte apoptosis has been reported to instigate the pathogenesis of GS and DN 
(Niranjan et al., 2008, Susztak et al., 2006, Li et al., 2013). By performing a number of 
different apoptosis assays in our inducible model, we show that podocyte apoptosis 
plays a key role in GS following Wt1 deletion. Cleaved caspase-3 protein is a common 
tool to detect apoptosis and is activated by the upstream caspases 8 and 9 (Barrett et 
al., 2001). Cleaved caspase-3 protein was observed as early as D4 P.I. in the adult Cre-
ERTM+/-;Wt1f/f mutants, before GS was detected. This protein was significantly increased 
in the mutants showing GS. TUNEL analysis and Annexin V staining were also used to 
validate podocyte apoptosis in the mutants. Whilst there was an increase in Annexin V 
in the mutants compared to controls, sample sizes were very low (n=2/group). This was 
due to the low survival of podocytes at D8 P.I., when GS was already evident. In addition, 
mRNA transcripts for the pro-apoptotic marker, Bax and anti-apoptotic marker, Bcl2 were 
tested on D4, 5 and 6 P.I. Interestingly, Bax, was reduced in the mutants at D6 P.I. vs. 
controls in comparison to D4 and D5 P.I., however this was not statistically significant. 
Bcl2 was also reduced in the mutants at this time point, with no significance compared 
to the controls. It was difficult to draw conclusions from these data due to the low sample 
number analysed (n=3 at D6 P.I.). These results demonstrate that a loss of Wt1 in mature 
podocytes leads to podocyte apoptosis. 
 
Previous work has shown that ectopic induction of the Notch pathway in developing and 
mature podocytes can induce FSGS and DMS, with an associated activation of 
apoptosis (Niranjan et al., 2008, Waters et al., 2008). Following this theory, the current 
project demonstrated both FSGS and DMS following Wt1 deletion, with an activation of 
apoptosis. The next question in this project was to determine whether the Notch pathway 
was mediating podocyte apoptosis.  
 
The Notch pathway plays a role in the pathogenesis of Wt1 glomerulopathy 
 
The Notch pathway is activated in early proximal nephron development, and the 
inhibition of Notch signalling during development affects proximal tubule formation 
(Cheng et al., 2003). During terminal podocyte differentiation, the Notch components, 
including the bHLH transcription factors, Hes/Hey are progressively downregulated 
(Piscione et al., 2004, Chen and Al-Awqati, 2005). Here, we demonstrate that Notch 
signalling is activated in our mutants following Wt1 deletion. Prior to GS, cleaved Notch 
1 and Hes1 proteins are seen in the podocytes of the mutants post-Wt1 deletion. At the 
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onset of GS, there is an upregulation of the canonical Notch targets, as well as Notch1 
and Nrarp, its transcriptional target gene (Krebs et al., 2001). 
 
Vertebrate podocyte differentiation has been shown to be regulated by a transcriptional 
network of wt1, foxC1/C2, and rbpj (O'Brien et al., 2011, White et al., 2010). WT1-binding 
regions have also been found to target FOX transcription factor binding motifs, further 
supporting their coordinating relationship in podocyte regulation (Lefebvre et al., 2015, 
Kann et al., 2015b). In zebrafish, podocyte depletion has been linked to double 
knockdown of either wt1a/rbpj or wt1a/foxc1a, highlighting the significance of interaction 
between these genes in regulating podocyte differentiation (O'Brien et al., 2011). Our 
model of Wt1 glomerulopathy shows reduced FoxC2 transcript levels and an increase in 
Notch signalling at the onset of GS. We postulate that FoxC2 is repressing the Notch 
bHLH genes, including Hey2, due to their increased transcript levels in the mutants. 
Supporting this, a previous study demonstrated that FOXC2 targeted HEY2 in 
endothelial cells (Hayashi and Kume, 2008). Further studies showed that WT1 was able 
to inhibit NICD1 from activating a synthetic Notch reporter controlled by Rbpj sites 
(O'Brien et al., 2011), suggesting that both WT1 and Foxc1/2 can antagonise the Notch 
pathway in mature podocytes. Based on our current findings, podocyte-specific gene 
expression may be rescued following restoration of FoxC2 levels in the adult Cre-
ERTM+/-;Wt1f/f mutants, which may in turn inhibit Notch bHLH gene expression. 
 
The current data shows that the canonical Notch target, Hey1, is also increased in the 
mutants at the onset of GS. Co-immunoprecipitation studies revealed an interaction 
among WT1, RPBJ and FOXC2 proteins and a combination of these genes induce Hey1 
expression (O'Brien et al., 2011). In xenopus, xwt1 knockdown leads to reduced xhrt1 
expression (Hey1 orthologue) in the developing glomus (glomerulus of the pronephric 
kidney in Xenopus), but not in the late glomus, proposing a role for xwt1 mediating xhrt1 
expression in early glomerulogenesis (Taelman et al., 2006). Subsequent investigations 
revealed that WT1 regulates HeyL expression in pre-tubular aggregates as well as binds 
to the HeyL promoter (Hartwig et al., 2010). Together, these findings support a role for 
WT1 and FOXC1/2 modulating Notch targets during nephrogenesis.  
 
Our model of Wt1 glomerulopathy shows an upregulation of the EMT genes, Snail and 
Slug at the onset of GS. This data proposes that the loss of Wt1 in mature podocytes 
activates Notch signalling, which may mediate podocyte EMT and apoptosis. Increased 
Hes1 transcript levels were accompanied by increased Snail and Slug at the onset of 
GS. Hes1 has been reported to induce EMT in various cancers (Thiery and Sleeman, 
2006). To further validate Hes1-mediated EMT in our model of Wt1 glomerulopathy, 
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Nphs2;rtTA primary podocytes were induced to overexpress HES1. This led to an 
upregulation of the EMT markers, Snail and Slug, suggesting that Notch was triggering 
genes promoting EMT in our model of Wt1 glomerulopathy. Further evidence of Notch 
being associated with both podocyte apoptosis and EMT has been demonstrated in 
earlier studies where the conditional deletion of Notch1 in DN abrogated GS with a 
reduced expression of Snail1 mRNA and protein (Sweetwyne et al., 2015). 
 
An earlier study demonstrated that podocytes transduced with Notch1 ICD inhibits 
apoptosis following pifithrin-α treatment, proposing that Notch1 may be inducing 
podocyte apoptosis via the p53 pathway (Niranjan et al., 2008). In the current study, it is 
possible that p53 may be playing a role in mediating podocyte apoptosis in the 
pathogenesis of Wt1 glomerulopathy. An interesting way to investigate this would be to 
conditionally-inactivate Notch1 in podocytes of the adult Cre-ERTM+/-;Wt1f/f mice. In our 
model of Wt1 glomerulopathy, Notch inhibition was carried out using a γ-secretase 
inhibitor at different stages of the disease. The inhibition of Notch at D4 and D5 P.I. 
showed decreased severity of GS and albuminuria. However, Notch inhibition at D7 and 
D8 P.I. failed to rescue the disease, and albuminuria was not reduced. Early intervention 
of γ-secretase inhibition reveals the importance of the Notch pathway at the initiation and 
during early manifestation of disease. 
  
Podocyte Notch activation post-Wt1 deletion may also be mediated by Hippo signalling 
activation. Hippo signalling has been shown to be a transcriptional target of Notch ligands 
in human epidermal stem cells (Totaro et al., 2017). An earlier study exposed TEAD 
transcription motifs (Hippo signalling effectors) within WT1 ChIP sequencing peaks 
(Kann et al., 2015b). Therefore, Wt1 deletion in mature podocytes may also induce Notch 
activation through regulating Hippo components. 
 
Notch glycosylation is evident post-Wt1 deletion 
 
The current data reveals that Jag1 and Pofut1 are expressed at the onset of GS, 
supporting ligand-dependant Notch activation in podocytes at disease manifestation. 
The Notch pathway is activated by o-glycosylation of the extracellular domains of the 
Notch ligands and receptors (Stanley and Okajima, 2010). Pofut1, is an O-
fucosyltransferase 1 enzyme that mediates fucosylation of the Notch ECD. Pofut1 has 
been reported to regulate cell surface expression of Notch1 (Okajima et al., 2003). Manic 
Fringe, a β3-N-acetylglucosaminyltransferase, that mediates glycosylation of the Notch 
ECD, was also increased in our Cre-ERTM+/-;Wt1f/f mutants. Studies have argued that Dll1 
activation of the Notch pathway is mainly influenced by Fringe-mediated NOTCH1 
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glycosylation (Kakuda and Haltiwanger, 2017). The current study, however, has 
demonstrated jagged1 expression in the Cre-ERTM+/-;Wt1f/f mutants as well as in human 
biopsies of WT1-glomerular disease, followed by an activation of Manic Fringe. It would 
therefore be interesting to examine the relationship between Fringe proteins and Notch 
ligands, namely, Mfng and Jag1 in the context of podocyte injury. 
 
One avenue to explore would be to study Notch1 EGF domains and its activation through 
the Fringe proteins in the context of podocyte injury. Earlier research has already shown 
that Notch1 can be activated or inhibited by Fringe modifications on specific EGF 
domains (Kakuda and Haltiwanger, 2017). Mutations in specific EGF domains of Notch 
receptors can reduce Delta-1 mediated Notch signalling from all Fringes. Mfng and Lfng 
modify similar EGF domains of Notch1, while Rfng modifies a portion, thus enhancing 
Notch activation through both ligands (Kakuda and Haltiwanger, 2017). Knowing that 
Fringe modification can impact Notch signalling, exploring and manipulating Fringe 
expression in injured podocytes will allow us to appreciate Notch glycosylation in the 
context of podocyte injury. 
 
Previous work in Drosophila explored EGF8 in Notch 2 and showed that Dll1/Jag1-
mediated Notch2 activation can occur without EGF8 modification, indicating that the 
Notch orthologues and their EGF repeats show differences in where Fringe modification 
occurs (Yamamoto et al., 2012). Fringe modification causes conformational changes in 
NOTCH1, exposing its EGF repeats to POFUT1, thus becoming more modified by O-
fucosylation and inducing Notch proteolytic activation. The absence of Fringe therefore 
decreases Notch modification. An example of Pofut1 modification occurs in EGF26 
following Fringe elongation, where NOTCH1 conformational changes exposes its EGF 
domain and allows POFUT1 to bind to it (Kakuda and Haltiwanger, 2017). 
 
Studying alternative Notch receptors could further illuminate the role of Notch 
glycosylation. Fringe glycosylation also occurs in Notch2, stimulating Dll1/Jag1-mediated 
Notch activity or Jag1-induced Notch inhibition by Lfng and Mfng. Although Notch1 and 
Notch2 are structurally parallel with their 36 EGF repeats, their chemical requirements 
for activation vary. Studies have reported that Notch2 is more prone to ligand mediated 
activation than Notch1, perhaps due to the distinct conformational changes in their NRR 
to expose the S2 site for proteolytic cleavage (Stephenson and Avis, 2012). 
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Notch ligands exhibited in early disease progression 
 
In the current study, the Notch ligand Jag1 was expressed in both podocytes and parietal 
epithelium at the early stages of GS in the WT1 deleted mouse, observations supported 
by evidence from earlier studies (Niranjan et al., 2008, Murea et al., 2010). In contrast, 
the Dll1 ligand showed no quantitative difference between the Cre-ERTM+/-;Wt1f/f mutants 
and controls at any time point. During kidney development, Jag1 and Dll1 expression 
overlaps within the middle portion of the S-shaped body. Moreover, their loss in 
Cre;Dll1f/f;Jag1f/f mouse mutants leads to a significant decrease in glomeruli and proximal 
tubules (Liu et al., 2013), highlighting their importance in mediating Notch activation 
during renal development. Jag1 plays a role in determining podocyte fate induction; Dll1 
replacement by a Jag1 allele rescues WT1-positive podocytes (Liu et al., 2013). 
Furthermore, Niranjan et al. showed that in podocyte injury, Jag1 was upregulated 
following TFG- β1 treatment, suggesting a role for Jag1 in podocyte fate (Niranjan et al., 
2008). A more recent study using genome-wide expression analysis in human tubular 
epithelial cells has shown that JAG1 and NOTCH2 are increased in kidney fibrosis 
(Huang et al., 2018). Mouse models of nephropathy corroborated these findings, 
showing higher levels of Jag1 and Notch2 in renal fibrosis (Huang et al., 2018). Given 
that there is an increase in podocyte expression of Notch1 and Jag1 in our mutants, 
future work could focus on conditionally deleting each of these in adult Cre-ERTM+/-;Wt1f/f 
transgenic mice. Subsequent evaluation of disease manifestation might help identify 
which ligand and receptor pair are responsible for the manifestation of GS in Wt1 
glomerulopathy.  
 
In summary, upregulation of specific Notch components and EMT genes together with 
reduced FoxC2 expression correlated with the onset of GS in Cre-ERTM+/-;Wt1f/f 
transgenic mice. In addition, induced HES1 podocyte expression lead to increased 
expression of the EMT markers, Snail and Slug, supporting a role for HES1 in regulating 
podocyte EMT. Downregulation of FoxC2 expression led to the activation of Notch 
signalling. These data support the hypothesis that Wt1 deletion in podocytes results in 
apoptosis that contributes to the initiation of glomerular fibrosis. This is supported by the 
observation that early pharmacological inhibition of the Notch pathway reduced 
albuminuria and GS severity.  
 
Nonetheless, WT1 is a complex gene with multiple roles within the podocyte. As such, 
to explore further its mechanisms of action including its relationship to Notch signalling 
and programmed cell death in glomerular fibrosis in more detail, further study of 
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transgenic mice, for example with Wt1 point mutations relating to human disease would 
help explore further mechanisms involved.  
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Chapter 4 - Ascl1 expression precedes podocyte 
Notch activation in Wt1 glomerulopathy 
4.1 Introduction 
 
RNA sequencing of glomerular isolates in Wt1-deleted mutants at D4 P.I. indicated that 
mRNA expression of another downstream effector of the Notch signalling pathway, 
achaete-scute complex homologue-1 (ASCL1) is increased. Thus, to complement 
investigation of Notch pathway activation in murine WT1 mediated glomerulopathy, the 
role of ASCL1 in podocyte differentiation and WT1 glomerulopathy was examined 
further. The aim was to build on existing experimental evidence that ASCL1 upregulation 
may precede Notch pathway activation and consequently play an important part in the 
pathogenesis of GS in murine Wt1 glomerulopathy. 
 
ASCL1 has a key role in Notch signalling during neuronal differentiation and proliferation 
(Kageyama et al., 2005, Vasconcelos and Castro, 2014), further supporting evidence 
that it may also mediate podocyte differentiation. Ascl1 both regulates and is regulated 
by, the Notch signalling pathway (Figure 4.1). 
 
Ascl1 stimulates neuronal differentiation by directly activating the Notch ligand, Dll1, 
eventually leading to the activation of the transcriptional repressors, Hes1 and Hes5 
(Borromeo et al., 2014, Raposo et al., 2015). These repressors inhibit proneural gene 
expression by binding to their promoters, thereby repressing neuronal differentiation 
(Kageyama et al., 2005). This process prevents all progenitors from simultaneously 
differentiating, guaranteeing that a suitable number are sustained during embryonic 
development (Vasconcelos and Castro, 2014). 
 
ASCL1, the proneural bHLH TF  
 
ASCL1, also known as Mammalian achaete-scute complex homologue-1 (Mash1), is a 
class II proneural basic-helix-loop-helix transcription factor mainly known for its key role 
in initiating neurogenesis (Guillemot et al., 1993). ASCL1 binds to E-box motif (5’-
CANNTG-3’) and dimerises with other bHLH proteins to activate transcription (Nakada 
et al., 2004). 
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Figure 4.1. Interplay between Ascl1 and Notch signalling during neurogenesis 
Neuronal differentiation is controlled by the activator-type and repressor-type bHLH transcription 
factors. (1) In a neural stem cell, Delta-Notch binding triggers Notch signalling. (2) NICD is cleaved 
and translocates to the nucleus, where it co-binds with Rbpj, activating Hes1 and Hes5 
expression. (3) These genes inhibit the activity the activator genes (Ascl1 [Mash1], Math3, Ngn2) 
by sequestering E47, a bHLH transcription factor. Transcription of the activator genes is also 
inhibited due to Hes1 and Hes5 binding to their promoters and employing the corepressor 
TLE/Grg. (4) in the differentiating neuron, Notch signalling is downregulated, and the repressor-
type TFs Hes1 and Hes5 expression is inhibited by RBPJ. (5) Expression of the activator-type 
bHLH TFs is triggered. (6) The activator-type bHLH TFs activate Hes6 expression, which 
represses Hes1 activity. (7) Other specific neuronal genes are stimulated by the activator type 
bHLH TFs, including the Delta ligand, which induces Notch activity in neighbouring cells (lateral 
induction). Right image displays modes of Ascl1 expression in neural stem cells; The oscillation 
between Ascl1 and Hes1 occurs within a 2-3 hour period, where their modes of expression are 
out of phase. Hes1 expression is terminated following neuronal differentiation, while Ascl1 
expression becomes sustained. Adapted from (Kageyama et al., 2005, Vasconcelos and Castro, 
2014). 
 
ASCL1 has multiple roles in sequentially triggering target genes in the progenitors of 
differentiating and proliferating neurons (Raposo et al., 2015), which not only induce cell 
cycle exit, but promote proliferation in specific cell contexts (Castro et al., 2011, 
Wilkinson et al., 2013). Its dual role during neurogenesis, including the proliferation of 
neural progenitor cells (NPCs), is controlled by other genes including Hes1, the 
downstream Notch target, which represses Ascl1, thus regulating neuronal proliferation 
(Dhanesh et al., 2016, Shimojo et al., 2008). Proliferation and differentiation of NPCs 
depend on Ascl1’s expression being either transient or sustained (Imayoshi et al., 2013, 
Urban et al., 2016). 
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ASCL1 has been identified to regulate genes associated with podocyte differentiation, 
including, Lmx1b (Borromeo et al., 2014) and Wnt1 (Burghardt et al., 2013). ASCL1 
represses Wnt1 in the spinal cord during early dorsal ventral patterning (Augustine et al., 
1995, Lee and Jessell, 1999, Herzlinger et al., 1994). 
 
ASCL1 mediates Notch signalling 
 
Experiments in chick retinal progenitors support an association between Ascl1 and Dll 
genes (Nelson et al., 2009) in that co-expression increased Dll gene expression and 
Notch signalling in retinal progenitors. During neuronal differentiation, Dll1, Dll4, and 
Ascl1 demonstrate similar expression patterns. Overexpression of Ascl1 potentiates 
Notch signalling by inducing Dll1 and Dll4 gene expression (Nelson and Reh, 2008). 
ASCL1 binds DLL1 through the former’s E-box domain (Castro et al., 2006). Ascl1 binds 
to a specific enhancer of Dll4 during ventral spinal cord development, activating Dll4 
expression (Bertrand et al., 2002, Misra et al., 2014). Similarly, Dll3 expression is mainly 
reliant on Ascl1, which binds to Dll3’s E box subdomain during neurogenesis (Henke et 
al., 2009). 
 
Both Rbpj and Ascl1 have been shown to interact transcriptionally in the ventral 
telencephalon of Drosophila, mainly promoting proliferation (Nellesen et al., 1999, Castro 
et al., 2011). 
 
Murine in vivo studies associated with Ascl1 and the Notch pathway  
 
Ascl1 activates Notch signalling through Dll and Jag induction (Castro et al., 2006). Both, 
Dll1 and 3 have been found to be expressed in the mouse ventral telencephalon. Mutant 
Ascl1 embryos revealed a loss of both Dll genes, highlighting Ascl1’s importance in 
Notch ligand expression (Casarosa et al., 1999). Research in Ascl1-deficient mouse 
retina also showed a significant reduction in Dll1 expression (Nelson et al., 2009). 
Expression of the murine Hes5 gene was reduced following Notch signalling disruption 
in the Ascl1 mutants, further confirming the relevance of Ascl1 in Notch signalling 
(Casarosa et al., 1999). 
 
Previous findings have reported that Ascl1 is able to convert astrocytes to neurons in 
vivo; one study discovered that stroke and attenuated Notch signalling in mice led to 
Ascl1 expression in striatal astrocytes and transdifferentiation into neurons (Magnusson 
et al., 2014). The combination of Ascl1 overexpression and Notch inhibition has been 
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revealed to be a potential treatment in glioblastomas, where Ascl1 expression can 
reduce cancer cell proliferation and encourage cell cycle exit (Park et al., 2017). 
 
The relationship between the proneural bHLH repressors and Ascl1 
 
The bHLH Hes1 has been shown to play a role in repressing Ascl1 either transcriptionally 
or through protein-protein interaction during neural stem cell differentiation (Kageyama 
et al., 2005). Both repressor bHLH HES1 and activator-type bHLH (ASCL1) work 
together to promote fate determination in a subset of cells, while others remain as neural 
cells (Shimojo et al., 2008).  
 
Since a definitive role for ASCL1 in nephrogenesis has not been established, in order to 
elucidate its contribution to the early mechanisms of Notch induction in Wt1 
glomerulopathy, glomerular RNA from mice at day 4 post Tamoxifen induction was 
sequenced (n=3/group). Interestingly, Ascl1 transcript was increased in the mutants 
compared to controls, suggesting a role for Ascl1 in the manifestation of GS. Gene 
expression analysis was performed for several genes, listed in Appendix A. 
 
Our qPCR and Western blot data presented in this chapter, demonstrate increased Ascl1 
RNA and protein expression in our Cre-ERTM+/-;Wt1f/f mutants compared to Cre-ERTM-/-
;WT1f/f controls in D4 and D5 P.I. primary podocytes. Furthermore, tissue IHC at D4, 5 
and 12 P.I. reveal ASCL1 protein in the podocytes. ASCL1 expression during 
nephrogenesis has not been published to date, therefore its expression pattern was 
analysed by IHC during early and late glomerulogenesis. Finally, Ascl1 gene expression 
was induced in differentiating and mature podocytes in vivo to examine whether an 
increase in Ascl1 induces Notch signalling and GS. 
 
4.2  Results 
 
4.2.1 Ascl1 is upregulated in D4 P.I. Cre-ERTM+/-;Wt1f/f mutant glomeruli 
 
Following Wt1 deletion at D4 P.I., RNA data showed an upregulation of Ascl1 in the 
mutants compared to the controls (Figure 4.2A). This was further validated through real-
time qPCR, demonstrating an increase in the Cre-ERTM+/-;Wt1f/f mutants compared to 
Cre-ERTM-/-;Wt1f/f controls at D4 P.I., but this failed to reach statistical significance (Figure 
4.2B). Studies have reported that Ascl1 and Hes1 expression patterns oscillate in 
neurogenesis (Vasconcelos and Castro, 2014). Here, we show that there is a fluctuation 
in Ascl1 mRNA levels from D4-D6 P.I. in the mutants. Transcript levels of Ascl1 were 
 Page 136 of 214 
 
reduced in the mutants at D5 P.I., followed by an increase in mRNA levels at D6 P.I., but 
this failed to reach statistical significance (Figure 4.2B). 
 
ASCL1 protein levels were examined using Western blot analysis (Figure 4.2C) and 
immunostaining (Figure 4.2D-I’) to validate Ascl1 increase in the mutants. Western blot 
analysis demonstrated an increase in ASCL1 protein levels at D4 P.I. in the mutant vs. 
control (Figure 4.2C). 
 
Furthermore, immunostaining at D4 P.I. revealed ASCL1 nuclear expression within the 
podocytes of the mutants (Figure 4.2E, F, inset F’), whilst the controls did not display 
any ASCL1 protein within the glomerulus (Figure 4.2D). At D5 P.I., ASCL1 was also 
detected in the mutants, namely in the podocytes and possibly in the PECs (Figure 4.2H, 
I, inset, H’, I’) compared to the control, where it was faintly identified (Figure 4.2G). Insets 
illustrate ASCL1 expression in the nucleus (Figure 4.2F’, H’, I’). 
 
Genes significant for podocyte biology were also shown to be up or downregulated 
following Wt1 deletion at D4 P.I. Wifi1, Nphs1, Nphs2, Kirrel2, Lmx1b were all decreased 
in the mutants at D4 P.I. (Figure 4.2A), supporting previous studies of glomerular disease 
where reduced expression of these genes was demonstrated (Boute et al., 2000, Koziell 
et al., 2002, Caridi et al., 2005, Ihalmo et al., 2007, Boyer et al., 2013, Woroniecki and 
Kopp, 2007).  
 
Wnt3a, a member of the Wnt signalling pathway, involved in cell fate and patterning 
during embryogenesis, was increased in the mutants compared to the controls. Studies 
have shown that sustained activation of Wnt signalling can lead to renal fibrosis and 
chronic kidney disease. High glucose in mice has been reported to impair podocyte 
integrity by inducing Wnt3a and suppressing podocyte-specific genes, Nphs1 and Nphs2 
(Wang et al., 2018). Here, we show that Nphs1 and Nphs2 are downregulated in the 
mutants, with increased Wnt3a expression, suggesting a role for the Wnt pathway in Wt1 
glomerulopathy. Intriguingly, the Notch components, Notch2, Hes1, Hes5, Dll1, Dll4, 
Jag1 and Lfng showed no difference between the mutants and the controls. Real-time 
qPCR at D4 P.I., however, showed Lfng to be significantly decreased in the mutants 
compared to the controls (Figure 3.14A). 
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Figure 4.2. Upregulation of Ascl1 mRNA and protein in D4 P.I. Cre-ERTM+/-;Wt1f/f mutant 
glomeruli 
(A) Heatmap demonstrating differential gene expression of genes in Cre-ERTM-/-;Wt1f/f controls 
(n=3) vs. Cre-ERTM+/-;WT1f/f  mutants (n=3) with a 2.0-fold change; Ascl1, -0.02 vs. 1.39; Wifi1, 
0.18 vs. -2.93; Nphs1, 0.31 vs. -1.12; Nphs2, 0.15 vs. -1.12; Wnt3a, -2.11 vs. 2.53; Gas1, -0.52 
vs. 0.48; Cdkn1c, -0.90 vs. 0.72; Mmp7, -0.40 vs. 0.41; Hes1, -0.29 vs. 0.09; Hes5, 0.275 vs. -
0.20; Notch2, -0.03 vs. 0; Dll1, -0.04 vs. 0.01; Jag1, -.0.01 vs 0.16; Kirrel2, 0.54 vs. -1.32; Smad3, 
-0.03 vs. 0.06; Esr1, -1.29 vs. 1.50; Hhip, -0.37 vs. 0.68; Lfng, -0.08 vs. 0.07; Foxa2, 0 vs. 1.37; 
Lmx1b; 0.20 vs. -0.52. (B) Dot plot showing relative transcript levels of Ascl1 in Cre-ERTM-/-;Wt1f/f 
controls (n=3) vs. Cre-ERTM+/-;WT1f/f mutants (n=3) representing the median and error bars IQR, 
D4 P.I., 1.1 (IQR: 0.8, 1.2) vs. 2 (IQR: 1.5, 3.2), p=0.1; D5 P.I., 1.2 (IQR: 0.7, 1.6) vs. 1 (IQR: 0.8, 
1.8), p=0.9; D6 P.I., 0.8 (IQR: 0.2, 1.3) vs. 5.4 (IQR: 1.3, 9.6), p=0.07. Mann Whitney U test. (C) 
Representative image of Western blot analysis of protein derived primary podocytes isolated from 
controls vs. mutant mice. Immunoblot reveals increased ASCL1 expression in the mutants at D4 
P.I., with weaker expression of the protein in the controls. (D-I’) Shown are representative 
micrographs of double immunofluorescence labelled glomeruli marked with podoplanin (Alexa 
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Fluor 488) and ASCL1 (Alexa Fluor 594), counterstained with DAPI at D4 P.I. (D-F’) and D5 P.I. 
(G-I’) controls vs. mutants. ASCL1 is not present in D4 controls (D), however co-nuclear 
expression of ASCL1 is revealed in the mutants, within the podocytes (E, F, red arrows). Inset 
shows a higher power view of ASCL1 nuclear expression in D4 P.I. mutants (F’). ASCL1 protein 
is not seen in D5 P.I. controls (G), however it is present in the podocytes of D5 P.I. mutants (H, I, 
red arrows), with insets showing higher power images of ASCL1 positive cells (H’, I’). Scalebar 
25 µm. 
 
It is important to note that the RNA sequencing data presented here were analysed from 
glomerular isolates. Glomerular isolates included a heterogenous population of 
podocytes, endothelial and mesangial cells. This may have resulted in the difference in 
expression levels between RNA sequencing and real-time qPCR. RNA sequencing was 
also performed on only 3 mice/group, whereas the qPCR data was analysed on a larger 
number of mice, giving us a more accurate conclusion. Esr1 (Estrogen Receptor 1) was 
also increased in the mutants, and has been known to be expressed in pathological 
processes, such as breast cancer (Martin et al., 2017). The Forkhead Box A2 (Foxa2) 
was upregulated in the mutants, a transcription factor associated with embryonic 
development as well as regulating gene expression in differentiated tissues. 
Interestingly, Lmx1b has been shown to interact with genes including Foxa2 during 
neurogenesis (Nakatani et al., 2010) and Foxa2 plays a specific role in the differentiation 
of dopaminergic neurones (Domanskyi et al., 2014). The downregulation of Lmx1b may 
have had an effect on Foxa2 expression. 
 
Hes1 and Ascl1 mRNA levels were compared from D4 to D6 P.I. in the mutants (Figure 
4.3). Expression levels of Ascl1 oscillated at D4 (Figure 4.3A, B), D5 (Figure 4.3A, C) 
and D6 P.I. (Figure 4.3A, D). Hes1 mRNA levels were lower than Ascl1 at D6 P.I., 
however remained higher in the mutants compared to controls (Figure 3.16A). Studies 
have shown an association between Ascl1 and Hes1 in neurogenesis (Vasconcelos and 
Castro, 2014). The data here shows that Notch activation at disease onset may be due 
to an interaction between Ascl1 and Hes1 expression, regulating Notch signalling. 
Reduced levels of Hes1 are associated with increased levels of Ascl1. At D4 P.I., Hes1 
mRNA is higher than Ascl1. Levels of both transcripts are almost equal at D5 P.I., with 
their expression levels switching by D6 P.I. 
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Figure 4.3. Ascl1 and Hes1 mRNA levels oscillate in Cre-ERTM+/-;Wt1f/f mutants from D4 to 
D6 P.I. 
(A) Graph showing relative transcript levels of Ascl1 vs. Hes1 in Cre-ERTM+/-;Wt1f/f mutants at D4 
(n=3 vs n=5), D5 (n=3 vs =8) and D6 P.I. (n=5 vs n=11). Bars represent the median, error bars 
represent IQR. D4 P.I., 2 (IQR: 1.5, 3.2) vs 4 (IQR: 2.5, 4.3), p=0.14; D5 P.I., 1 (IQR: 0.8, 1.8) vs 
1.5 (IQR: 1.4, 3), p=0.24; D6 P.I., 5 (IQR: 1.3, 9.6) vs 1.3 (IQR: 1, 2.2), p=0.09 (ns). Analysed by 
Mann-Whitney. (B) Dot plot analysis showing the median relative transcript levels of Ascl1 vs 
Hes1 at D4 P.I. (C) Dot plot analysis of Ascl1 vs Hes1 at D5 P.I. (D) Dot plot analysis of Ascl1 vs 
Hes1 at D6 P.I. Bars represent the IQR. 
 
4.2.2 Glomerular ASCL1 and HES1 protein in patient WT1 glomerulopathies 
 
Since Ascl1 was increased in the mouse mutants vs. controls, its expression pattern was 
examined in human kidney biopsies from patients with DDS caused by mutations of 
WT1: R390X and R362X. Findings were compared with time-zero renal allograft biopsies 
of normal kidneys as controls. The oscillatory relationship between the transcription 
factors, Hes1 and Ascl1 described during neurogenesis was examined in association in 
human WT1 mutations. Immunostaining revealed higher expression of HES1 in both 
WT1 R390X and WT1 R362X compared with controls (Figure 4.4A-C). Additionally, 
upregulation of nuclear ASCL1 expression was evident in both WT1 mutant biopsies 
compared with controls (Figure 4.4D-F), where only low, non-nuclear expression of the 
protein was observed. HES1 protein expression was detected at higher levels than 
ASCL1 in the human mutants, supporting a role of the Notch pathway in glomerular 
injury. 
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Figure 4.4. ASCL1 and HES1 are expressed in WT1 glomeruli 
(A-F) Representative micrographs of immunofluorescence labelling with HES1 (Alexa Fluor 594) 
and ASCL1 (Alexa Fluor 594) in patient glomeruli. Control biopsies (time-zero renal allografts) 
reveal no glomerular HES1 expression (A) compared to patients carrying WT1 mutations (B, C, 
red arrows), with increased expression of the protein in both glomeruli. Control biopsies display 
low glomerular ASCL1 protein expression (D) but are increased in the patients of WT1 mutations 
(E, F, red arrows). Scalebar 25 µm. 
 
4.2.3  TUNEL is not detected in all ASCL1-positive cells in late GS 
 
ASCL1 was upregulated in both murine and human samples with WT1 mutations. In view 
of the role of Notch/ASCL1 signalling in apoptosis, this was examined in ASCL1-positive 
cells. TUNEL analysis was used to identify cell apoptosis along with ASCL1 
immunostaining in both Cre-ERTM-/-;Wt1f/f controls vs. Cre-ERTM+/-;Wt1f/f mutants at D12 
P.I. (Figure 4.5A-L). Only one ASCL1-positive cell was also TUNEL-positive in the Cre-
ERTM+/-;Wt1f/f mutants (Figure 4.5E-L), suggesting that podocyte apoptosis is not 
associated with ASCL1. 
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Figure 4.5. ASCL1 protein is expressed in D12 P.I. Cre-ERTM+/-;Wt1f/f glomeruli 
Representative micrographs of immunofluorescence labelled glomeruli with Ascl1 (Alexa Fluor 
594) and apoptosis detection by TUNEL assay reveals no ASCL1 or TUNEL positive cells in the 
Cre-ERTM-/-;Wt1f/f controls (A-D). D12 Cre-ERTM+/-;Wt1f/f mutants (E-L); ASCL1-positive cells (F), 
with no TUNEL (G, H), ASCL1-positive cells (J) and TUNEL-positive cells (K,L). Scalebar, 25 µm. 
(n=3 mice) 
 
4.2.4 Patterns of ASCL1 expression during glomerulogenesis 
 
Initial data indicated that ASCL1 was upregulated in the mutants and in patients with 
WT1 mutations. In view of its participation in neurogenesis and the similarities with 
nephrogenesis regarding Notch signalling, a role for ASCL1 in nephrogenesis was 
examined. Mouse kidneys were collected at E17.5 and P7, and ASCL1 protein was 
analysed at different stages to identify its expression pattern during nephrogenesis 
(Figure 4.6, Figure 4.7). Embryonic kidneys isolated at E17.5 were immunostained with 
ASCL1, co-stained with LAMB2 to mark the podocytes, CD31, to mark the endothelial 
cells, and DESMIN, to mark the mesangial cells (Figure 4.6). ASCL1 demonstrated a 
perinuclear expression pattern in the mid-S-shaped body (Figure 4.6A-C) with 
expression sustained into the capillary loop stage, primarily in podocyte progenitors 
(Figure 4.6J-L), as well as mesangial cells (Figure 4.6G-I). ASCL1 expression was 
absent in endothelial cells (Figure 4.6D-F). 
 
P7 kidneys were also isolated to examine the role of ASCL1 in late glomerulogenesis 
(Figure 4.7). Interestingly, its expression pattern had changed from being perinuclear to 
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being nuclear at the capillary loop stage. Cells were also co-stained with podoplanin to 
mark the developing glomerulus. Clusters of ASCL1-positive cells were mainly podocyte-
specific, suggesting a role for ASCL1 during podocyte differentiation (Figure 4.7A-F). 
 
 
Figure 4.6. ASCL1 protein expression during early glomerulogenesis  
(A-L) Shown are representative micrographs of double immunofluorescence labelled glomeruli 
highlighting ASCL1 expression (Alexa Fluor 594), Lamb2 (podocyte marker, Alexa Fluor 488), 
CD31 (endothelial marker, Alexa Fluor 488), Desmin (mesangial marker, Alexa Fluor 488) at 
E17.5. ASCL1 protein is expressed in the middle segment of the S-shaped body, marked with 
Lamb2 (B, C) The comma-shaped body exhibits increased ASCL1 protein expression, showing 
a perinuclear pattern of expression (F, I, L, red arrows). Scalebar 25µm. 
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Figure 4.7. ASCL1 protein expression during late glomerulogenesis 
(A-F) Representative micrographs of double immunofluorescence labelled glomeruli 
demonstrating ASCL1 protein expression in the differentiating capillary loops of the glomerulus. 
Three different representative images of the same stage reveal an abundant expression of the 
protein during this stage of development, predominantly in the podocytes, as indicated by the 
white arrows (C, F, I). Scalebar, 25 µm. 
 
4.2.5 Doxycycline-induced Ascl1 expression in TetOAscl1;NPHS2;rtTA mice  
 
Initial data demonstrated upregulation of ASCL1 in Wt1 glomerulopathy and during 
nephrogenesis. The next aim was to determine whether cell-specific overexpression of 
ASCL1 might result in a glomerular phenotype. Mice carrying the reverse tetracycline 
receptor (rtTA) under the control of the human Podocin promoter (NPHS2) were crossed 
with transgenic mice carrying the tetracycline-responsive element with the Ascl1 gene 
under the mCherry reporter (TetOAscl1). Overexpression of Ascl1 was induced in the 
podocytes following administration of doxycycline. Ascl1 upregulation was analysed in 
3-week-old mice following 2 weeks of 2mg/ml doxycycline in 5% sucrose water. Primary 
podocytes were then cultured and treated with 4µg/ml doxycycline for another four days. 
 
To confirm overexpression, mCherry reporter gene was tested using fresh cryosections 
to determine the presence of Ascl1 (Figure 4.8A-G). Additionally, glomerular RNA was 
collected from these kidney tissues and analysed by real-time qPCR to validate 
upregulation of Ascl1 compared with no-doxycycline treated TetOAscl1;NPHS2;rtTA 
mice (Figure 4.8H). Podocytes were also isolated from fresh kidneys of doxycycline- vs. 
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no-doxycycline-treated mice, cultured and fixed to confirm mCherry presence (Figure 
4.8I-Q). 
 
Cryosections of the kidney revealed mCherry expression in glomeruli of the doxycycline-
treated TetOAscl1;rtTA;NPHS2 mice (Figure 4.8E-G) compared to the non-treated 
TetOAscl1;rtTA;NPHS2 mice, where mCherry expression was absent (Figure 4.8A-D). 
In support of these findings, real-time qPCR confirmed a significant increase in Ascl1 
expression in the doxycycline-treated TetOAscl1;rtTA;NPHS2 mutants vs. 
TetOAscl1;rtTA;NPHS2 controls (**p=0.0063), where Ascl1 expression was 
undetectable (Figure 4.8H). In addition, primary podocyte cells confirmed the 
upregulation of Ascl1, where there was clear detection of mCherry reporter expression 
(Figure 4.8I-Q). 
 
These results confirmed that the TetOAscl1;rtTA;NPHS2 system resulted in upregulation 
of Ascl1 in the doxycycline-treated mice compared with negative controls. Following 
validation of Ascl1 overexpression model, urine was collected for measurement of urine 
protein levels and mice sacrificed in order to ascertain the glomerular phenotype. 
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Figure 4.8. Upregulation of Ascl1 mRNA and protein in doxycycline-induced 
TetOAscl1;NPHS2rtTA primary podocytes 
(A-I) Shown are representative micrographs of mouse kidney cryosections highlighting mCherry 
expression in the podocytes (F, G) post-doxycycline treatment, indicating an increase in Ascl1 
expression (Scalebar, 25μm). Relative transcript levels showing the mean expression of Ascl1 in 
doxycycline-treated (D) vs. non-treated (ND) TetO:Ascl1;NPHS2;rtTA transgenic mice (H) Ascl1 
transcript levels are significantly increased post-doxycycline treatment; mean±SEM non-treated 
(n=2) vs. treated (n=2), 1.02±0.19 vs. 6745±539.5, **p=0.0063. Representative images showing 
mCherry expression in doxycycline-treated TetO:Ascl1;NPHS2;rtTA transgenic mice of primary 
podocytes (I-Q) ASCL1 protein expression is revealed in the podocytes via mCherry in the 
doxycycline treated cells. Scalebar, 10μm. 
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4.2.5.1 Increased doxycycline dosage in TetOAscl1;NPHS2;rtTA mice does not lead to 
glomerulopathy  
 
Administration of 2mg/ml doxycycline in TetOAscl1;rtTA;NPHS2 mutants resulted in a 
significant increase of Ascl1. However, this did not result in a phenotype as urine protein 
levels and glomerular phenotypes remained normal. The doxycycline dosage was 
therefore increased to 4-5g/day in chow in three-week-old mice, and urine protein loss 
measured on alternate days. Histological analysis by H&E to establish whether a 
glomerular phenotype was present was performed on kidneys collected at 2, 4 and 6 
weeks post-doxycycline and histological analysis by H&E was performed (Figure 4.9). 
 
At 2 weeks post-doxycycline, there was no glomerular or tubular phenotype present in 
either treated mice or non-treated controls (Figure 4.9B, B’) in comparison to the non-
treated controls (Figure 4.9A, A’). Glomeruli were intact with a normal number of cells 
and no red cells, or proteinaceous or hyaline material observed in the tubules. At four 
weeks, the glomeruli remained normal with no evidence of GS or tubulointerstitial 
abnormalities (Figure 4.9D, D’) compared to their non-treated controls (Figure 4.9C, C’). 
Cryosections of kidneys, 6 weeks post-doxycycline, showed no evidence of GS nor 
tubule interstitial fibrosis with hyaline material (Figure 4.9F, F’). Higher magnification of 
the glomerulus showed a normal mesangial matrix with no hypo- nor hypercellularity. 
Tubules contained no hyaline material (Figure 4.9F’) compared to the non-treated 
controls, where both groups were indistinguishable (Figure 4.9E, E’). 
 
Urine was collected every other day and was analysed for proteinuria following 
doxycycline treatment (Figure 4.9G). Four different groups were analysed, including the 
mutant group, doxycycline-treated TetOAscl1;rtTA;NPHS2 vs. three control groups; no-
doxycycline-treated TetOAscl1;rtTA;NPHS2, doxycycline-treated TetOAscl1, and 
doxycycline-treated rtTA;NPHS2 mice. Urine was collected up to 11 days and tested 
using urine reagent strips to measure protein levels. We were unable to collect urine at 
later time-points as the metabolic cages were not available in the following weeks. 
Protein levels did not reach above 1+, which was considered normal and all groups were 
comparable, including the mutants, where all mice had either 0 or 1+ protein in their 
urine. Protein levels did not increase in the days post-doxycycline and remained similar 
to the control groups, showing no indication of proteinuria (Figure 4.9G). 
 
At 6 weeks of doxycycline administration, both histology and urine-protein analysis 
remained normal. This indicated that in contrast to Wt1-deleted mutants, overexpression 
of Ascl1 did not result in a renal phenotype. Therefore, although there was an increase 
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in Ascl1 in Wt1-glomerulopathy, this might simply be secondary or compensated by 




Figure 4.9. Doxycycline-induced TetO:Ascl1;NPHS2;rtTA exhibit normal glomerular 
morphology 
Shown are representative H&E sections of TetO:Ascl1;NPHS2;rtTA mice after 2, 4 and 6 weeks 
of non-doxycycline (A-E’) and doxycycline (B-F’) treatment. Low power images of non-treated 
mice reveal no abnormality in the tubules and glomeruli (A,C,E). Higher power images show intact 
glomeruli with a normal number of cells (A’, C’, E’). Low power image of the kidney after 2 weeks 
of doxycycline treatment exhibited no phenotype in the interstitium which remained normal after 
4 and 6 weeks of doxycycline treatment in the TetO:Ascl1;NPHS2;rtTA mice (B, D, F). Higher 
power images of the glomerulus at these time points revealed healthy glomeruli (B’, D’, F’). 
Scalebar 25 μm. Table demonstrating levels of proteinuria in doxycycline-treated 
TetO:Ascl1;NPHS2;rtTA mice vs. controls; non-doxycycline-treated TetO:Ascl1;NPHS2;rtTA, 
doxycycline-treated TetOAscl1 and doxycycline-treated NPHS2;rtTA mice (G) Levels of urine 
protein remain consistent amongst mutants and controls throughout the treatment. 




This chapter has investigated a role for Ascl1 in Wt1 glomerulopathy and nephrogenesis. 
RNA and protein analysis showed that levels of Ascl1 are indeed increased at D4, D5 
and D6 P.I. mutants compared to the controls. Ascl1 function has been studied in 
neurogenesis and has been shown to play a role in cell cycle promotion and termination 
(Castro et al., 2011, Ge et al., 2006). In this study, we explored the role of ASCL1 in early 
and late nephrogenesis. Interestingly, the expression patterns of ASCL1 transformed 
from perinuclear to nuclear from early to late nephrogenesis This is suggestive of a role 
in Notch signalling mediated transcriptional activation. 
 
The effect of Ascl1 overexpression on differentiating podocytes was examined by 
crossing transgenic mice carrying the dox-inducible podocin-rtTA with transgenic mice 
carrying TetO-Ascl1 under the mCherry reporter. Following 6 weeks of doxycycline 
treatment, mice did not show any histological renal phenotype nor evidence of 
proteinuria. These results suggest that Ascl1 does not participate in podocyte injury 
following Wt1 deletion and its upregulation may only be relevant to regulation of Notch 
pathway signalling. 
 
Ascl1 mRNA levels oscillate from D4 to D6 P.I. Cre-ERTM+/-;Wt1f/f mutants  
 
Ascl1 transcript levels were increased in the Cre-ERTM+/-;Wt1f/f mutants compared to 
controls at D4 and D6 P.I. Transcript levels of Ascl1 oscillated at each time-point, 
showing reduced Ascl1 mRNA levels at D5 P.I. in the mutants. Previous research has 
highlighted the role of Ascl1 during different stages of neurogenesis, where its 
expression patterns oscillate with the Notch bHLH transcription factor, Hes1 
(Vasconcelos and Castro, 2014). The proneural transcription factors, including Ascl1, 
play a crucial role in both proliferation and complete differentiation of neuronal 
development, with the assistance of specific genes, including Hes1 of the Notch 
pathway. Genetic ablation of Ascl1 results in decreased neuron generation (Casarosa et 
al., 1999, Horton et al., 1999), whilst overexpression of Ascl1 induces cell cycle exit and 
complete neuronal differentiation (Castro et al., 2006, Berninger et al., 2007, Geoffroy et 
al., 2009), highlighting its importance in regulating vertebrate neurogenesis. 
 
Our data shows that increased Ascl1 mRNA expression at D6 P.I. is accompanied by 
reduced levels of Hes1 in the mutants which to some extent mirrors the oscillatory 
expression pattern seen in neurogenesis. Hes1 levels were higher in the mutants 
compared to controls at each time-point. Ascl1 oscillations depend on Hes1 oscillations 
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in neurogenesis, regulating active or quiescent neural stem cells. The oscillation 
between Hes1 and Ascl1 levels in our model may suggest that both genes interact to 
regulate the Notch pathway in podocytes. The expression of podocyte ASCL1 was 
further validated through Western blot analysis at D4 P.I., showing a clear increase of 
the protein in the Cre-ERTM+/-;Wt1f/f mutants. By immunofluorescence, ASCL1 protein 
was nuclear and mainly restricted to podocytes, indicating that ASCL1 may be activated 
in Wt1 glomerulopathy, and may interact with HES1 during Notch activation. 
 
Earlier findings have proposed that Wt1 acts upstream of Ascl1 during olfactory neuron 
development. Wt1 KTS-/- mouse mutants had reduced Ascl1 and severely impaired 
neural retina, with thinner retinas and fewer cells (Wagner et al., 2005). Hes1 and Wt1 
are the two main transcription factors regulating Ascl1 during embryonic olfactory 
development. Hes1 and Hes5 are its downstream targets and their expression prevents 
premature differentiation of neurons (Cau et al., 2000, Nicolay et al., 2006), whilst Wt1 
is upstream (Wagner et al., 2005). Although little is known about the molecular control of 
Ascl1 expression, earlier research (Wagner et al., 2005) and work presented in this 
chapter suggest that Wt1 deletion may increase Ascl1 mRNA levels in Wt1 
glomerulopathy. Furthermore, Hes1 and Hes5 expression are affected following Wt1 
deletion, which may be a consequence of Ascl1 overexpression, manipulating the 
expression levels of the canonical Notch targets. One way to further examine this would 
be to investigate the Notch pathway following Ascl1 overexpression in the 
TetOAscl1;rtTA;NPHS2 mutants.  
 
The specific expression patterns of both ASCL1 and HES1 in the podocytes 
corroborated our findings of increased mRNA levels of both bHLH transcription factors 
in podocyte injury and onset of GS. Patients with R390X and R362X WT1 mutations also 
showed ASCL1 overexpression in their glomeruli compared to control biopsies. HES1 
was also overexpressed in the glomeruli of the patients. Both of our WT1 patient samples 
carry a mutation lacking three of the four zinc fingers in which the KTS isoforms are 
present, leading to DDS. Here, we show that WT1 mutations and deletion result in 
increased ASCL1 expression with glomerular injury, suggesting that WT1 may be 
controlling ASCL1 activity. By contrast, Wt1 +KTS mutations in mice have shown 
reduced Ascl1 expression during olfactory development (Wagner et al., 2002). By 
studying–KTS/+KTS isoforms, we could further explore the relationship between Wt1 
and Ascl1 in podocyte development and injury.  
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Ascl1-positive podocytes do not undergo apoptosis in late GS 
 
Since apoptosis is a major mechanism following podocyte injury (Chapter 3.2.2), the aim 
was to investigate whether Ascl1 participated in inducing cell death. Apoptosis was 
detected by TUNEL analysis in D12 P.I. mutants, where a very small number of ASCL1-
positive cells were observed. TUNEL was not detected in the majority of ASCL1-positive 
podocytes. This suggests that podocyte apoptosis is not activated by increased ASCL1 
expression. Conversely, Ascl1 mRNA has been associated with apoptosis in the adult 
rat brain (Kolobov et al., 2012). While research has focused on ASCL1 contributing to 
apoptosis in SCLC and the brain, no work has explored its role in the pathogenesis of 
podocyte injury and apoptosis. The preliminary data presented here shows that there is 
an upregulation of Ascl1 in our D4 to D6 P.I. mutants, however, this does not contribute 
to apoptosis or the progression of GS. 
 
Ascl1 is expressed during podocyte differentiation 
 
The current data shows that Ascl1 is increased in our model of Wt1 glomerulopathy. 
Given its oscillatory role with Hes1 in neurogenesis and the role of the Notch pathway 
during nephrogenesis, we sought to investigate whether Ascl1 plays a role during 
nephrogenesis. 
 
Results revealed that in murine E17.5, ASCL1 was present in the middle region of the 
S-shaped body during glomerulogenesis, similar to components of the Notch pathway, 
namely HES1 and HES5 (Piscione et al., 2004). ASCL1 displayed a perinuclear pattern 
of expression at this time-point, rather than nuclear, indicating that it may be playing 
several roles during nephrogenesis, as it does in neurogenesis (Garcez et al., 2015, Britz 
et al., 2006, Pacary et al., 2011, Liu et al., 2017). One of its major roles in neurogenesis 
is during mitotic spindle assembly, which may explain its specific pattern of expression 
in the S-shaped body, as ASCL1 is detected at each end of the nucleus, indicating that 
mitosis may be occurring at that point in time. 
 
At post-embryonic stage, P7, ASCL1 was detected in the nuclei of the capillary loops, 
further emphasising its numerous roles during development. At this time-point, ASCL1 
was mainly detected within the podocytes and within the same regions as the Notch 
components, suggesting an association between Ascl1 and the Notch pathway during 
nephrogenesis. 
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ASCL1 has been shown to play certain roles with the Notch pathway during neuronal 
differentiation. One study demonstrated its interaction with specific E-box sites within the 
Dll3 promoter in vitro during neural tube development (Henke et al., 2009). Furthermore, 
in situ hybridisation revealed its expression within the developing mouse hypothalamus 
along with Dll1, Hes5 and Hey1, where its pattern of expression overlapped with both 
Dll1 and Hes5 (Guillemot et al., 1993). Its relationship with the Dll genes was further 
revealed in chick retinal progenitors, where it was co-expressed in Dll progenitors of 
differentiating neurons and its presence was necessary for normal Dll gene expression 
(Nelson et al., 2009). Moreover, ASCL1 was discovered to regulate Hes6 during neural 
differentiation (Nelson et al., 2009), adding to its importance in regulating the Notch 
pathway. Phosphorylation of ASCL1 serine residues regulate DNA binding, resulting in 
selection of transcriptional target genes with open chromatin, including Dll1 (Guillemot 
and Hassan, 2017). 
 
Together, these elements highlight ASCL1’s importance and association with the Notch 
pathway during differentiation and its possible role with the Notch pathway during 
nephrogenesis. Since the Notch pathway plays a crucial role during early podocyte 
differentiation as well as being regulated by ASCL1 during neuronal development, 
ASCL1’s expression patterns during glomerular development does not seem surprising. 
Perhaps, during podocyte development, ASCL1 regulates the Notch pathway to induce 
cell proliferation and differentiation, as part of glomerular morphogenesis. A more reliable 
method to explore Ascl1 expression during podocyte differentiation would be by lineage 
tracing. An Ascl1-GFP mouse line can be analysed at different stages of development, 
such as E13.5, E15.5, E18.5 and P7. 
 
Overexpression of Ascl1 in the podocytes does not induce podocyte injury  
 
The upregulation of Ascl1 in Wt1 deleted Cre-ERTM+/-;Wt1f/f mutants encouraged us to 
explore whether ectopic expression of Ascl1 in murine podocytes would induce podocyte 
injury manifested as GS. Overexpression of Ascl1 was validated by real-time qPCR as 
well as mCherry reporter gene expression in kidney cryosections and podocyte cells. 
Although Ascl1 RNA expression was increased at D4 P.I. in the mutants compared to 
the controls, overexpression up until 6 weeks in the TetoAscl1;rtTA;NPHS2 system did 
not reveal any signs podocyte injury, including proteinuria and GS. Previous studies 
revealed that ectopically induced Notch1 in the developing and differentiated podocytes 
resulted in GS and podocyte apoptosis (Waters et al., 2008, Niranjan et al., 2008), thus 
suggesting that Ascl1 is not the main inducer of podocyte injury in Wt1 glomerulopathy. 
Although it may have a role in regulating the Notch pathway, there are other possible 
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upstream players that may influence the Notch pathway to stimulate podocyte injury and 
GS. Furthermore, while Ascl1 overexpression was confirmed in this mouse model, 6 
weeks of doxycycline may have not been enough time to induce injury. In future, 
extending doxycycline treatment for a longer period of time, or challenging the mice with 
toxic agents could result in a diseased phenotype and allow us to further understand 
Ascl1 expression patterns in the podocyte injury further. 
 
Overall, this chapter has demonstrated an increase in Ascl1 in our model of Wt1 
glomerulopathy. Increased levels of Ascl1 mRNA is associated with reduced levels of 
Hes1, the canonical target of the Notch pathway. The oscillation between both genes 
suggests that Ascl1 and the Notch pathway may be regulating each other in the context 
of podocyte injury to rescue disease. This correlates with our findings of ASCL1 being 
expressed in the middle region of the S shaped body in early nephrogenesis, similar to 
the Notch components, HES1 and HES5. Overexpression of Ascl1 in transgenic mice 
does not induce podocyte apoptosis or GS, suggesting that it may be activated to rescue 
disease as a result of podocyte injury. To further investigate the role of Ascl1 in 
nephrogenesis, future experiments could focus on analysing an Ascl1-GFP mouse line 
at different stages of nephrogenesis. RNA studies, including in situ hybridisation could 
be used to highlight the association between Ascl1 and the Notch pathway during 
nephrogenesis. To conclude, Ascl1 may be a participant in regulating Notch signalling 
activity during glomerulogenesis and podocyte injury.  
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Chapter 5 - Discussion and Future Directions 
5.1 Overall Discussion 
 
5.1.1 Utility of inducible models to study mechanisms underlying disease onset 
 
Data presented in this thesis has demonstrated a novel role for Jag1-mediated Notch 
activation in Wt1 glomerulopathy, with semi-quantitative evidence of GS in an inducible 
model of mature podocyte injury. 
 
Podocyte apoptosis is evident in the early proteinuric stages, accompanied by FP 
effacement. Increased levels of albuminuria correlate with the loss of podocytes following 
Wt1 deletion. GS is evident at later stages of Wt1 deletion with increased expression of 
mesenchymal markers, including Snail and Slug, highlighting an EMT in the primary 
mutant podocytes. 
 
Previous studies demonstrated that ectopically activating Notch in developing and 
mature podocytes leads to podocyte injury associated with podocyte apoptosis and 
dedifferentiation, as well as DMS and FSGS histological phenotypes (Waters et al., 2008, 
Niranjan et al., 2008), and this also correlated with WT1 mutations (Chernin et al., 2010, 
Lipska et al., 2014). Our model revealed an upregulation of several Notch components 
in primary podocytes following Wt1 deletion, including the Notch bHLH transcription 
factors, Notch1 and Nrarp (Krebs et al., 2001). Primary mutant podocytes also revealed 
an upregulation of JAGGED1 and POFUT1, suggesting a ligand-dependent mechanism 
of podocyte Notch activation at the progression of disease. Additionally, HES1 induction 
in Nphs2;rtTA primary podocytes increased Snail and Slug expression, further 
supporting the role of Notch stimulating EMT. 
 
γ-secretase inhibitors administered prior to disease onset prevented GS and albuminuria, 
proposing a role for Notch-mediated activation of podocyte apoptosis and EMT in Wt1 
glomerulopathy. In support of this, earlier findings demonstrated podocyte Notch 
activation in human biopsies of glomerular injury and in models of GS (Niranjan et al., 
2008, Murea et al., 2010, Sweetwyne et al., 2015, Morimoto et al., 2016). Increased 
expression of the canonical Notch targets, including Hes1, Hes3, Hes5, Hey1, Hey2 and 
HeyL were demonstrated in STZ- and PAN-induced models of GS (Niranjan et al., 2008). 
Increased Notch activity has been found to promote podocyte apoptosis, and in turn 
podocyte apoptosis has been shown to induce FSGS pathogenesis. Apoptotic genes 
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including Trp53 and Apaf1, as well as positive TUNEL staining, have been detected in 
murine models of induced Notch1 ICD in mature podocytes (Niranjan et al., 2008). 
Podocyte apoptosis is inhibited following pifithrin-α induction in the Notch1 ICD-induced 
models, suggesting a role for the p53 pathway in Notch-mediated apoptosis (Niranjan et 
al., 2008). The role of p53 mediated apoptosis might to be involved in the pathogenesis 
of GS in our Wt1 glomerulopathy model. Further evidence of Notch-induced podocyte 
apoptosis has been provided by conditionally deleting podocyte Rbpj in mice with DN, 
where podocyte apoptosis was decreased (Niranjan et al., 2008). Given that Notch1 
deletion has been associated with abrogating GS in models of DN, as well as 
downregulating Snail1, an EMT marker (Sweetwyne et al., 2015), it would be noteworthy 
to explore whether conditional Notch1 deletion would reduce podocyte apoptosis and 
EMT in our model. Conditional inactivation of Notch1 and its canonical targets in early 
and late Wt1 glomerulopathy will allow us to further delineate Notch’s role in disease 
pathogenesis. 
 
Notch bHLH transcription factors, Hes/Hey genes are downregulated following terminal 
podocyte differentiation (Piscione et al., 2004) and podocyte differentiation has been 
found to be regulated by a transcriptional network of genes, including Wt1, Foxc1/c2, 
and Rbpj (O'Brien et al., 2011, White et al., 2010). Binding motifs of FOX have been 
linked with WT1 binding regions, supporting their synchronised relationship in podocyte 
regulation (Lefebvre et al., 2015, Kann et al., 2015b). Podocyte numbers are seen to be 
reduced in zebrafish following double knockdown of wt1a/rbpj or wt1a/foxc1a compared 
to single knockdown of any of the three genes, supporting a collaborating network 
between the genes in regulating podocyte specification (O'Brien et al., 2011). Moreover, 
an interaction between WT1, FoxC2 and RBPJ has been reported on a protein level, and 
HEY1 expression can be triggered through the combination of WT1, NICD and FOXC1/2 
(O'Brien et al., 2011). Wt1 regulates expression of the Hey1 orthologue, XHRT, in 
Xenopus, in early glomus development (Taelman et al., 2006) as well as modulating 
HeyL expression during murine metanephric development in pre-tubular aggregates, by 
binding to its promoter (Hartwig et al., 2010). Collectively, these studies highlight the 
relevance of Wt1 and Foxc1/2 in regulating Notch transcriptional targets during 
nephrogenesis. 
 
As highlighted above, normal mature podocytes no longer express Notch components. 
Wt1 deletion in our model led to an upregulation of the Notch pathway markers, Notch1, 
Nrarp, Hey1, HeyL, Hes1, Hes3 and Hes5. These changes are reminiscent of earlier 
findings in zebrafish that Wt1 and Foxc1a repress NICD1’s ability to activate a synthetic 
Notch reporter driven by Rbpj sites (O'Brien et al., 2011), proposing a role for WT1 and 
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FOXC1/2 to antagonise Notch signalling. Our data also reveals downregulation of Foxc2 
expression following Wt1 deletion, with increased Notch transcript expression at the 
onset of GS and proteinuria. Our current findings demonstrate an increase in Hey2 
transcript expression concurrent with a downregulation of Foxc2 in the mature 
podocytes, advocating a role for FoxC2 in inhibiting Hey2 expression, as well as other 
Notch components, in differentiated podocytes. Earlier studies in endothelial cells 
revealed that Hey2 is a transcriptional target of FoxC2 (Hayashi and Kume, 2008), which 
correlates with our current findings. Therefore, restoring FoxC2 quantities in the adult 
Cre-ERTM+/-;Wt1f/f mutants may supress Notch bHLH gene activity, and restore podocyte-
specific gene expression. Alternatively, Hippo signalling may be another pathway 
mediating Notch activity in Wt1 glomerulopathy. Hippo signalling has been found to 
target Notch components (Totaro et al., 2017), as well as being a target of Wt1 during 
podocyte specification (Kann et al., 2015b). This can be explored by knocking down or 
overexpressing Hippo signalling components in our model of Wt1 glomerulopathy. 
 
Notch glycosylation is necessary for the activation of Notch signalling through the binding 
of Notch receptors and ligands (Chung et al., 2017). Our data revealed increased 
expression of the O-fucosyltransferase POFUT1 in the Cre-ERTM+/-;Wt1f/f mutant 
podocytes, as well as Mfng, which facilitates Notch ECD glycosylation (Bruckner et al., 
2000, Kakuda and Haltiwanger, 2017). Typically, Fringe glycosylation of Notch1 
activates Notch signalling through the Dll1 ligand. A more recent study showed Notch2 
and Jag1 play a role in kidney fibrosis. Our data reveals increased expression of Jag1 
and Manic Fringe in our Cre-ERTM+/-;Wt1f/f mutants as well as in human samples of WT1-
mutated GS, with increased Notch activity. This data suggests that Mfng and Jag1 
contribute to Notch signalling activation in our model of Wt1 glomerulopathy. 
 
JAG1 protein was increased in our mutant podocytes in the early stages of disease, 
which correlates with earlier reports showing Jag1 in GS (Niranjan et al., 2008, Murea et 
al., 2010). Dll1 expression, on the other hand, showed no difference between the 
mutants and the controls at this time point. Both ligands overlap in the middle region of 
the S-shaped body during kidney development, and murine models showing double 
deletion of both ligands results in reduced numbers of proximal tubules and glomeruli, 
highlighting Notch’s importance in proximal nephron development (Liu et al., 2013). 
Moreover, the Jag1 allele has been shown to rescue some WT1-positive podocytes in 
Dll1-null mice, highlighting its potential role in podocyte fate induction (Liu et al., 2013). 
Therefore, deletion of Jag1 in adult Cre-ERTM+/-;Wt1f/f mice will allow us to further analyse 
targets of disease manifestation. 
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The proneural transcription factor Ascl1 was also increased in the Cre-ERTM+/-;Wt1f/f 
mutants at the early stages of disease. Several studies have highlighted the role of Ascl1 
and an overlapping relationship with the Notch pathway in neurogenesis. Intriguingly, 
Ascl1 plays a role in the maintenance of Hes1 oscillations in neural stem cells 
(Vasconcelos and Castro, 2014), correlating with our model showing oscillating Ascl1 
and Hes1 mRNA levels during early stages of the disease. Our data demonstrates Notch 
signalling is potentially activated through Jag1 binding, proposing a role for Ascl1-
mediated Jagged Notch activation. Former investigations revealed that Wt1 expression 
is upstream of Ascl1 during olfactory development (Wagner et al., 2005), highlighting a 
link between both genes during neurogenesis. The deletion of Wt1 in our adult mice may 
result in Ascl1 overexpression in the podocytes, contributing to aberrant Notch activation. 
These findings are consistent with patient biopsies of WT1 mutations (namely in R390X 
and R362X mutations), where ASCL1 protein expression was increased, further 
supporting the theory of WT1 deletions/mutations altering Ascl1 expression patterns. Our 
model shows that Ascl1 may contribute to the temporal gene expression of Hes1 in 
podocyte injury. 
 
5.1.2 Utility of primary podocyte culture 
 
The isolation of primary podocytes has proven to be a valuable tool in investigating the 
mechanisms and pathways associated with podocyte injury. To confirm that our cells 
were purely podocytes, cells were stained with the podocyte-specific antibody, Nestin. 





Despite achieving the overall goals of the project, technical challenges were encountered 
along the way. RNA sequencing was achieved through glomerular isolation. This work 
was undertaken at an early stage of the project; thus, the analysis was based on a 
heterogenous population including podocytes, mesangial and endothelial cells. Primary 
podocyte isolation was then utilised, which will allow future RNA sequencing analysis to 
be achieved with pure podocytes. Furthermore, due to the injury to the cells, their viability 
and ability to survive in culture was limited, thus restricting us from carrying out later 
experiments on the cells. With this in mind, genetic rescue experiments were limited due 
to the low viability of the primary cells. 
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5.2 Future work 
 
5.2.1 Pharmacological inhibition of Notch to prevent late stages of disease 
 
GSI-IX treatment reduced Notch activity in adult Cre-ERTM+/-;Wt1f/f mice at D4-D5 P.I., 
preventing GS and reducing albuminuria. While prophylactic treatment prevented onset 
of disease progression, GSI-IX treatment did not rescue disease at the later stages (D7-
D8 P.I.). Increasing the sample size, this would validate existing findings with regards to 
rescuing a disease phenotype using GSI-IX. It would also be worth treating mutant mice 
at D6 P.I., where there is onset of disease. Gastrointestinal toxicity has been reported to 
be a major side-effect of GSI-IX (Barten et al., 2006). It has also been shown to alter 
lymphocyte development (Wong et al., 2004). Alternative compounds inhibiting Notch 
activity include SAHM1, which interferes with the Notch1 transactivation complex, 
repressing its downstream targets. Previous reports have shown that SAHM1 specifically 
represses Notch signalling in human T-ALL (T-cell acute lymphoblastic leukaemia) cells 
and a mouse model of NOTCH1-driven T-ALL, with no toxic effects in comparison to 
DAPT (Moellering et al., 2009). This therefore will be a valuable avenue to pursue by 
exploring its effects on Wt1 glomerulopathy. 
 
5.2.2 Investigating Fringe and ligand-mediated Notch signalling in podocytes 
 
Our data reveals an upregulation of Notch signalling with increased Manic Fringe and 
JAG1 expression in the mutants compared to the controls. Elucidating the effects of 
Manic Fringe on JAG1-mediated Notch1 signalling would be an interesting avenue to 
explore. One way of approaching this would be to overexpress Manic Fringe by 
transfecting it into immortalised podocytes co-transfected with a Notch1 luciferase 
reporter construct. These would then be co-cultured with DLL1 or JAG1 expressing CHO 
cells in order to reveal which ligand induces Notch1 activity. An experimental design to 
overexpress Manic Fringe in immortalised podocytes is illustrated in Figure 5.1. Past 
studies have utilised this method in order to determine ligand-mediated Notch signalling 
in other cells/species (Yang et al., 2005, Ilagan et al., 2011, Chen et al., 2001). Luciferase 
assays would reveal Notch signalling and upregulation of its downstream bHLH targets, 
including HES and HEY would be explored through protein and transcript analysis. This 
approach may highlight which ligand is potentiating Notch activity by Manic Fringe, or if 
in fact other Fringes are participants. Furthermore, by using shRNA knockdown of Manic 
Fringe in the mutant podocytes to inhibit Notch activity, EMT and podocyte apoptosis 
may be prevented. Preliminary data (Figure 3.26) using shMfng has already shown 
evidence of target knockdown, as well as reduced Notch activity through its bHLH TFs. 
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Additionally, EMT genes Snail and Slug were downregulated (Figure 3.26). Despite there 
being a decrease in the above markers, p values were not significant, and differential 
gene expression between scrambled and Mfng shRNA were also not significant. 
Increasing sample numbers (n=10) would allow us to produce a more significant and 
accurate result. Additionally, knockdown of other acetylglucosaminyltransferases may 
also be necessary to further dissect the role of Fringe-mediated Notch signalling in the 
context of podocyte injury. 
 
 
Figure 5.1. Experimental design for Manic Fringe overexpression in podocytes 
 
5.2.3 Strategies to investigate transcriptional networks 
 
Ascl1 expression and the Notch pathway oscillate during neurogenesis (Vasconcelos 
and Castro, 2014); future experiments examining Ascl1’s temporal and spatial role 
alongside the Notch components and Wt1 during nephrogenesis will allow us to 
appreciate their relationship further. Our data revealed that ASCL1 protein is expressed 
during glomerulogenesis (4.2.4); Additional experiments analysing ASCL1 protein 
expression, in conjunction with in situ hybridisation of Notch components and Wt1, will 
allow further appreciation of ASCL1’s role in early kidney development. During 
nephrogenesis, the Notch transcription factors are known to become downregulated 
(Barak et al., 2012, Asanuma et al., 2017), suggesting a role for Notch in podocyte fate 
specification. Utilising a transgenic mouse in which the Ascl1 locus carries a GFP 
element would allow us to further explore the spatial and temporal expression of the 
gene during nephrogenesis at E13.5, E15.5, E18.5 and P7, where Notch expression is 
downregulated. Another approach would be to cross CreTM-Wt1 mice with Ascl1-GFP 
mice, induce with tamoxifen, and harvest the kidneys at D4 post-tamoxifen (only 
proteinuria is detected), D5 (early GS), D6 and D7 P.I. (established GS with significant 
albuminuria). Primary podocytes would be isolated and the Ascl1-GFP positive 
podocytes sorted from the Ascl1-GFP-negative podocytes. RNA would be extracted from 
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both and differential Notch pathway expression investigated in both groups by real-time 
qPCR. This would allow us to understand the relationship between Wt1 and Ascl1. 
Furthermore, analysing podocyte differentiation in Ascl1-/- null mice (from Professor 
Francois Guillemot), would allow us to further validate whether Ascl1 has a significant 
role during podocyte development. We know that Dll1 is expressed in the proximal 
domain of the RV during nephrogenesis (Kopan et al., 2007, O'Brien and McMahon, 
2014) and ASCL1 binds to the enhancer of Dll1 during neurogenesis, triggering its 
transcription (Nelson and Reh, 2008, Nelson et al., 2009). Thus, it would be of interest 
to examine their association during nephrogenesis. Ascl1 expression would be examined 
in the glomeruli, S-shaped bodies and the tubules in Ascl1-null mice versus wild-types. 
 
Examination of Ascl1’s promoter sequence revealed conserved binding sites for Wt1 
(Figure 5.2). Additionally, the Notch bHLH protein, HeyL is a direct transcriptional target 
of Wt1 (Hartwig et al., 2010) and conserved binding sites for Wt1 have been revealed in 
the Notch bHLH protein, Hes1 (Figure 5.2). Studies have highlighted a transcriptional 
complex between WT1 and ASCL1 (Wagner et al., 2005, Kang et al., 2014) as well as 
Hes1/Ascl1 (Vasconcelos and Castro, 2014). Therefore, ChIPSeq of ASCL1 and WT1 
as well as Notch components in the context of podocyte injury would be an interesting 
avenue to explore. 
 
Wt1, FoxC and Notch signalling collaborate transcriptionally during podocyte 
differentiation (O'Brien et al., 2011, Kann et al., 2015b). In this project, FoxC2 transcript 
was downregulated following Wt1 deletion, with increased expression of the Notch bHLH 
TF, Hey2, at the onset of GS. By overexpressing FoxC2 in vivo and in vitro in models of 
GS through a podocyte-specific tetO;rtTA system, we can examine whether podocyte-
specific markers are upregulated, with reduced Notch signalling. RNA and ChIPSeq 
analysis of cells overexpressing FoxC2 could further confirm the relationship between 
FoxC2/Notch/Wt1 in models of GS. 
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Figure 5.2. Binding domains within the WT1 promoter for Notch bHLH genes 
(% of ECR [evolutionary conserved regions]) 
 
5.2.4 Genetic rescue strategies  
 
While GSI-IX treatment has been a mode of inhibiting the Notch pathway post-tamoxifen 
induction, toxic side-effects have been reported (Barten et al., 2006). An alternative 
method would be to genetically inhibit the Notch pathway by repressing the activation of 
its components, namely Rbpj, Hes1 and Notch1 in the Cre-ERTM+/-;Wt1f/f mouse line. 
Gene editing these Notch components has been achieved in the past using several 
mouse models of disease (Niranjan et al., 2008, Imayoshi et al., 2008, Yang et al., 
2004b). With this approach, adult Cre-ERT-/-;Wt1f/f controls (group 1) vs. Cre-ERTM+/-
;Wt1f/f mutants (group 2) vs. Cre-ERTM+/-;Wt1f/f;Rbpjf/f/ or Hes1f/f/or Notch1f/f rescue mice 
(group 3) mice could be analysed at different time-points to examine whether the genetic 
inhibition of Notch signalling prevents disease manifestation (Figure 5.3). The aim would 
be to knockout Wt1 and the Notch targets through tamoxifen induction in all groups, then 
compare and examine them at each stage of disease by histological and urine analysis. 
By removing Rbpj/, Hes or Notch1, we aim to rescue glomerulopathy, which would be 
confirmed through mRNA and protein analysis of Notch and podocyte components, 
including the bHLH transcription factors, Hes and Hey, and podocyte markers Nphs1, 
Nphs2. Furthermore, the antagonising relationship of FoxC on Notch signalling could be 
further validated in these systems by analysing FoxC expression following Notch 
signalling knockout. Podocyte apoptosis, proliferation, and EMT would be examined in 
all groups to confirm whether deleting Notch components ameliorates glomerular 
disease and podocyte injury. 




Figure 5.3. Experimental strategy to genetically inhibit Notch target genes in Wt1 
glomerulopathy 
 
Another avenue to explore would be to validate the role of the canonical Notch targets, 
Hes1 and Hes5 in podocyte apoptosis in vivo. Recently, Ohtsukas’s group 
overexpressed Hes1 and Hes5 in podocytes of Nestin-rtTA;TetOHes1 or Hes5 
transgenic mice through doxycycline treatment to study neurogenesis and gliogenesis in 
neocortical development (Bansod et al., 2017). This would be a good model to examine 
whether these genes do indeed play a role in promoting podocyte apoptosis, as well as 
EMT upregulation in GS. Furthermore, this model will allow us to investigate other 
mechanisms involved in bHLH-induced podocyte injury. 
 
5.2.5 Transgenic Wt1R394W mutant mice  
 
While ubiquitous Wt1 deletion revealed GS with induced Notch signalling and apoptosis, 
examining models of SRNS with specific WT1 point mutations would be a valuable route 
to pursue. GS accounts for 5-10% of ESRD with a recurrence of 30-60% in renal 
allografts (Saran et al., 2015). Genetically-mediated SRNS develops in approximately 
70% of infants within the first 3 months, and 50% of children between 4 and 12 months 
(Rheault and Gbadegesin, 2016). WT1 mutations contribute to about 3% of paediatric 
SRNS, where no treatments are currently available (Rheault and Gbadegesin, 2016, 
Lipska et al., 2014). The missense mutation WT1 R394W, known to be a C-to-T 
transition, results in the substitution of tryptophan to arginine at amino acid 34 (R394W), 
disrupting zinc finger 3, and deleting the KTS insert and zinc finger 4 (Gao et al., 2004). 
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R394W mutations affect WT1 DNA binding, and DDS (Lipska et al., 2014). GS presents 
in Wt1r394w/+ heterozygous mice by 4 months postnatally (Gao et al., 2004), providing a 
useful model to further examine the pathogenic role of Notch activation in Wt1 
glomerulopathy. Our data also revealed an activation of Notch in patient biopsies with 
de novo heterozygous WT1 mutations associated with DMS (Figure 3.22), a phenotype 
also manifested in the Wt1r394w/+   transgenic mice. This represents an opportunity to 
investigate Notch signalling in WT1 glomerulopathy further by confirming a histological 
phenotype and proteinuria. Immunohistochemistry analysis of the TGF-β pathway, 
including Smad2/3 activation as well as markers of EMT, would be analysed to assess 
the development of tubulointerstitial disease. Furthermore, temporal analysis of Notch 
activation would be examined at different ages in kidney sections. 
 
5.2.6 Notch pathway analysis in other murine models of GS 
 
WT1 mutations account for around 2-3% of SRNS, whereas mutations in other podocyte-
specific genes, account for around 27-30% of SRNS (Jain et al., 2014). Our data 
supports Notch as a key player in GS linked to WT1 abnormalities. WT1 is known to act 
as a “master controller” of gene transcription within the podocyte, regulating many other 
podocyte genes linked to podocytopathy. Therefore, by conditionally deleting other key 
podocyte genes with tamoxifen, we would be able to explore the pathogenic mechanisms 




In summary, Wt1 deletion in adult podocytes leads to podocyte apoptosis at the very 
early stages of GS. Notch signalling and EMT components are upregulated at the onset 
of disease. Induced podocyte HES1 expression results in increased Snail and Slug 
expression, advocating a role for HES1 in podocyte EMT. Early pharmacological 
inhibition of the Notch pathway reduces the severity of GS and albuminuria. Our data 
illustrates a possibility for repressed FoxC2 expression to be mediating Notch activity. 
Due to WT1’s intricate biological structure and roles, examining mouse models of Wt1 
point mutations will provide unique tools to decipher the underlying transcriptional and 
post-transcriptional mechanisms involved in WT1 GS. 
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Heatmap displaying differential gene expression of D4 PI glomerular RNA isolates. 
Based on the average FPKM (fragments per kilobase of exon model per million reads 
mapped) reads per sample. Differential gene expression was analysed by the genomics 
department, UCL. Heatmap was developed using Microsoft Excel. A group of 3 mutants 
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Appendix B  
Figure B.1. Dot plot analyses showing each gene of the Notch pathway at D4 P.I. (Cre-
ERTM-/-;Wt1f/f vs. Cre-ERTM+/-;Wt1f/f). Middle horizontal lines mark median mRNA 





 Page 209 of 214 
 
 




Figure B.2. Dot plot analyses showing each gene of the Notch pathway at D5 P.I. (Cre-
ERTM-/-;Wt1f/f vs. Cre-ERTM+/-;Wt1f/f). Middle horizontal lines mark median mRNA 
transcript levels relative to Gapdh, upper and lower horizontal lines mark the IQR. 
 
 








Figure B.3. Dot plot analyses showing each gene of the Notch pathway at D6 P.I. (Cre-
ERTM-/-;Wt1f/f vs. Cre-ERTM+/-;Wt1f/f). Middle horizontal lines mark median mRNA 
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